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General introduction and outline of the thesis
PART 1
Restenosis, stent malapposition and other aspects of vascular disease.
After a percutaneous coronary intervention (PCI) with stent placement re-endotheli-
alization should occur as part of a normal wound healing response. In a considerable 
amount of patients treated with a bare metal stent (BMS) a dysregulation of this response 
leads to neointimal hyperplasia and partial reocclusion of the intervention site, which 
is known as restenosis. As nowadays the use of stents, either bare metal or drug-eluting, 
has become standard, which largely rules out restenosis due to vascular recoil, we will 
focus on in-stent restenosis, which is mainly due to neointimal proliferation. After bare 
metal stenting, the incidence of target vessel revascularization, which is considered to 
be the most important endpoint by regulatory agencies, is approximately 10%. From 
the combined data of randomized controlled trials we know that patients treated with 
a drug eluting stent (DES) have approximately half this risk.1 However, disadvantages 
related to late acquired stent malapposition2,3 and delayed endothelialization with longer 
required use of P2Y12 antagonists, do not favour the use of DES in every patient. Taking 
into account that DES have not eradicated restenosis completely and that at least certain 
groups of patients benefit more from BMS, it is important to improve risk stratifica-
tion and to tailor individual therapy. However, only few clinical and lesion-related risk 
factors have been found to predict the development of restenosis. From many studies, 
with different indications for PCI and different endpoint definitions, we have learned 
that Diabetes Mellitus is the only strong en consistent clinical predictor of restenosis.4-6 
Hypertension has also been reported to increase the risk for restenosis.6, 7 In addition, 
several lesion-related and procedural characteristics such as stenosis severity (before 
stenting) and residual stenosis (after stenting), which were regularly reported to be as-
sociated with restenosis risk,6, 8, 9 can be used as clues to select the appropriate treatment.
Clinical risk factors such as diabetes en hypertension are also since long known to play 
a role in the development of atherosclerosis, a disease process with several similarities to 
restenosis, leading to world-wide frequently occurring diseases such as angina pectoris, 
myocardial infarction and stroke. Restenosis, coronary atherosclerosis and also athero-
sclerosis in other arteries are proliferative processes driven by inflammation. However, 
the relative importance of risk factors differs between these diseases. In contrast to reste-
nosis, the development of atherosclerosis is strongly influenced by circulating lipids and 
smoking. And the precise risk profile in atherosclerosis even differs depending on the 
location of the plaque. Stroke is relatively more determined by hypertension, whereas 
plasma cholesterol is more important in coronary disease.
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The importance of genetics
The different aspects of vascular disease have in common that multiple genetic factors 
play an important role in their development. The actual impact of any clinical risk factor 
on an individual depends for a large part on his/her genetic susceptibility to this factor. 
The value of genetics in cardiovascular disease is corroborated by the strong predictive 
value of a positive family history and further confirmed by twin studies showing that 
death from coronary artery disease at an early age of one twin is a strong predictor of the 
risk in the other twin.10 Many genes in inflammatory and proliferative processes, but also 
in processes important in hemostasis, cell signaling, lipid metabolism and endothelial 
function, have already been found to play a role in vascular disease.11, 12
The first chapter of part 1 of this thesis (chapter 2) will review current views on the role 
of genetics in restenosis after BMS placement and acquired malapposition after treat-
ment with a DES. The remainder of part 1 (chapter 3-7) will discuss new data further 
establishing the important influence of genetic factors in the development of adverse 
events after PCI and other aspects of vascular disease such as stroke. Each chapter ad-
dresses a specific process and its relative importance in one of these vascular diseases, 
mostly restenosis after PCI in the GENDER-study, which included 3104 patients after 
successful PCI for stable angina pectoris or non-ST-elevation myocardial infarction.
Considering that a reliable risk estimate cannot be made on the basis of clinical fac-
tors, genetic epidemiology can provide new risk markers to improve risk stratification. 




Since long we know that the final fenotype of an organism, and also its tendency to 
develop disease, is the result of the interplay between nature and nurture. It has now 
become clear that environmental influence (nurture) can exert its effect not only by 
Part 1 Process Endpoint Population
Chapter 3 Hemostasis Restenosis GENDER
Chapter 4 VSMC prol./hemostasis Restenosis/stroke GENDER/PROSPER
Chapter 5 Matrix formation Restenosis GENDER
Chapter 6 VSMC function Restenosis GENDER
Chapter 7 Endothelial function Restenosis GENDER
Chapter 8 Inflammation Stent malapposition MISSION
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influencing the code of DNA, but also (far more easily) by regulating gene expression 
without changing the code.13, 14
Early research by Kaati et al., investigating early nutritional influences on cardiovas-
cular mortality, already demonstrated heritability of environmental effects.15 They ex-
ploited records of annual harvests from an isolated community in northern Sweden that 
go back as far as 1799 to explore the effects of food availability across three generations. 
Kaati and coworkers showed a remarkable effect of food availability during the slow 
growth period (SGP) just before puberty of the paternal grandfather on the longevity of 
the probands. Scarcity of food in grandfather’s SGP was associated with a significantly 
extended survival of his grandchildren for many years, whilst food abundance was as-
sociated with a greatly
shortened life span of the grandchildren.15 These findings are most probably an ex-
ample of non-DNA sequence-related heredity, which we now refer to as “epigenetics”. In 
contrast to classical mendelian views on inheritance, epigenetics focuses on the heredity 
of environmental effects, a phenomenon that is called ‘epigenetic inheritance’. Although 
the precise mechanism remains unknown, it seems likely that the phenomenon observed 
by Kaati et al. is the result of DNA-methylation, the best understood example of epigen-
etic modification which is known to be involved in ‘genetic imprinting’.16 Methylation of 
DNA leads to silencing of genes and is maintained during cell division by virtue of the 
enzyme DNA methyltransferase I.
Several other findings implicate genetic imprinting in similar transgenerational ef-
fects. Mice experiments with the Agouti-allele, which normally leads to a yellow pheno-
type, have shown that a methyl-rich diet, when given to pregnant mice not carrying the 
Agouti-allele, could silence the Agouti-gene in their offspring.17 Especially interesting 
was the finding that methylation of the Agouti-allele was more likely to be maintained 
when the allele was maternally inherited. In humans, investigations into the underlying 
cause of the Prader-Willi and Angelman syndromes have lead to the discovery of a simi-
lar example of epigenetic inheritance. Due to a different DNA-methylation imprint, loss 
of the paternal copy of 15q11-q13 was found to lead to Prader-Willi syndrome, which is 
characterized by obesity, a short stature, extreme flexibility and delayed puberty, whereas 
maternal deletion of the same region on chromosome 15 has been shown to lead to 
Angelman syndrome,18 a neuro-genetic disorder characterized by intellectual and devel-
opmental delay, sleep disturbance, seizures, jerky movements (especially hand-flapping) 
and frequent laughter or smiling.
A second well-studied example of epigenetic change is chromatin modification; rear-
rangement of nucleosomes, which include covalent post-translational modifications 
of histone tails. Of several types of chemical modification, also including methylation, 
phosphorylation and ubiquitinylation, especially acetylation of lysine residues in the 
histone tails is considered a key process in gene regulation and is the main subject of part 
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II of this thesis. The histone acetylation status is regulated by two sets of enzymes: lysine 
acetyltransferases (KATs) and lysine deacetylases (KDACs). KATs acetylate histones 
by transfer of an acetyl-group to the ε-portion of lysine residues, which results in an 
open modification of chromatin structure and in accessibility of DNA to transcription 
factors and recruitment of the basal transcription initiation machinery.19, 20 Conversely, 
gene repression is mediated via KDACs, which remove acetyl groups and counteract 
the activity of KATs resulting in a closed chromatin structure. Unlike DNA methyla-
tion, a possible mechanism of maintaining histone acetylation through generations is 
not well understood. However, the modern definition of epigenetics does not require 
meiotic heritability, but should mention DNA modifications, other than DNA sequence 
variation, that carry information content during cell division.14 Although a replicating 
enzyme has yet to be discovered, histone acetylation changes might turn out to be self-
perpetuating.21 A possible mechanism is suggested by the phenomenon of ‘spreading’ 
of silencing in yeast which is mediated by the histone deacetylase activity of Sir2p.22 
Sir2p-induced hypoacetylation of nucleosomes attracts other Sir proteins and leads to 
spreading of silent chromatin along the chromosome in S. cerevisiae. Irrespective of 
these findings the process of histone acetylation/deacetylation is generally accepted as 
one of the pillars in epigenetic research.
Epigenetic regulation of gene expression is also known to be important for cell dif-
ferentiation. In every cell two thirds of our more than 25.000 genes are repressed by 
epigenetic mechanisms and every cell-type expresses a totally different set of genes. 
Furthermore, epigenetic mechanisms have been found to play a role in the development 
of human complex diseases such as cancer.23, 24 Chapter 9 of Part 2 of this thesis will 
discuss new insights in the role of epigenetic gene regulation (chromatin remodeling) 
also in determining susceptibility to cardiovascular disease, a new area of research. This 
chapter will also discuss the reversibility of epigenetic changes and the promising role of 
these mechanisms in the development of future therapy.
Epigenetic epidemiology
Thus far, the main focus has been to investigate the environmental influence on epi-
genetic processes. From literature we know that epigenetic differences arise during the 
lifetime of monozygotic twins25 and that oxidative stress influences the balance between 
KATs and KDACs in favour of KATs, leading to an increase in inflammation.26 Part 2 
of this thesis introduces the concept that epigenetic processes are also under genetic 
control and that, besides the environment, genetic variation in genes encoding KATs 
and KDACs could also be an important determinant of susceptibility to complex human 
diseases such as cardiovascular disease.
It has already been shown that single gene disorders of the epigenetic machinery 
also impair normal gene expression. Lack of the MeCP2 protein, which recognizes 
15
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methylated DNA and helps to repress gene expression, is known to lead to the Rett 
syndrome.27 Similarly, loss of one functional copy of the CREB-binding protein (CBP), 
a transcriptional co-activator with intrinsic KAT-activity, underlies all abnormalities in 
patients with the Rubinstein-Taybi Syndrome.28, 29 Single nucleotide polymorphisms in 
the sequence of these epigenetic genes could act generally on disease susceptibility by 
affecting the fidelity of the histone acetylation machinery. In the worm C. Elegans, the 
genetic variants which were found to have the broadest influence on gene expression, 
affecting many signaling pathways, were found to be present in chromatin-modifying 
genes.30 Furthermore, in humans, recent finding demonstrate that common genetic 
variants in the CBP gene are associated with altered cognitive function in the PROSPER-
study, which included 5804 elderly patients at risk for vascular disease.31
Chapter 10 of this thesis will focus on this relatively new area of research, which we 
call ‘epigenetic epidemiology’. In this chapter the PCAF gene will be introduced, encod-
ing a co-activator with intrinsic KAT-activity and a broad influence on inflammatory 
and proliferative gene expression. This chapter addresses its newly identified role in 
cardiovascular disease and the significance of common genetic variation in epigenetic 
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Potential genetic determinants of adverse 
outcome after stent implantation: results, 
limitations and perspectives
Sandrin C Bergheanu, Douwe Pons, Ioannis Karalis, Orçun Özsoy, Jeffrey 
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Despite its unequivocal superiority compared with balloon angioplasty, coronary stent-
ing did not abolish the restenosis problem and even brought along a completely new 
type of pathology. Bare-metal stents still associate with around 20-30% in-stent resteno-
sis rate and need for repeat revascularization. Drug-eluting stents (which unfortunately 
did not completely prevent restenosis either) sometimes determine late-acquired stent 
malapposition in a significant number of patients. This is followed occasionally by a 
very serious event – stent thrombosis. Patient co-morbidities, stent design, procedural 
characteristics and anti-platelet therapy influence the risk of post-stenting complica-
tions. Research in the recent years has revealed that also individual genetic profile plays 
an important role in adverse outcome after stent implantation. This manuscript reviews 
the evidence of genetic variations associated with stent restenosis, late-acquired stent 
malapposition and stent thrombosis.
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INTRODUCTION
The era of percutaneous coronary intervention (PCI) began with the first balloon an-
gioplasty performed by Andreas Gruentzig in 1977.1 Although this technique provided 
impressive immediate results, mid and long term follow up was characterized by high 
restenosis rates and need for repeat revascularization.1,2 Evolving our techniques, bare-
metal prosthetic devices (stents) were designed to act as a barrier against intima growth 
and recoil, assuring long-time patency of the coronary vessel. In 1986 Sigwart and Puel 
implanted the first coronary stent in a human patient.3 Superior to balloon angioplasty 
alone (32-42% restenosis rate), bare-metal stent (BMS) implantation remains however 
vulnerable to restenosis (22-32% of cases)4,5,6 and often requires re-intervention. Drug-
eluting stents (DES) were conceived as an answer to this problem. They, for the majority, 
consist of a metalic platform covered with a combination of polymer and cellular pro-
liferation inhibitor. The antiproliferative agent is gradually released in the arterial wall 
at the site of stent deployment preventing restenosis. The first successful DES trials were 
with sirolimus stents and led to their approval for use in 2002 in Europe and 2003 in 
USA.7,8 Currently, other DES based upon paclitaxel, everolimus, zotarolimus, biolimus 
and tacrolimus are available. DES have successfully achieved their task of preventing 
restenosis but the experience of the last years revealed an increased incidence of stent 
malapposition and stent thrombosis associated with their use.9 The aim of this article is 
to briefly present incidence and mechanisms of 1) stent restenosis, 2) stent malapposi-
tion and 3) stent thrombosis and to focus on potential genetic factors related to these 
complications. The majority of available data is retrieved from candidate gene approach 
studies, limiting thus the results to specific pre-targeted pathophysiologic sequences. 
Further novel pharmacogenomic approaches such as GWAS (genome wide association 
studies) may be able to identify new genetic factors for a better prediction of outcome 
after coronary stent deployment.
IN-STENT RESTENOSIS
In-stent restenosis (ISR) is defined angiographically when neo-formation tissue repre-
sents more than 50% of the lumen diameter at the site of the stented vessel (Figure 
1). The clinical confirmation of ISR is the recurrence of angina pectoris, which further 
requires intervention: TLR (target lesion revascularization) or TVR (target vessel 
revascularization). Although the severity of angiographic stenosis correlates with the 
need for TLR, half of the patients with angiographically confirmed ISR do not manifest 
clinical complains.6,10 For this reason authors generally prefer to conduct their research 
in relation to angiographically documented ISR when an insight in the mechanism of 
Chapter 2
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restenosis is aimed, while studies comparing different stents are in relation to clinically-
driven TLR or TVR.
ISR is the result of in-stent cellular proliferation and migration along with extracel-
lular matrix accumulation.11 Classic predictors of angiographic ISR (both in BMS and 
DES) include diabetes, renal failure, lesion length, reference vessel diameter and post-
intervention lumen area.12,13 Inflammation plays a pivotal role in ISR and it is triggered 
by the vascular injury during the stent deployment and by the presence of stent struts 
within the vessel wall.14,15 Together with inflammation, major contributors are smooth 
muscle cell migration and proliferation but the process of restenosis involves many dif-
ferent cell-types, among which platelets and endothelial cells, and is also characterized 
by thrombus formation and to a lesser extent by matrix remodelling.
GENETIC FACTORS RELATED TO IN-STENT RESTENOSIS
Genetic variations in thrombus formation
In principle, any vascular intervention initiates the formation of a thrombus. Initial 
studies have shown associations of only a few polymorphisms in the hemostatic system 
with the risk for adverse events following a PCI. These early reports showed significant 
associations of the PLA1/A2 polymorphism with acute stent-thrombosis and coronary 
restenosis.16,17 However, other studies in this field could not confirm these associations.18,19 
On grounds of the hypothesis that carriers of the PLA2 allele have a more intense bind-










Figure 1. In-stent restenosis
Fig. 1 a) Angiographically documented in-stent restenosis; b) IVUS documented in-stent restenosis. 1 – neointima; 2 – stent contour; 3 – vessel 
contour.
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formation, the PLA2 allele can be expected to lead to an increased risk for acute stent 
thrombosis. However, as platelet inhibition by IIb/IIIa and P2Y12 antagonists does 
reduce acute stent thrombosis, but not in-stent restenosis rates,20 thrombus formation is 
probably not a main player in the development of restenosis. This hypothesis is further 
confirmed by findings showing that especially the strong pro-thrombotic genetic risk 
factors for venous thrombosis do not increase the risk for restenosis.21 Moreover, results 
from the GENDER study21 have shown that the Factor V Leiden polymorphism (a well-
known prothrombotic risk factor) was even found to reduce the risk for restenosis after 
PCI. A total of 3104 consecutive patients with stable angina pectoris or non-STEMI, of 
whom 2309 (74.4%) received stents, were included.21 The factor V (1691 G>A or factor V 
Leiden) amino acid substitution was associated with a decreased risk of TVR (HR=0.41, 
95%CI 0.19–0.86). The Factor V allele, which is known to lead to increased activation 
of protein C, might therefore influence restenosis risk by mechanisms not involved in 
coagulation, but in processes that have a more prominent role in neointimal growth, 
such as inflammation. Even though in another study of the same patient sample, as-
sociations were found between P2Y12 receptor haplotypes and restenosis,22 fewer and 
smaller effects were present in the stented subgroup. The decrease of the effects in this 
group could be due to inhibition of this receptor by clopidogrel (although several stud-
ies23,24,25,26 failed to demonstrate a functional role of the P2Y12 receptor polymorphism 
in patients receiving dual antiplatelet therapy). Therefore, the genetic variation in this 
receptor, and also in many other genes with a role in the hemostatic system, may have 
been more important at a time in which not every patient was receiving a stent and 
concomitant platelet inhibition.
The 4G/4G genotype of the PAI-1 4G/5G polymorphism determines higher PAI-1 
levels in plasma27,28,29 and tissue.30,31,32 The PAI-1 4G allele was associated with an in-
creased risk of restenosis after PCI in the GENDER study.21 When compared to 5G/5G 
homozygotes, heterozygous patients were at higher risk for clinically-driven TVR 
(HR=1.46, 95%CI 1.05–2.03), whereas patients with the 4G/4G genotype had an even 
further increased risk (HR=1.69, 95%CI 1.19 – 2.41). Although one smaller study could 
not confirm this association,33 many reports found a positive correlation between post-
PCI PAI-1 levels or activity and restenosis.34,35 Nevertheless, PAI-1 has a diverse role in 
several processes involved in restenosis, also in inflammation and proliferation.36 Even if 
the 4G allele would increase the risk for restenosis, this could be mediated by a mechan-
sism not related to fibrinolysis inhibition. Taking these findings together, we suggest that 
coagulation is not a main determinant of the long-term process that leads to restenosis.
Genetic variations in inflammatory factors
Early studies investigating the role of genetics in restenosis showed associations between 
variants in genes encoding cytokines37 and selectins,38 important mediators of inflam-
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mation, and suggested a role for inflammation in restenosis. One of these studies was 
performed by Kastrati et al.,37 and included 1850 consecutive stented patients. They 
demonstrated a protective effect of allele 2 of a polymorphism in exon 2 of the gene en-
coding the IL-1 receptor antagonist (IL-1ra), an anti-inflammatory interleukin, on both 
angiographic and clinical restenosis (OR=0.78, 95%CI 0.63-0.97 and OR=0.73, 95%CI 
0.58-0.92, respectively). Monraats et al. have further established the important role of 
inflammatory genes in the development of restenosis. In the GENDER study, the rare 
alleles of the -260 C/T polymorphism in the CD14 gene, the 117 IIe/Thr polymorphism 
in the colony stimulating factor 2 gene (also known as granulocyte-macrophage
colony stimulating factor, GM-CSF) and the -1328 G/A polymorphism in the eotaxin 
gene were associated with decreased risk of TVR.39 Eotaxin is a chemokine which se-
lectively recruits eosinophils and was previously reported to be elevated in plasma of 
patients with advanced atherosclerosis. After coronary interventions, eotaxin levels 
increase and remain high for at least 24 hours but no longer than 3 months.40
Furthermore, the variant alleles of two promoter polymorphisms in the Tumor Ne-
crosis Factor alpha (TNF-α) gene have been shown to protect against the development 
of restenosis.41 Stented patients with the -238A/A genotype (HR=0.44, 95%CI 0.23-0.83) 
and patients with the -1031C/C genotype (HR=0.72, 95%CI 0.52-1.00) needed TVR less 
frequently. Several other inflammatory genes were shown to be involved in the process 
of restenosis in this cohort, among which interleukin 10 and caspase-1 (IL-1β converting 
enzyme).42,43 All these findings support the hypothesis that restenosis is largely (albeit 
not solely) determined by inflammation.
Genes involved in smooth muscle cell proliferation
Stents specifically aiming to inhibit inflammation (dexamethasone eluting stents) were 
not proven as effective as stents inhibiting both inflammation and cell proliferation.44 
Despite the fact that restenosis is mainly determined by proliferation and migration of 
vacular smooth muscle cells (VSMCs), relatively few studies investigated genes involved 
in proliferation, such as cell-cycle regulatory genes. A recent important finding in this 
field by Van Tiel et al.45 was an association between the -838 G/A polymorphism in 
the cyclin-dependent kinase inhibitor p27(kip1) (a key regulator of SMC proliferation) 
with ISR. Three polymorphisms concerning the p27(kip1) gene (-838C>A; -79C>T; 
+326G>T) were determined in a cohort of 715 patients undergoing coronary angioplasty 
and stent placement. Patients with the p27(kip1) -838AA genotype had a decreased 
risk of ISR (HR=0.28, 95%CI 0.10-0.77). This finding was replicated in another cohort 
study of 2309 patients (HR= 0.61, 95%CI 0.40-0.93). The -838 A allele corresponded to 
enhanced promoter activity which in turn may explain decreased SMC proliferation.
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Genetic variations in matrix metalloproteinases
Matrix metalloproteinases (MMPs) are Zn2+ -requiring proteases capable of degrad-
ing a variety of extracellular matrix components. Due to their significance in vascular 
remodeling, MMPs are suspected to play an (important) role in the pathogenesis of 
atherosclerosis and restenosis.46 Especially MMP2, MMP3 and MMP9 are potential 
players in the process of restenosis after PCI. MMP2 and MMP9 (the gelatinases) are 
produced by vascular VSMCs and degrade basement membrane components and other 
matrix proteins to allow migration and proliferation of vascular smooth muscle cells 
(VSMCs).47 They are upregulated and activated in VSMCs during intima formation in 
many different animal models for restenosis involving balloon angioplasty.47 An increase 
in MMP2 levels and activity was demonstrated in human coronary sinus blood samples 
4 and 24 hours after elective coronary angioplasty.48 This small study, in which only 
21 of 47 patients were stented, also showed an association between MMP2 levels and 
restenosis. MMP3 (stromelysin-1) expression has been found to be related to plaque-
instability in pathological studies.49 MMP3 reduces the matrix content of the vascular 
wall and is therefore expected to protect against restenosis.49 Functional studies have 
shown that the MMP3 -1612 5A/6A promoter polymorphism is associated with altered 
MMP3 expression. Carriers of the 6A/6A genotype were found to have a reduced MMP3 
expression50,51,52,53 and were at increased risk of developing restenosis  in a subset of the 
REGRESS study, in which stents were not yet frequently used,54 and in two other stud-
ies with luminal narrowing after plain balloon angioplasty.55,56 However, an association 
between the MMP3 5A/6A polymorphism could not be confirmed in a study which in-
cluded 217 stented patients. Unpublished results from the GENDER study indeed show 
no association between this polymorphism and clinical restenosis in stented patients. 
Therefore, even though matrix formation is an important process in the development of 
restenosis, variations in genes involved in matrix remodeling were infrequently investi-
gated or studies yielding negative results and were not published.
STENT MALAPPOSITION
Stent malapposition (SM), commonly detected by intravascular ultrasonography 
(IVUS), represents a separation of the stent struts from the intimal surface of the arterial 
wall (in the absence of a side branch) with evidence of blood speckles behind the struts57 
(Figure 2a). SM may be acute (present immediately after implantation), persistent (pres-
ent both immediately after implantation and at follow-up) or late-acquired (present only 
at follow-up). Acute and persistent SM are mainly procedure-driven while late-acquired 
stent malapposition (LASM) is a consequence of positive remodelling of the vessel wall 
and and/or of  plaque volume decrease behind the stent (including clot lysis or plaque 
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regression).58,59,60,61,62 The main repercussion of late SM (persistent or acquired) is stent 
thrombosis (ST).9 Independent predictors of LASM include lesion length, unstable 
angina, absence of diabetes and primary stenting in acute MI.63,59 The risk of LASM in 
patients with DES is approximately 4 times higher compared to those with BMS.9 This 
is due to the fact that in BMS, hypersensitivity to the metallic stent is mostly associated 
with restenosis, whereas in DES, the hypersensitivity to the metallic stent, the polymer 
or to the drug is associated with positive remodelling and excessive inflammation in the 
vessel wall.64
GENETIC FACTORS RELATED TO STENT MALAPPOSITION
We have previously investigated 7 polymorphisms (involved in inflammatory processes 
and related to restenosis) on the risk of LASM in SES patients.65 In total, 104 STEMI 
patients from the MISSION! intervention study62 were genotyped for the caspase-1 5352 
G/A, eotaxin 1382 A/G, CD14 260 A/G , colony stimulating factor 2 1943 C/T, IL10 
-1117 C/T , IL10 4251 C/T  and the TNF-α 1211 C/T polymorphisms. LASM occurred 
in 26/104 (25%) of patients. We found a significantly higher risk for LASM in patients 
carrying the caspase-1 (CASP1) 5352 A allele (RR= 2.32, 95% CI 1.22-4.42). In addition, 
mean neointimal growth was significantly lower in patients carrying this LASM risk al-
lele (1.6 vs 4.1%, p=0.014). The other 6 polymorphisms related to inflammation were not 
significantly related to the risk of LASM. Given the limited number of patients included 










Figure 2. Stent malapposition and thrombosis
Fig. 2 a) IVUS documented stent malapposition; b) angiographically documented stent thrombosis. 1 – lumen contour behind stent struts; 2 – 
vessel contour; 3 – stent thrombosis.
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tion between the CASP1 5352 A allele and the risk of ST was not investigated. To our 
knowledge, no other studies yet scrutinized the role of genetic variations in LASM.
STENT THROMBOSIS
Stent thrombosis (ST) (Figure 2b) is a complication which occurs in 0.8-2% of patients 
undergoing PCI and is associated with large MI and death.66 ST is categorized into 
“acute” ST (within 24 hours from stent implantation), “subacute” ST (within 1 – 30 days 
from stent implantation), “late” ST (within 30 days – 1 year) and “very late” ST (> 1 year 
after stent implantation). Subacute and acute ST are classically related to procedure pa-
rameters such as stent underdeployment (acute SM)67,68 or procedure related complica-
tions such as coronary dissections.69,70 In contrast, (very) late ST appears to be an active 
phenomenon associated with late SM (persistent or acquired),9,71 stent type9 duration 
of dual anti-platelet therapy66 and inflammation.58 Gene variations in the platelet ag-
gregation pathway, responsiveness to clopidogrel or presence of inherited thrombophilic 
disorders were associated with both acute and late ST.
GENETIC FACTORS RELATED TO STENT THROMBOSIS
Platelet receptor gene polymorphism
Platelet aggregation involves the binding of fibrinogen to the glycoprotein (GP) IIb/
IIIa receptor on the platelet surface. One polymorphism of the GP IIIa gene (PLA1/
A2 or HPA – 1a/1b) has been related to the inherited risk of coronary thrombosis.72 
Of importance, the same polymorphism had no influence on the degree of myocardial 
salvage achieved in 133 acute MI patients undergoing coronary stenting and abciximab 
administration.73 The PLA2 polymorphism is a substitution of cytosine for thymidine 
at position 1565 in exon 2. Walter et al.74 investigated the association of PLA2 allele 
with acute and subacute stent thrombosis in 318 consecutive BMS patients stented for 
coronary dissection, acute occlusion or high residual restenosis after PTCA lesions in 
by-pass grafts, and restenotic lesions. They found that patients with the PLA2 allele had 
and increased risk of stent thrombosis compared with patients homozygous for PLA1 
(OR=5.26, 95%CI 1.55-17.85). Kastrati et al.75 confirmed these findings partially in their 
prospective study including 1759 patients with stable and unstable angina pectoris. No 
difference was seen at 30 days after stent placement in terms of ST or a composite end-
point of death, MI or urgent revascularization between PLA1/A1 and PLA1/A2 carriers. 
However, the incidence of ST and the composite end-point were higher in the PLA2 
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homozygotes versus PLA1 homozygotes (8.7% vs. 1.7%, p=0.002 and 13.0% vs. 5.4%, 
p=0.06, respectively).
More recently, Sucker et al.76 assessed the relevance of prothrombotic platelet recep-
tor polymorphisms for the onset of coronary stent thrombosis in 316 patients. They 
compared the prevalence of GP Ibα, GP IIb, GP IIIa (including PLA1/A2) and GP Ia 
prothrombotic polymorphisms in patients with coronary stent thrombosis occurring 
in the first 6 month after stent implantation and healthy control subjects. Carriers of 
the above mentioned prothrombotic versions did not appear to be at any increased risk 
for stent thrombosis. Selection of patients (differences in number of elective and acute 
stent implantations) and the treatment of more complex coronary lesions in the latter 
study or the limited power might explain these discrepancies.76 Angiolillo et al.77 have 
investigated the differential platelet sensitivity between PLA1 homozygotes and PLA2 
carriers in 38 patients undergoing coronary stent implantation and receiving a 300 mg 
clopidogrel loading dose. They have shown that PLA2 carriers have a lower inhibition of 
platelet reactivity following the standard clopidogrel loading dose, which might finally 
lead to stent thrombosis.
Genetic variations in response to clopidogrel
In current practice, patients undergoing PCI and stent deployment are given 300-600 
mg clopidogrel as a loading dose followed by 1 year dual anti-platelet therapy (aspirin 
80-325 mg and clopidogrel 75 mg daily) and continued with life-long aspirin intake.
A good responsiveness to clopidogrel is therefore crucial in order to prevent throm-
botic events after stent deployment.
Clopidogrel is an inactive prodrug which requires a two-step oxidation by the hepatic 
cytocrome P450 (CYP) enzymes to transform into an active metabolite which further 
inhibits the ADP P2Y12 receptor producing the anti-aggregation effect. The genes 
encoding the CYP enzymes are polymorphic and several variants were related to a 
decreased catalytic activity and subsequent attenuated effect of the drug.
The CYP3A5 gene has a functional polymorphism which includes the expressor 
(*1) and non-expressor (*3) alleles.78,79 Suh et al.79 compared clinical outcome in 348 
patients (with stable angina, unstable angina or non-STEMI) who had PCI with BMS 
implantation. Antiplatelet therapy consisted of aspirin (100-300 mg daily, prescribed 
indefinitely) and clopidogrel (75 mg daily after 300 mg loading dose) administered for 
at least 4 weeks after the procedure. Atherothrombotic events (a composite of cardiac 
death, MI and non-hemorrhagic stroke) occurred more frequently within 6 months af-
ter stent implantation among the patients with the non-expressor genotype than among 
those with the expressor genotype (14/193 vs. 3/155, p=0.023). Moreover, the CYP3A5 
polymorphism was a predictor of athrothrombotic events in clopidogrel users.
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These findings are interesting especially since a number of studies (which did not 
aim at clinical end-points) found no association between the CYP3A5 variants and 
clopidogrel response and/or residual platelet aggregation (RPA)80,81,82 nor did a number 
of studies with clinical end-points.83,84
Trenk et al.85 investigated whether the CYP2C19 681G>A *2 polymorphism was as-
sociated with high (>14%) RPA on clopidogrel and whether high on-clopidogrel RPA 
affects clinical outcome after elective coronary stent placement. RPA was assessed in 797 
consecutive patients after a 600 mg loading dose and after the first 75 mg maintenance 
dose of clopidogrel before discharge. Patients were followed-up for 1 year. Between 
the *2 carriers and *1/*1 carriers (wild-type) the authors found significant (p<0.001) 
differences in the proportion of patients with RPA>14%, both after loading (62.4% vs. 
43.4%) and at pre-discharge (41.3% vs. 22.5%). RPA >14% at discharge was associated 
with a 3-fold increase (95%CI 1.4-6.8, p=0.004) in the 1-year incidence of death and 
myocardial infarction. However, authors could not show a direct relation between the 
CYP2C19*2 allele and clinical outcome.
This relation was demonstrated by Giusti el al.86 in a subanalysis of the RECLOSE trial. 
The role of the CYP2C19*2 polymorphism in the occurrence of DES ST (definite or 
probable) or the composite end-point of ST (definite or probable) and cardiac mortality 
within 6-month follow-up was assessed in 772 patients undergoing PCI and receiving 
either sirolimus or paclitaxel DES. Patients with ACS and STEMI were included as well 
as patients with left main disease, chronic total occlusions, bifurcation lesions or diffuse 
disease. All patients received aspirin (325 mg) and a loading dose of clopidogrel 600 mg 
before the procedure followed by a maintenance dose of clopidogrel 75 mg and aspirin 
325 mg daily. Patients with ST or ST and cardiac mortality end-point had a higher 
prevalence of the *2 allele (54.1% vs. 31.3%; p=0.025 and 51.7% vs. 31.2%; p=0.020, 
respectively). At multivariate logistic regression analysis, the CYP2C19*2 allele was 
an independent risk factor for ST (OR=3.43, 95%CI 1.01-12.78, p=0.047) and ST and 
cardiac mortality (OR=2.7, 95%CI 1.00-8.42, p=0.049).
Mega et al.83 reconfirmed these findings on long term assessment of patients from 
TRITON-TIMI 38 study. A number of 1389 patients treated with clopidogrel who 
underwent PCI and stenting were followed-up for 15 months. Patients were initially 
admitted with non-STEMI (71%) and STEMI (29%). They received a 300 mg clopidogrel 
loading dose, followed by 75 mg daily maintenance dose for up to 15 months. For the 
CYP2C19, the presence of at least one copy of the *2 allele was associated with a higher 
rate of composite death from cardiovascular causes, non-fatal MI, non-fatal stroke 
(HR=1.42, 95%CI 0.98-2.05) and of definite/probable ST (HR=3.33, 95%CI 1.28-8.62) 
than did non-carriers.
Sibbing et al.87 assessed the role of the mutant *2 allele of the CYP2C19 polymorphism 
on the 30-day incidence of definite ST in 2485 consecutive patients undergoing coronary 
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stent placement. There are a number of differences with regard to the previous study83: 
(1) STEMI patients were excluded, (2) the end-point was acute and subacute definite 
ST and (3) patients received 600 mg clopidogrel loading dose.DES were used in 25% 
and BMS in 75% of the patients. Of the patients studied, 73% were CYP2C19 wild-type 
homozygotes (*1/*1) and 27% carried at least one of the *2 allele. The cumulative 30-
day incidence of ST was significantly higher in CYP2C19*2 allele carriers vs. wild-type 
homozygotes (1.5% vs. 0.4%, HR=3.81, 95%CI 1.45-10.02, P=0.006). The risk of ST was 
highest (2.1%) in patients carrying the CYP2C19 *2/*2 genotype (p=0.002).
Recently, Collet et al.88 demonstrated the role of the CYP2C19*2 allele in 259 young 
patients (aged <45 years) who survived a first MI and received clopidogrel treatment 
for at least a month. The primary endpoint was a composite of death, MI, and urgent 
coronary revascularization occurring during exposure to clopidogrel. The secondary 
endpoint was angiography-documented stent thrombosis Median clopidogrel treatment 
duration was approximately one year. The primary endpoint occurred more frequently 
in carriers than in non-carriers (15 vs. 11 events; HR=3.69, 95%CI 1.69-8.05, P=0.0005), 
as did stent thrombosis (8 vs. 4 events; HR=6.02, 95%CI 1.81-20.04, P=0.0009). The 
effect of the CYP2C19*2 genetic variant persisted from 6 months after clopidogrel initia-
tion up to the end of follow-up (HR=3.00, 95%CI 1.27-7.10, p=0.009). The CYP2C19*2 
genetic variant appeared the only independent predictor of cardiovascular events 
(HR=4.04, 95%CI 1.81-9.02, P=0.0006).
In a study84 of 2208 patients presenting with acute MI (among which 1535 underwent 
PCI), patients carrying any two CYP2C19 loss-of-function alleles (*2, *3, *4, or *5), had 
a higher rate of death from any cause, nonfatal stroke, or myocardial infarction during 
1 year of follow-up than patients with none (21.5% vs. 13.3%; adjusted HR=1.98; 95%CI 
1.10-3.58). Among the patients who underwent PCI during hospitalization, the rate 
of cardiovascular events among carriers of CYP2C19 loss-of-function alleles was 3.58 
(95%CI 1.71-7.51).times higher than among those with none.
For the development of a risk score for better prediction of RPA, Geisler et al.81 
analyzed the CYP2C19*2 genotype and previously identified non-genetic risk factors 
(age >65 years, type 2 diabetes mellitus, decreased left ventricular function, renal 
failure and acute coronary syndrome). They demonstrated a significant correlation of 
the non-genetic factors (χ² = 5.32; P = 0.021) and CYP2C19*2 (χ²= 21.31; P < 0.0001) 
with high RPA, and the highest association for the combination of both (χ²= 25.85; P < 
0.0001). This was the first study to show that prediction of clopidogrel responsiveness 
may substantially be improved by adding CYP2C19*2 genotype to non-genetic risk fac-
tors. The important influence of the CYP2C19*2 genotype over platelet function and 
cardiovascular outcomes was recently confirmed by Shuldiner et al.89 in the first GWAS 
paper identifying CYP2C19 as a candidate gene. In the Pharmacogenomics of Antiplate-
let Intervention (PAPI) Study, clopidogrel was administered for 7 days to 429 healthy 
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individuals and the response was measured by ex vivo platelet aggregometry. A GWAS 
was performed followed by genotyping the loss-of-function cytochrome CYP2C19*2 
variant. The relation between CYP2C19*2 genotype and platelet aggregation was repli-
cated in 227 clopidogrel-treated patients undergoing PCI (P = 0.02). Patients with the 
CYP2C19*2 variant were more likely (20.9% vs 10.0%) to have a cardiovascular ischemic 
event or death during 1 year of follow-up (HR=2.42, 95%CI 1.18-4.99, P = 0.02).
Factor V Leiden mutation
Factor V Leiden is the most common inherited thrombophilic disorder, resulting from 
a single mutation (1691 G>A) in the factor V gene. Individual heterozygous for this 
mutation are at increased risk for venous thrombosis, and in homozygous the risk be-
comes extremely high. Although conceivable, there is only one case report to document 
a possible relation between a factor V Leiden heterozygous patient and stent thrombosis 
(simultaneous occlusion of two stents, one in left anterior descending artery and one 
in the right coronary artery at 4 days after implantation in a patient receiving standard 
dual anti-platelet therapy).90 Further larger studies are therefore needed before factor V 
Leiden may be linked to ST.
LIMITATIONS
Many studies have managed to identify genes and polymorphisms involved in the post-
stenting outcome after scrutinizing various plausible pathophysiologic mechanisms. 
However, to predict an accurate scale of adverse effects, an interaction assessment 
between genetic, non genetic (traditional risk factors) as well as epigenetic factors is of 
extreme importance. This information remains momentarily scarce. .
Also of importance, findings from certain studies cannot sometimes be confirmed by 
other studies. This is largely explained by variation in study settings and therefore the 
replication of findings in independent studies needs to be further emphasized.
The candidate gene approach used to date in the majority of investigations narrows 
the results to specific areas of interest.
CONCLUSION
In-stent restenosis and stent thrombosis remain important limitations of the current 
PCI practice. Besides the procedure-related risk factors and medication, solid evidence 
shows that patient’s own response to stent implantation influences the outcome. Indi-
vidual genetic response involves inflammation, cellular proliferation, platelet receptors 
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and drug metabolism pathways. A better understanding of the stent pathology has lead 
to the identification of new important genes and genetic polymorphisms. They may help 
us better identify the vulnerable patients who need extraordinary therapeutic measures. 
Conversely, genetic-epidemiologic studies have identified genes which subsequently 
have revealed important pathophysiologic mechanisms.
FUTURE PERSPECTIVES
The speed by which new genes are being related to stent pathology is matched by the 
speed of new developments in stent technology and medication. Novel pharmacoge-
nomic approaches (such as GWAS, 1000 genome project91 etc) may help to identify 
unknown genetic factors for a better prediction of outcome after stent implantation.
It is however difficult to estimate whether screening for established polymorphisms 
will prove in the future a cost-effective method for a better stent type selection or medi-
cation in the daily routine.
The classic stents seem to rapidly make place to new and complex body-polymer-drug 
constructions that address most, if not all, of the current problems. The new genera-
tion of stents may appear capable of modulating local inflammation, to permit a good 
re-endothelization, to prevent stent thrombosis, to reduce the duration of anti-platelet 
medication and, if necessary, even to degrade after local healing is achieved.
New drugs such as prasugrel, ticagrelor and cangrelor seem to effectively inhibit plate-
let aggregation with no or little inter-individual response variability. The combination of 
lessons learned form genetic and pathophysiologic studies, the newly available resources 
(stents, antiplatelet drugs, imagistic) and refined implantation techniques will definitely 
improve PCI performances and extend its use.
EXECUTIVE SUMMARY
Genetic variants associated with an increased or decreased risk of in-stent restenosis 
(ISR) and stent thrombosis (ST)
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In-stent restenosis (ISR)
 Ø Genetic variations in thrombus formation
  Associated with decreased risk:
  Factor V 1691G>A (factor V Leiden) amino acid substitution
  Associated with increased risk:
  4G allele of the PAI-1 4G/5G polymorphism
 Ø Genetic variations in inflammatory factors
  Associated with decreased risk:
  *2 allele of the IL-1ra gene
  T /T genoype of the CD14-260 C/T polymorphism
  Thr allele of the CSF2-117 Ile/Thr polymorphism
  A allele of the CCL 11 (Eotaxin) 1328 G/A polymorphism
  A/A genotype of the TNF -238 G/A polymorphism
  C/C genotype of the TNF -1031 T/C polymorphism
  Associated with increased risk:
  A/A genotype of the IL-10 -2849 G/A polymorphism
  A/A genotype of the IL-10 -1082 G/A polymorphism
  G/G genotype of the IL-10 +4259 A/G polymorphism
  A/A genotype of the Caspase-1 5352 G/A polymorphism
 Ø Genes involved in smooth muscle cell proliferation
  Associated with decreased risk:
  A/A genotype of the p27(kip1)-838G/A polymorphism
Stent thrombosis (ST)
 Ø Platelet receptor gene polymorphism
  Associated with increased risk:
  PLA2 allele of the GP IIIa PLA1/A2
 Ø Genetic variations  in  response to clopidogrel
  Associated with increased risk:
  *3 allele of the CYP3A5 gene (encodes hepatic cytocrome P450 CYP enzymes)
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Since activation of the hemostatic system is an important feature of the wound healing 
response triggered by arterial injury, variations in genes involved in thrombus formation 
may play a role in restenosis after percutaneous coronary interventions (PCI).
Therefore, our aim was to examine the relationship between polymorphisms that 
are known to play a role in the hemostatic system and the risk of clinical restenosis in 
the GENetic DEterminants of Restenosis (GENDER) study, a multicenter prospective 
study design that enrolled 3,104 consecutive patients after successful PCI. Target Vessel 
Revascularization (TVR) was the primary endpoint. All patients were genotyped for 6 
polymorphisms in the Factor II, Factor V, Factor VII and PAI-1 genes.
The PAI-1 4G variant was associated with an increased risk of TVR. When compared 
to 5G/5G homozygotes, heterozygous patients were at higher risk for TVR (HR: 1.46, 
95%CI: 1.05-2.03), whereas patients with the 4G/4G genotype had an even further 
increased risk (HR: 1.69, 95%CI: 1.19-2.41). In contrast, the factor V 506Gln (Factor V 
Leiden) amino acid substitution was associated with a decreased risk of TVR (HR: 0.41, 
95%CI: 0.19-0.86).
Our findings indicate that polymorphisms in the Factor V and PAI-1 genes may play 
a role in the process of restenosis.
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INTRODUCTION
Restenosis has always been a major limitation to the long term benefit of percutaneous 
coronary intervention (PCI). Despite the reduction in restenosis rates obtained by stent-
ing and the use of drug-eluting stents, the incidence of restenosis remains a significant 
problem. Moreover, the development of these increasingly protective, but more expen-
sive treatment options raises the need to stratify patients with regard to their risk for 
restenosis and to tailor individual treatment. Thus far, it has proven insufficient to make 
this stratification on the basis of clinical or procedural risk factors.1 A promising tool to 
improve risk stratification may be found in a search for genetic risk factors, which may 
also provide targets for more effective therapy.
Injury to the vessel wall after PCI causes thrombus formation and subsequent invasion 
of leucocytes, followed by expression of growth factors and cytokines, leading to altera-
tions in matrix composition and migration and proliferation of vascular smooth muscle 
cells (VSMCs). There is increasing evidence that polymorphisms in genes involved in 
inflammation and matrix formation are associated with the risk of restenosis.2 However, 
the relevance of factors involved in thrombus formation remains uncertain, also because 
high doses of platelet-inhibitors are given at the time of the PCI to prevent acute stent 
thrombosis. The purpose of this study was to evaluate in a large unselected patient 
population whether polymorphisms in genes known to be of clinical importance with 
respect to thrombosis, predict the risk of clinical restenosis after PCI.
METHODS
Study design
The present study sample has been described previously.3-5 In brief, the GENetic DEter-
minants of Restenosis project (GENDER) was designed to study the association between 
various gene polymorphisms and clinical restenosis, defined in our study by Target 
Vessel Revascularization (TVR). Patients were eligible for inclusion if they were success-
fully treated by PCI for stable angina, non-ST-elevation acute coronary syndromes or 
silent ischemia. Patients treated for acute ST elevation myocardial infarction (MI) were 
excluded. All patients were treated in four referral centers for interventional cardiology 
in the Netherlands (Academic Medical Center Amsterdam, University Medical Center 
Groningen, Leiden University Medical Center and Academic Hospital Maastricht). The 
inclusion period lasted from March 1999 until June 2001. In total, 3177 consecutive 
patients were included in this prospective multicenter follow-up study. Patients were 
considered to be diabetic if they were using oral anti-diabetic medication (N=303) or 
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insulin (N=150) at study entry. Smokers were defined as individuals who smoked within 
the month preceding the PCI.
The study protocol conforms to the Declaration of Helsinki and was approved by the 
Medical Ethics Committees of each participating institution. Written informed consent 
was obtained from each participant before the PCI procedure.
PCI procedure
Standard angioplasty and stent placement were performed by experienced operators 
using a radial or femoral approach. Before the procedure patients received aspirin (300 
mg) and heparin (7500 IU). The use of intracoronary stents and additional medication, 
such as glycoprotein IIb/IIIa inhibitors, was at the discretion of the operator. When a 
stent was implanted, patients received either ticlopidine or clopidogrel for at least one 
month following the procedure depending on local practice. During the study no drug-
eluting stents were used.
Follow-up and study endpoints
Follow-up lasted at least nine months or until a coronary event occurred. Patients were 
either seen in the outpatient clinic or contacted by telephone. TVR, either by PCI or 
coronary artery bypass grafting (CABG), was considered as the primary endpoint, since 
it is considered most relevant for clinical practice by regulatory agencies. An indepen-
dent clinical events committee adjudicated the clinical events. Since the purpose of this 
study was to examine the risk of restenosis, and not sub-acute stent thrombosis, events 
occurring within one month after the procedure were excluded from the analysis. Data 
were collected with standardized case-report forms that were completed by the research 
coordinator at each site who was blinded to the genotype of the patients. Representatives 
from the data-coordinating center monitored the sites.
Genetic methodology
Blood was collected in EDTA tubes at baseline and genomic DNA was extracted fol-
lowing standard procedures. Six polymorphisms; PAI-1 -695 4G/5G, PAI-1 11053 T/G 
(rs7242), Factor II (prothrombin) 20210 G/A, Factor V G1691A Arg506Gln (Factor V 
Leiden, rs6025), Factor VII -323 del/ins (CCTATATCCT) and Factor VII Arg353Gln 
(rs6046) were determined by a validated multilocus genotyping assay (Roche Molecular 
Systems). All polymorphisms were selected for their previously described association 
with thrombotic cardiovascular disease or with the concentration of proteins involved 
in hemostasis.
Each DNA sample was amplified in multiple polymerase chain reactions (PCRs) 
using biotinylated primers. The PCR product was then hybridised to a corresponding 
panel of sequence-specific oligonucleotide probes that had been immobilized in a linear 
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array on nylon membrane strips.6 A colorimetric detection method based on incuba-
tion with streptavidin-horseradish peroxidase conjugate, using hydrogen peroxide and 
3,3’,5,5’-tetramethylbenzidine as substrates, was used. Operators blinded to patient data 
performed genotyping. To confirm genotype assignments, PCR analysis was randomly 
replicated on 10% of the samples. Two independent observers carried out scoring. Dis-
agreements (<1%) were resolved by further joint reading, and when necessary a repeat 
genotyping reaction was performed.
Statistical methodology
Allele frequencies were determined by gene counting. The 95% confidence intervals of 
the allele frequencies were calculated from sample allele frequencies based on the ap-
proximation of the binominal and normal distributions in large sample sizes.
In the first stage we determined the association between each of the 6 polymorphisms 
and TVR using a Cox proportional regression model. If less than 50 patients were ho-
mozygous for the minor allele, the homozygotes and heterozygotes were combined. No 
adjustment for covariates was performed at this stage to allow for the assessment of the 
possible involvement of the polymorphisms in the causal pathway of TVR.
Finally, polymorphisms with independent prognostic value were selected in a multi-
variable regression model, also containing clinical and procedural risk factors. Statistical 
analyses were carried out using SPSS 12 (SPSS Inc., Chicago, IL).
RESULTS
Patient characteristics
The characteristics of this patient sample have been described previously.3 In summary, 
3509 patients were eligible for the study of which 3177 were included. A total of 3146 
patients had a complete follow-up (99.3%) with a median duration of 9.6 months (in-
terquartile range 3.9). Out of 3146 patients 42 had an event in the first 30 days. These 
patients were excluded from further analysis, according to the protocol. The remaining 
3104 patients had a mean age of 62.1 ± 10.7  years. Of the patients 888 (28.6%) were 
women, and 453 (14.6%) had diabetes mellitus. The majority of the patients were Cau-
casian (97%) and stents were used in 2309 (74.4%) patients. Nearly all patients received 
either clopidogrel (n=2076) or ticlopidin (n=1016) and 812 patients (26.2%) received 
glycoprotein IIb/IIIa inhibitors. A total of 4061 lesions were treated in this unselected 
patient sample. Complex (type C) lesions, classified according to the modified American 
College of Cardiology and American Heart Association Task Force classification, were 




Of the 3104 patients, 304 (9.8%) patients underwent TVR during follow-up. Fifty-one 
patients died (1.6%) and 22 (0.7%) suffered from MI. Genotype distributions and minor 
allele frequencies of the polymorphisms are shown in table 1. For the PAI-1 4G/5G, 
PAI-1 11053 T/G , Factor II 20210 G/A, Factor V Arg506Gln, Factor VII -323 del/ins 
and Factor VII Arg353Gln polymorphisms genotyping was successful in 3018, 3063, 
3059, 3044, 3053 and 3045 patients, respectively. Patients with unknown genotype, due 
to unavailable DNA or inconclusive genotyping, did not differ in any characteristic from 
patients who were successfully genotyped. All genotype distributions were consistent 
with HWE (p>0.05). The low frequency of the Factor II 20210A, the Factor V Leiden 
506Gln, the Factor VII -323ins and the Factor VII 353Gln alleles has prompted us to 
pool heterozygotes and homozygotes for these variants as specified in the statistical 
approach.
Table 1. Allele frequencies, genotype distributions and individual analysis of polymorphisms in association with TVR
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Univariate Cox regression shows that the PAI-1 4G/5G polymorphism and the Factor 
V Arg506Gln polymorphism were significantly associated with TVR. When compared 
to 5G/5G homozygotes, heterozygous patients were at higher risk for TVR (HR: 1.46, 
95%CI: 1.05-2.03), whereas patients with the 4G/4G genotype had an even further in-
creased risk (HR: 1.69, 95%CI: 1.19-2.41). In contrast, TVR was less frequent in carriers 
of the Factor V Leiden 506Gln variant, than in patients without the Factor V Leiden 
mutation (HR: 0.41, 95%CI: 0.19-0.86). None of the other variants were associated with 
the risk for TVR (Table 1).
After adjustment for possible confounders, such as age, sex, hypertension, diabetes, 
current smoking, stenting, total occlusion and residual stenosis>20%, both the PAI-1 
4G/5G and the Factor V Leiden polymorphisms remained predictors of TVR (HR: 1.26, 
95%CI: 1.07-1.49 and HR: 0.40, 95%CI: 0.19-0.85, respectively) (Table 2).
Diabetes
Diabetic patients are known to have increased levels of PAI-17,8 and PAI-1 dependent 
mechanisms have been implicated in the pathogenesis of insulin resistance and type 
2 diabetes.9 Therefore, we performed separate analyses in a prespecified subgroup of 
patients with diabetes. Mean glucose levels were 9.4 (sd 4.3) mmol/L in diabetic patients 
versus 5.8 (sd 1.4) in patients without diabetes (p<0.001). At follow-up 63 patients 
(13.9%) in the diabetic group (N=543) versus 241 (9.1%) in the non-diabetic group 
(N=2651) had to undergo TVR. Cox regression showed an association of diabetes with 
TVR (HR: 1.6, 95%CI: 1.2-2.1).
Despite clues for an interaction between insulin levels and the PAI-1 4G/5G poly-
morphism in risk of myocardial infarction,10 the effect of this polymorphism on TVR 
risk was similar in patients with and without diabetes (Table 3). However, there was 
a remarkable difference for the PAI-1 11053 T/G polymorphism. The hazard ratio for 
this polymorphism was higher in the group of patients with diabetes (HR: 1.41, 95%CI: 
Table 2. Multivariable Cox regression of polymorphisms associated with TVR, including clinical factors
HR 95% CI
Age 0.99 0.98 1.00
Sex 0.96 0.74 1.25
Diabetes 1.51 1.14 2.01
Hypertension 1.21 0.96  1.53
Current smoker 0.71 0.53 0.96
Stenting 0.78 0.59 1.02
Total occlusion 1.46 1.09 1.97
Residual stenosis>20% 1.36 0.97 1.90
FV Arg506Gln 0.40 0.19 0.85
PAI-1 4G/5G 1.26 1.07 1.49
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0.98-2.04) than in the group of patients without diabetes (HR: 1.03, 95%CI: 0.85-1.23) 
(Table 3), but did not reach statistical significance (p=0.066).
Smoking
Since it was suggested that smoking carriers of the PAI-1 5G/5G genotype are predis-
posed to develop restenosis,11 we stratified our population in current smokers and non-
smokers. From the literature it is known that smokers have a decreased risk of restenosis. 
Also in our study, current smokers were at reduced risk to develop restenosis (HR 0.77, 
95%CI: 0.6-1.0). At follow-up 62 (8.1%) smokers (N=762) versus 242 (10.3%) non-
smokers (N=2342) had to undergo TVR. Carriership of PAI-4G was associated with 
TVR occurrence in smokers and non-smokers alike, with a slightly higher hazard ratio 
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in smokers (HR: 1.5, 95%CI: 1.1-2.2) than in non-smokers (HR: 1.2, 95%CI: 1.0-1.5) 
(Table 3).
DISCUSSION
In a large prospective multicenter follow-up study, we investigated 6 polymorphisms in 
hemostatic genes that may also play a role in clinical restenosis. In our study, the PAI-1 
4G variant is associated with an increased risk of TVR after PCI, and carriership of the 
Factor V Leiden 506Gln amino acid substitution is associated with a decreased risk of 
TVR.
Since the PAI-1 4G variant has been shown to be associated with higher PAI-1 levels 
in plasm12-14 and in tissue,15-17 our data suggest that PAI-1 promotes neointima prolif-
eration. This hypothesis for the role of PAI-1 is supported by a number of reports on a 
positive correlation between post-PTCA PAI-1 levels or activity and restenosis,18-23 but 
contradicted by one study which could not find an association between the PAI-1 4G/5G 
polymorphism and restenosis.24
Several underlying mechanisms by which PAI-1 could influence the process of reste-
nosis have been reported. Firstly, PAI-1 prevents the degradation of fibrin by inhibiting 
the formation of plasmin. Since fibrin is a provisional matrix for the invasion of VSMCs 
and may directly stimulate VSMC proliferation,25 inhibiton of fibrin degradation could 
promote restenosis. On the other hand, it has been suggested that PAI-1 has a protective 
role because of its inhibitory actions in the migration and proliferation of VSMCs and 
the invasion of inflammatory cells.26 However, data on the role of PAI-1 in cell migration 
are conflicting.25,27 PAI-1 can regulate cell migration by several mechanisms and the 
net effect has been suggested to depend on the composition of the local environment 
and PAI-1 levels.27 Furthermore, aortic VSMCs from PAI-1 knockout mice have been 
shown to be more susceptible to plasmin-induced apoptosis than VSMCs from wild type 
mice,28 which also fits into the hypothesis that PAI-1 promotes neointima formation.
Factor V Leiden was associated in our study with protection against clinical resteno-
sis. In a study by Volzke et al.,29 this association was not observed, but their study had 
limited statistical power and the genotype distribution of the Factor V Leiden polymor-
phism was not in Hardy-Weinberg equilibrium. The Factor V Leiden polymorphism is a 
well-known risk factor for venous thrombosis. The Arg506Gln amino acid substitution 
at the APC cleavage site in the heavy chain of Factor V leads to APC resistance and 
subsequently to increased production of thrombin and fibrin. Apart from its role in 
venous thrombosis, Factor V Leiden has also been found to be moderately associated 
with the risk of myocardial infarction.30, 31 Then, what could be the explanation for a 
protective effect of a well established prothrombotic factor in the process of restenosis?
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Carriers of the Factor V Leiden mutation were found to have a survival advantage 
when suffering from severe sepsis.32 The underlying mechanism may be an increased 
production of thrombin and activated protein C (APC) in Factor V Leiden carriers.32 
In concordance with this hypothesis, the PROWESS trial demonstrated that treatment 
with human recombinant APC reduced mortality in patients with severe sepsis.33
The beneficial effect of APC in sepsis may in part be explained by its strong anti-
inflammatory properties.34 It inhibits the release of TNF, blocks leukocyte adhesion 
and interferes with monocyte activation.35 Since inflammation is a main determinant of 
neointima formation,36,37 APC could protect against the development of restenosis via 
similar mechanisms.
Diabetes
Although diabetic patients are known to have an increased risk of developing restenosis, 
there is not yet a genetic explanation for their enhanced susceptibility. Polymorphisms 
can be responsible for differences in gene expression in response to their altered meta-
bolic state. In order to identify polymorphisms that selectively increase the risk of TVR 
in diabetics, we repeated the analysis of the PAI-1 polymorphisms in a prespecified 
subpopulation of diabetics. Although differences did not reach statistical significance, 
our data show a tendency towards a higher TVR risk associated with the 11053G allele, 
only in patients with diabetes. Although there is no evidence yet on the functionality of 
the 11053 T/G polymorphism, we do know that metabolic circumstances can induce 
PAI-1 expression. High glucose has been shown to induce PAI-1 expression in human 
adipose tissue.38,39 Furthermore, PAI-1 plasma levels seem to be determined by glucose 
in humans.7,8 Polymorphisms in the PAI-1 gene could alter gene expression in response 
to these factors.
Smoking
In agreement with our results, Ortlepp et al. have demonstrated that the PAI-1 5G allele 
lowered the risk of restenosis in non-smokers.11 However, we could not confirm their 
finding that the 5G allele increased the risk for restenosis in smokers. We found similar 
hazard ratios in smokers and non-smokers. The discrepancy could be due to the small 
population of smoking 5G homozygotes in their study (N=42).
Limitations of the study
In our study we lack data on PAI-1 and APC concentration and activity in plasma. How-
ever, we believe that our data do not suffer from this due to a number of reasons. In the 
first place, the PAI-1 4G/5G polymorphism is known to be functional. The functionality 
of PAI-1 has been extensively investigated and the majority of results indicate that the 
4G variant leads to higher expression levels.12,13, 15-17 In contrast, little evidence is avail-
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able regarding APC levels in Factor V Leiden carriers and carriers of the PAI-1 4G/5G 
genotypes. P. Weiler et al. observed only marginal augmentation of protein C activation 
in Factor V Leiden-mice.40 In their human studies, augmentation of APC levels was 
not detectable with the sensitivity of the employed assay. In our study, circulating APC 
protein levels were not assessed since basal (pre-PCI) plasma measurements of the gene 
product are not likely to reflect the genetically determined differences in reaction to a 
local trauma such as PCI. Furthermore, local differences in PAI-1 and APC sensitive 
reactions, such as occurring in the vessel wall at the site of PCI, cannot be measured 
systemically, as it is not yet possible to measure gene products in the vessel wall locally 
in the acute phase of treatment and the following days.
Conclusion
In conclusion, our data suggest that the PAI-1 4G allele, which is known to be associated 
with higher PAI-1 levels, increases the risk of clinical restenosis, while carriership of 
the Factor V Leiden allele reduces the risk of clinical restenosis after PCI. As Factor 
V Leiden, an established prothrombotic risk factor, seems associated with a decreased 
risk of restenosis, it may be considered that this polymorphism may also play a role in 
restenosis by mechanisms not involved in coagulation.
After confirmation of our results, genotyping for the Factor V Leiden and PAI-1 
4G/5G polymorphisms may lead to better risk stratification and more tailored therapy 
in the prevention of restenosis after PCI. Furthermore, our results could contribute to 
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Introduction: FSAP is a plasma serine-protease that is localized within atherosclerotic 
lesions. The FSAP-Marburg I polymorphism (G534E), which reduces FSAP activity, 
has been shown to be associated with late complications of carotid stenosis in humans 
and with a reduced capability to suppress vascular smooth muscle cell proliferation and 
neointima formation in an animal model. Therefore we investigated the influence of the 
Marburg I polymorphism and the closely linked Marburg II polymorphism (E393Q) on 
various cardiovascular outcomes in two independent large study populations.
Methods: The Marburg I and Marburg II polymorphisms in the HABP2 gene encoding 
FSAP, were genotyped in a large population of elderly patients at risk for vascular disease 
(the PROSPER-study, n=5804) and in a study population treated with a percutaneous 
coronary intervention (the GENDER-study, n=3104). Associations between the Mar-
burg I and II polymorphisms and various cardiovascular outcomes were assessed with 
Cox-regression adjusted for sex and age.
Results: The Marburg I polymorphism was associated with an increased risk of clinical 
stroke (HR: 1.60, 95%CI: 1.13-2.28) and all-cause mortality (HR: 1.33, 95%CI: 1.04-
1.71) in the PROSPER study. On the other hand, carriers of this variant seemed at lower 
risk of developing restenosis (HR: 0.59, 95%CI: 0.34-1.01) in the GENDER study. The 
Marburg II polymorphism is in linkage disequilibrium with the Marburg I polymor-
phism and indeed showed therefore similar, although weaker results.
Discussion: The observed increase in stroke risk in Marburg I carriers could be a con-
sequence of differential effects on smooth muscle cells as well as on matrix metallopro-
teinases, thereby influencing plaque stability. The possible protective effect on restenosis 
could be the result of reduced activation of zymogens such as pro-urokinase or matrix 
metalloproteinases which are involved in haemostasis and matrix remodeling.
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INTRODUCTION
Factor seven activating protease (FSAP) is a plasma serine-protease which is known to 
activate factor VII (FVII)1 and pro-urokinase (pro-uPA).2 Despite these actions, it is 
unclear if endogenous FSAP has a relevant role in haemostasis. The Marburg I (G534E) 
polymorphism in the HABP2 gene encoding FSAP, which leads to an amino-acid change 
in the protease domain of this protein, may lead to a pro-thrombotic phenotype when 
it is associated with reduced activation of pro-uPA, but unchanged activation of FVII.3 
Although its possible association with venous thrombosis remains controversial,4-6 the 
Marburg I variant has been shown to be a risk factor for late complications of carotid 
stenosis7 and coronary heart disease.8
Furthermore, FSAP has been identified as a potent inhibitor of smooth muscle cell 
proliferation and migration,9 specifically through its ability to cleave platelet derived 
growth factor-BB (PDGF-BB). The FSAP-Marburg I variant, which also has reduced 
proteolytic activity towards PDGF-BB, has been shown to be associated with a reduced 
capability to suppress neointima formation in an animal model.10 This might be another 
mechanism by which the Marburg I polymorphism could play a role in carotid stenosis 
and many other aspects of cardiovascular disease.11
Therefore, we investigated the influence of this polymorphism on clinical stroke, 
coronary events, vascular mortality and all-cause mortality in a large population of 
elderly patients at risk for vascular disease (the PROSPER-study, n=5804) and on clini-
cal restenosis after a percutaneous coronary intervention (the GENDER-study, n=3104). 
Although it is not associated with altered enzymatic activity, we also investigated the 
Marburg II variant (E393Q), a closely linked polymorphism that leads to an amino acid 
change in the protease domain of FSAP.
METHODS
Study design and follow-up of the PROSPER study
The protocol of PROSPER has been described in more detail elsewhere.12 PROSPER is 
a prospective multicenter randomized placebo-controlled trial to assess whether treat-
ment with pravastatin diminishes the risk of major vascular events in elderly individuals. 
Between December 1997 and May 1999, we screened and enrolled subjects in Scotland 
(Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men and women aged 70-82 
years were recruited if they had pre-existing vascular disease or increased risk of such 
disease because of smoking, hypertension, or diabetes. A total number of 5804 subjects 
were randomly assigned to pravastatin or placebo. In this genetic sub-study, we evalu-
ated the predefined endpoints all-cause mortality,  vascular mortality, and the secondary 
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endpoints fatal or non-fatal coronary events and fatal or non-fatal clinical stroke. Mean 
follow-up was 3.2 years (range 2.8-4.0) and 604 (10.4%) patients died during the study.13
Study design and follow-up of the GENDER study
The present study sample has been described previously.14 In brief, the GENetic DEter-
minants of Restenosis project (GENDER) was a multicenter follow-up study designed 
to study the association between various gene polymorphisms and clinical restenosis. 
A total number of 3104 patients eligible for inclusion in the GENDER-study were 
treated successfully for stable angina, non-ST-elevation acute coronary syndromes or 
silent ischemia by PCI in four out of 13-referral centers for interventional cardiology 
in the Netherlands. Patients treated for acute ST elevation myocardial infarction were 
excluded. Experienced operators, using a radial or femoral approach, performed stan-
dard angioplasty and stent placement. During the study, no drug-eluting stents were 
used. Follow-up lasted for at least nine months, except when a coronary event occurred. 
The primary endpoint was clinical restenosis, defined as target vessel revascularization 
(TVR), either by PCI or coronary artery bypass grafting (CABG). Median follow-up 
duration was 9.6 months (interquartile range 3.9) and 304 (9.8%) patients underwent 
TVR during follow-up.
For both studies, all endpoints were adjudicated by independent clinical events com-
mittees. The protocols meet the criteria of the Declaration of Helsinki and were approved 
by the Medical Ethics Committees of each participating institution. Written informed 
consent was obtained from all participating patients.
Genotyping
Blood was collected in EDTA tubes at baseline and genomic DNA was extracted fol-
lowing standard procedures. The Marburg I and II polymorphisms were determined 
using the Sequenom Massarray genotyping platform. A multiplex assay was designed 
using Assay designer software (Sequenom). As quality controls, 5-10% of the samples 
were genotyped in duplo. No inconsistencies were observed. Cluster plots were made 
of the signals from the low and the high mass allele. Two independent researchers car-
ried out scoring. Disagreements or vaguely positioned dots produced by Genotyper 4.0 
(Sequenom Inc.) were left out of the results.
Statistical analysis
Allele frequencies were determined by gene counting. The Chi-squared test was used to 
test the consistency of the genotype frequencies at the SNP locus with Hardy-Weinberg 
equilibrium. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated 
using a Cox-proportional hazards model. All analyses were adjusted for sex and age. 
The analyses with PROSPER data were additionally adjusted for pravastatin use and 
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country. In the GENDER-study, polymorphisms were included in a multivariable model 
containing clinical and procedural risk factors for restenosis, such as diabetes, smoking, 
hypertension, stenting, total occlusion and residual stenosis >20%. The SPSS software 
(version 12.0.1, SPSS Inc, Chicago, ILL) was used for all statistical analyses.
RESULTS
The PROSPER Study
Patient characteristics and minor allele frequencies are presented in table 1. Genotyping 
success rates were 98 % and 97 % for the Marburg I and II polymorphisms respectively 
and there were no significant deviations from Hardy-Weinberg equilibrium.
Using a Cox proportional hazards model, which included the variables sex, age, 
pravastatin use, and country, we found a significant association of the Marburg I poly-
morphism with clinical stroke. As presented in figure 1, the combined group of hetero-
zygotes (n=518) and homozygotes (n=17) was at increased risk for clinical stroke (HR: 
1.6, 95%CI: 1.13-2.28, p=0.009) when compared to the wild type group (n=5161). Also 
all-cause mortality was significantly higher in patients carrying one or two copies of 
this variant (HR: 1.33, 95%CI: 1.04-1.71, p=0.025). The increased mortality was mainly 
a result of an increase in vascular mortality (HR: 1.37, 95%CI: 0.96-1.97, p=0.082), 
whereas vascular mortality was mainly determined by death from stroke. The Marburg I 





Continuous variates (mean, SD)
    Age (years) 75.3 (3.3) 62.1 (10.7)
    Body mass index, (kg/m2) 26.8 (4.2) 27.0 (3.9)
Categorical variates (n, %)
    Male sex 2804 (48) 2216 (71)
    Current smoker 1558 (27) 762 (25)
    History of diabetes 623 (11) 453 (15)
    History of hypertension 3592 (62) 1259 (41)
    History of myocardial infarction 776 (13) 1239 (40)
    History of stable angina 1559 (27) 2079 (67)
Genotype, minor allele frequency (%)
    Marburg I G/A * 5 5
    Marburg II G/C ** 2 2
All data are presented in number (%) unless otherwise stated.
* In PROSPER and GENDER measured in 5583 and 2949 participants, respectively.
** In PROSPER and GENDER measured in 5595 and 2953 participants, respectively.
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polymorphism did not seem to influence the risk for coronary events (HR: 0.98, 95%CI: 
0.75-1.29).
Due to its location in the same coding sequence and its proximity to the Marburg 
I polymorphism we also present data of the Marburg II polymorphism which show 
significant effects on mortality (Figure 2). The similar trends that were observed for 





Figure 1. Marburg I hazard ratios for vascular endpoints in GENDER and PROSPER
The Marburg I (G534E) polymorphism is associated with an increased risk for stroke and mortality in the PROSPER study whereas it tends to 





Figure 2.  Marburg II hazard ratios for vascular endpoints in GENDER and PROSPER
As the Marburg II polymorphism does not lead to altered enzymatic activity, the similar trends that were observed for this variant are probably 
a result of the high linkage disequilibrium between the Marburg variants. Despite high confidence intervals, a significant effect was observed 
on mortality.
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Marburg variants. The LD-coefficient was 0.79 and 62% of Marburg II carriers were also 
genotyped with the Marburg I allele. Due to a lower allele frequency of the Marburg II 
polymorphism there were only 234 heterozygotes and 4 homozygotes with the variant 
allele. The large confidence intervals indeed indicate that these results are less reliable 
than the Marburg I findings.
The GENDER Study
Patient characteristics and minor allele frequencies are presented in table 1. Genotyping 
success rates were 95 % for both polymorphisms and there were no significant devia-
tions from Hardy-Weinberg equilibrium.
In contrast with the results from the PROSPER study, the Marburg I polymorphism 
tended to reduce the risk for clinical restenosis in the GENDER study (Figure 1, HR: 
0.59, 95%CI: 0.34-1.01, p=0.061). The protective effect was borderline significant. Car-
riership of the Marburg II variant only slightly and non-significantly reduced the risk of 
TVR (Figure 2).
DISCUSSION
Our data suggest that the Marburg I polymorphism, which leads to less FSAP-activity, 
increases stroke risk and mortality. The observed Marburg I associated increase in mor-
tality was mainly due to an increased risk of fatal stroke. Surprisingly, carriers of this 
variant seemed at lower risk of developing restenosis.
Although FSAP was originally identified as a potential activator of Factor VII and 
pro-urokinase (pro-uPA), its role in haemostasis remains unclear. Endogenous FSAP, 
of which intravascular levels are low, has not been clearly shown to influence blood 
coagulation or fibrinolysis.11 Moreover, earlier studies showed that the Marburg I poly-
morphism does not seem to influence the risk for venous thrombosis.6, 15 However, FSAP 
cleaves PDGF-BB and has been shown to inhibit vascular smooth muscle cell prolifera-
tion and migration in vitro9 and in vivo.10 The activity of FSAP in Marburg carriers is low 
and could therefore be a risk factor for atherosclerosis and restenosis, processes which 
are known to be determined by vascular smooth muscle cell proliferation.
A possible role for FSAP in human atherosclerosis was suggested by a study show-
ing an association of the Marburg I polymorphism with advanced atherogenesis in the 
carotid arteries.7 Despite the low number of carriers among cases (n=8) and controls 
(n=2), their findings suggest a role for Marburg I in carotid plaque formation. Another 
study, investigating the effect of Marburg I on coronary heart disease, could not find 
a significant effect in the whole population, but observed an interactive effect on risk 
between the Marburg I variant and elevated levels of cholesterol and triglyceride.8 The 
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primary endpoint in this study was a composite of myocardial infarction and the need 
for a PCI.
In agreement with these previous studies we also found no association of Marburg I 
with myocardial infarction in the whole population of patients taking part in PROSPER 
study, whereas we did find a significant association with stroke, which is known to be 
related to carotid plaque formation. The observed increase in stroke risk in Marburg I 
carriers could be a consequence of hyper-proliferation of smooth muscle cells, due to a 
reduced proteolytic activity of Marburg I-FSAP towards PDGF-BB.
The possible protective effect of Marburg I on clinical restenosis in patients treated 
for stable angina pectoris is difficult to explain. Despite some similarities between 
atherosclerosis and restenosis, such as the involvement of inflammation and smooth 
muscle cell proliferation, it is well known that there are important mechanistic differ-
ences between these processes. In contrast with atherosclerosis, which develops partly in 
response to elevated lipoprotein levels and cigarette smoke, the restenotic process is not 
particularly sensitive to circulating lipids and smokers even seem to have a reduced risk 
for restenosis.14 It is therefore not unlikely that a genetic risk factor would have opposite 
effects on stroke and clinical restenosis after PCI.
However, as opposed to WT-FSAP, Marburg I-FSAP was less effective in preventing 
neointima formation in an animal model for restenosis.10 Based on these findings, the 
Marburg I polymorphism was expected to increase the risk for restenosis in humans. 
Although the protective effect observed in the GENDER study was just not significant, 
there was a strong trend towards protection. The contradicting results could relate to the 
subjects (mice vs. humans) or the intervention site (femoral artery vs. coronary arter-
ies), but could also be the result of differences in the exact location and concentration 
of the Marburg I-FSAP-protein, which was locally applied in high concentrations to 
injured arteries in the mouse model. Furthermore, FSAP plays a role in many different 
processes which are known to be important in vascular remodeling. FSAP has recently 
been shown to activate the matrix metalloproteinases MMP2 and MMP9 (gelatinases),16 
which are important in matrix remodeling. Further research is needed to understand 
the precise role of FSAP in vascular remodeling and the pathogenesis of stroke.
The Marburg II polymorphism, also located in the protease domain of FSAP, has no 
known functional implications and is not associated with altered catalytic activity.
Due to its low allele frequency (2%), the Marburg II findings are less reliable. The 
similar, but much weaker trends that were observed for this polymorphism could be a 
result of the linkage disequilibrium with the Marburg I variant. Large confidence inter-
vals indicate that the observed significant association with vascular mortality, which is 
slightly stronger than the effect of Marburg I on vascular mortality, probably occurred 
by chance.
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In conclusion, we demonstrated that carriers of the Marburg I polymorphism are at 
increased risk for clinical stroke and stroke related mortality. Furthermore, a strong 
trend towards a reduced risk for clinical restenosis was observed in Marburg I carriers. 
As Marburg I-FSAP has reduced proteolytic activity towards PDGF-BB, the increase in 
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Objective: Mixed results have been reported of matrix metalloproteinases (MMP) and 
their association with restenosis after percutaneous coronary intervention (PCI). The 
current study examines whether multiple single nucleotide polymorphisms (SNPs), 
covering the full genomic region of MMP2 and MMP3, were associated with restenosis 
in the GENDER study population.
Methods and results: The GENetic DEterminants of Restenosis (GENDER) study en-
rolled 3104 consecutive patients after successful PCI. The primary endpoint was clinical 
restenosis, defined as target vessel revascularization (TVR), occurring in 9.8% of the pa-
tients. From the Hapmap database, 19 polymorphisms of MMP2 and 11 of MMP3 were 
selected. Furthermore, in a subpopulation, a genome-wide association analysis (GWA) 
was performed. No significant association was found with any of the investigated SNPs, 
including the previously reported 5A/6A polymorphism (rs3025058), with regard to 
TVR using single SNP analysis or haplotype analysis.
Conclusion: We found no significant association of MMP2 or MMP3 with TVR with 
this SNP-broad gene approach. Although we did not test all the known polymorphisms 
of these genes, using tagging analyses we examined those SNPs covering all known 
haplotypes of MMP2 and MMP3 to conclude that these genes do not correlate with a 
genetic risk of coronary restenosis after successful PCI.
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INTRODUCTION
Matrix metalloproteinases (MMPs) form a family of over 20 zinc-dependent enzymes 
with proteolytic activity against a variety of extracellular matrix components including 
collagen, proteoglycans and elastin. All MMPs have distinct although overlapping sub-
strate specificities.1 Increased expression and activity of MMPs have been identified in 
various pathological processes, such as general inflammation, tumor metastasis, respira-
tory diseases, myocardial injury, vascular aneurysms, and vascular remodeling.2 Vascu-
lar remodeling and inflammation are important features of restenosis after percutaneous 
coronary intervention (PCI) and several, mostly small, studies found associations of 
MMP plasma levels or genetic polymorphisms with restenosis.3-5
MMP2 (gelatinase A) is produced by vascular smooth muscle cells (VSMCs) to de-
grade basement membrane components and other matrix proteins during migration 
and proliferation of these cells. Different animal models for restenosis showed upregu-
lation of MMP2 during intima formation.6, 7 Furthermore, MMP2 plasma levels were 
found to be increased after PCI and associated with restenosis.4, 8, 9 Although genetic 
polymorphisms in the MMP2 gene have been associated with myocardial infarction 
(MI)10, 11 and heart failure,12, 13 there are no studies published describing their association 
with coronary restenosis.
MMP3 (stromelysin-1) cleaves a wide variety of matrix proteins and is considered to 
reduce the matrix content of the vascular wall. Higher MMP3 expression is associated 
with the development of atherosclerotic plaques with less matrix protein and as a result 
smaller and more prone to rupture plaques (i.e. lipid rich plaques). On the other hand, 
low MMP3 expression genotypes are predisposed to develop relatively larger and more 
sTable plaques (i.e. fibrotic plaques).2 However, in a MMP3 knockout mouse model, 
Johnson et al. found that in absence of MMP3 the plaques where not only larger but 
that they also had a lower smooth muscle cell content, making them less sTable.14 Part 
of their explanation was that MMP3 has a broad substrate specific, including activa-
tion of other MMPs and that therefore many mechanisms could account for the effects 
of MMP3.14 Functional studies have shown that the MMP3 -1612 5A/6A promoter 
polymorphism (rs3025058) is associated with decreased MMP3 expression levels.15-17 In 
addition, several studies describe the association of this polymorphism with restenosis. 
For example, de Maat et al found an association between the 6A6A MMP3 genotype and 
an increased risk of restenosis after balloon angioplasty.3 The same conclusion was made 
by Humphries et al.,5 however other studies could not identify this association.18, 19
MMPs have been extensively studied on their association with different cardiovascular 
endpoints. The results with regard to restenosis have been mixed. To clarify these uncertain-
ties we conducted this study in the large prospective GENetic DEterminants of Restenosis 
(GENDER) study population. With this study we systematically examined whether mul-
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tiple single nucleotide polymorphisms (SNPs), covering the full genomic region of MMP2 
and MMP3, were associated with clinical restenosis in the GENDER study population.
METHODS
Study design
The present study population has been described previously.20 In brief, the GENDER 
project was designed to study the association between various gene polymorphisms and 
clinical restenosis. All included patients were treated successfully for sTable angina, non-
ST-elevation acute coronary syndromes or silent ischemia by PCI in four out of the eight 
academic medical centers in the Netherlands. Patients treated for acute ST elevation 
myocardial infarction were excluded. Also excluded from analysis were patients suf-
fering from events occurring within one month after the procedure, since these events 
were mostly attribuTable to sub-acute stent thrombosis or occluding dissections, and 
not to restenosis. During the study, no drug-eluting stents were used. Follow-up lasted 
for at least nine months, except when a coronary event occurred. Clinical restenosis, 
defined as renewed symptoms requiring target vessel revascularization (TVR), either by 
repeated PCI or CABG, was designated to be the primary endpoint. The study protocol 
met the criteria of the Declaration of Helsinki and was approved by the Medical Ethics 
Committees of each participating institution. Written informed consent was obtained 
from all participating patients in advance of the PCI procedure. Blood was collected in 
EDTA tubes at baseline and genomic DNA was extracted following standard procedures.
Candidate gene approach
SNPs of MMP2 and MMP3 were selected from the HapMap database (http://www.
hapmap.org). Using the data from the CEU population, tagging SNPs, with a minor 
allele frequency >5%, were selected to cover each haplotype block within the genes (us-
ing Haploview program, version 4.1 21). Five SNPs in MMP2 were analyzed (rs243866, 
rs857403, rs243849, rs2287076 and rs10775332) and 2 SNPs in MMP3 (rs679620 and 
rs646910). Furthermore, the 5A6A promoter polymorphism of MMP3 (rs3025058) 
was added to the tagging SNPs. All SNPs were genotyped by matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (MS), using 
the Sequenom MassARRAYtm methodology (Sequenom Inc, San Diego, CA, USA), 
following manufacturer’s instructions. As quality controls, 368 (11%) of the samples 
were genotyped in duplo. No inconsistencies were observed. All the blanks (5%) were 
negative. Cluster plots were made of the signals from the low and the high mass allele. 
Independent researchers carried out scoring. Disagreements or vaguely positioned dots 
(<1%) produced by Typer 4.0 (Sequenom Inc.) were left out of the results.
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Genome wide association study
A genome wide association study was performed in a selection of cases and controls from 
the GENDER study and has been described previously 22. In brief, cases and controls 
were selected from the total GENDER study population and matched by age, gender 
and other clinical factors such as diabetes and current smoking that have been previ-
ously associated to restenosis. A genome-wide association analysis was conducted using 
the Illumina Human 610-Quad Beadchips following manufacturer’s instructions. These 
beadchips contain 620,901 single nucleotide polymorphism (SNP) and copy number 
variants (CNV) probes, covering 89% of the common genetic variation in the European 
population at r2>0.8. After genotyping, samples and genetic markers were subjected 
to a stringent quality control protocol. Of the initially selected patients (321 cases and 
620 controls), 295 cases and 571 controls fulfilled all criteria. The SNPs captured in the 
MMP2 region between positions 54060397 and 54102050 on chromosome 16 and the 
SNPs in the MMP3 region between positions 102206231 and 102225888 on chromo-
some 11 were selected for further analyses (see Table 2 and Table 3 for rs numbers).
Statistical analysis
Of the baseline characteristics the discrete variables are expressed as counts or percent-
ages and were compared with chi-square tests. Continuous variables are expressed as 
mean (± standard deviation) and were compared by means with unpaired 2-sided t-test. 
Associations of the genotypes of the individual SNPs with TVR were calculated assuming 
an additive model using a Cox proportional hazards model. We controlled for age, sex 
and ethnicity in the Cox-regression by including them as covariates. Furthermore, based 
on the baseline characteristics, we also corrected for diabetes, stenting, total occlusion 
and type C lesions in the analysis of the candidate approach SNPs. These additional cor-
rections were not necessary for the GWAS SNPs, since that subpopulation was matched 
for known risk factors as described above. Recessive and dominant models were also 
tested. After Bonferroni correction for multiple testing, we considered a statistically 
significant association (at p<0.05) for any SNP with p-value < 0.0017.
The program Haploview was used to estimate allele frequencies, test the consistency 
of the genotype frequencies at each SNP locus with Hardy-Weinberg equilibrium, and 
estimate and plot pairwise linkage disequilibrium (LD) measurements between SNPs.
Haplotypes and haplotype frequencies were calculated using PHASE software (http://
www.stat.washington.edu/stephens/).23-25 Haplotypes with a frequency of less than 5% 
were combined and included in all analyses, without reporting the results. The haplotype 
analysis approach performed in this study assumes an additive effect of the haplotypes, 
and details of this approach have been described elsewhere 26. Haplotype analyses were 
performed using STATA for haplotypes with a frequency >5%. Their effects were cal-
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culated using a Cox proportional hazards model including sex, age, and ethnicity and 
weighted for the probability of having the haplotype.
A p-value <0.05 was considered statistically significant. Statistical analysis was carried 
out using SPSS 17.0 for Windows.
RESULTS
Baseline characteristics
A total of 3,146 patients had a complete follow-up (99.3%) with a median duration of 
9.6 months (interquartile range 3.9). Out of 3,146 patients 42 had an event in the first 
30 days. These patients were excluded from further analysis, according to the protocol. 
Baseline characteristics of the population are shown in Table 1. Of the 3,104 patients, 304 
(9.8%) patients underwent TVR during follow-up. 51 patients died (1.6%) and 22 (0.7%) 
suffered from MI. In the total GENDER population use of lipid lowering medication 
was equal in both cases and controls. Diabetes, total occlusion and C-type lesion were 
significantly more frequent in the cases (p-value = 0.001, 0.01 and 0.03 respectively), 
whereas the percentage of patients receiving a coronary stent was significantly higher in 
the control group (p-value = 0.001).
Genotypic analyses
The SNPs included in this study are listed in Table 2 and Table 3 for MMP2 and MMP3, 
respectively. The 19 polymorphisms of MMP2 and 11 polymorphisms of MMP3 pro-
vided coverage of all haplotype blocks (Figure 1 and Figure 2, respectively) and were all 
in Hardy-Weinberg equilibrium (p-value >0.05). Associations with TVR as a marker of 
restenosis were calculated assuming an additive model. No significant associations were 
observed between any of the MMP2 and MMP3 polymorphisms, including the previ-
ously reported 5A/6A polymorphism (rs3025058), and TVR. Dominant and recessive 
models did not alter these effects (data not shown).
After analyzing the subpopulations of patients with (n = 2352) or without (n = 752) 
receiving coronary stents during PCI, similar results were obtained. None of the SNPs 
was associated with TVR in neither of the subpopulations.
Linkage disequilibrium structure is shown in Figure 1 and in Figure 2. MMP2 in-
cluded 4 haplotype blocks, whereas MMP3 had only 1. The haplotypes of the different 
blocks of MMP2 were calculated as shown in Table 4. The most frequent haplotype was 
used as reference. None of the haplotypes was significantly associated with the outcome 
parameter TVR. In line with the single SNP analysis, haplotype analysis of MMP3 also 
did not show any significant association with TVR (Table 5).
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DISCUSSION
Polymorphisms of MMPs have been associated with different cardiovascular events.2, 3, 
11, 12, 27, 28 Studies of their association with restenosis after PCI are however scarce. Most of 
these studies look into the relation of the 5A6A promoter polymorphism of MMP3 and 
restenosis, however those results are mixed.3, 5, 18, 19  The main finding of the present study 
is that after testing several polymorphisms in MMP2 and MMP3 using a candidate gene 
approach we did not find any significant association with coronary restenosis. Since in 
the meantime a GWAS was carried out in a subpopulation of the GENDER study,22 we 
decided to include the genotyped polymorphisms in the genomic regions of both MMP2 
and MMP3 in our analyses. None SNPs was associated with restenosis. Combining both 
Table 1. Demographic, clinical and lesion characteristics of the total GENDER population composed of 3104 patients.
Cases (n=304) Controls (n=2,800) p-value
Age (years) 61.7 ± 10.1 62.2 ± 10.8 0.46
BMI (kg.m-2) 26.9 ± 3.7 27.0 ± 3.9 0.70
Male sex 220 (72.4%) 1996 (71.3%) 0.69
Caucasian ancestry 295 (97.0%) 2714 (96.9%) 0.92
Diabetes 63 (20.7%) 390 (13.9%) 0.001
Hypercholesterolemia 188 (61.8%) 1702 (60.8%) 0.72
Hypertension 138 (45.4%) 1121 (40.0%) 0.07
Current smoker 62 (20.4%) 700 (25.0%) 0.08
Family history of MI 121 (39.8%) 977 (34.9%) 0.09
Previous MI 109 (35.9%) 1130 (40.4%) 0.13
Previous PCI 64 (21.1%) 493 (17.6%) 0.14
Previous CABG 36 (11.8%) 340 (12.1%) 0.88
STable angina 198 (65.1%) 1881 (67.2%) 0.47
Acute coronary syndrome 106 (34.9%) 974 (31.2%) 0.19
Multivessel disease 148 (48.7%) 1284 (45.9%) 0.35
Peripheral vessel disease 12 (3.9%) 92 (3.3%) 0.54
Lipid lowering medication 171 (56.3%) 1516 (54.1%) 0.48
Restenotic lesions 27 (8.9%) 181 (6.5%) 0.11
Total occlusions 56 (18.4%) 372 (13.3%) 0.01
Type C lesion 94 (30.9%) 708 (25.3%) 0.03
Proximal LAD 70 (23.0%) 619 (22.1%) 0.71
RCX 75 (24.7%) 764 (27.3%) 0.33
Stenting 207 (68.1%) 2145 (76.6%) 0.001
Number of stents 0.98 ± 0.05 1.01 ± 0.01 0.58
Values were given as n (%) or mean ± SD
BMI: body mass index, MI: myocardial infarction, LAD: left anterior descending branch of the left coronary artery, RCX: 
circumflex branch of the left coronary artery.
p-value determined Pearsons Chi-Square (discrete variables) or unpaired 2-sided t-test (continuous variables).
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region HR 95% CI p-value
rs893226 G T 0.40 GWAS -10496 Promoter 1,00 (0.840 1,20) 0,97
rs1005913 A C 0.29 GWAS -8871 Promoter 0.99 (0.82 - 1.20) 0.95
rs1347653 G T 0.17 GWAS -8352 Promoter 0.92 (0.72 - 1.17) 0.42
rs16955194 G A 0.06 GWAS -8064 Promoter 1.38 (0.90 - 2.11) 0.14
rs243866 G A 0.24 Candid. -1855 Promoter 0.90 (0.74 - 1.09) 0.28
rs857403 A T 0.18 Candid. 3316 Intron 0.83 (0.67 - 1.04) 0.11
rs17301608 C T 0.39 GWAS 5219 Intron 1.09 (0.92 - 1.29) 0.32
rs1053605 C T 0.08 GWAS 6216 Coding exon 1.15 (0.84- 1.57) 0.40
rs9302671 G T 0.37 GWAS 8334 Intron 1.09 (0.92- 1.30) 0.32
rs243849 C T 0.17 Candid. 10313 Coding exon 0.82 (0.65- 1.04) 0.11
rs243842 T C 0.34 GWAS 14031 Intron 0.96 (0.80 1.15) 0.63
rs183112 G A 0.15 GWAS 14291 Intron 1.24 (0.97- 1.58) 0.09
rs1992116 C T 0.46 GWAS 14500 Intron 1.16 (0.98- 1.37) 0.09
rs243840 A G 0.20 GWAS 14768 Intron 0.83 (0.65 - 1.04) 0.10
rs2287076 T C 0.47 Candid. 19066 Intron 1.17 (0.99 - 1.38) 0.08
rs243834 A G 0.47 GWAS 23296 Intron 0.88 (0.74- 1.04) 0.14
rs10775332 C T 0.46 Candid. 23335 Coding exon 1.10 (0.93 - 1.30) 0.22
rs1861320 G T 0.47 GWAS 27649 Downstream 1.12 (0.94 - 1.33) 0.19
rs8054459 A G 0.44 GWAS 31158 Downstream 0.84 (0.71- 1.01) 0.06
SNP, single nucleotide polymorphism; MAF, minor allele frequency; Rel., relative; HR, hazard ratio; CI, confidence interval; 
candid., candidate approach; GWAS, genome wide association scan.
Cox regression analysis with additive model with correction for sex, age and ethnicity in the GWAS SNPs and also 
correction for diabetes, total occlusion, stenting and type C lesions in the candidate SNPs.









region HR 95% CI p-value
rs645419 A G 0.48 GWAS -2045 Promoter 1.04 (0.87 - 1.25) 0.66
rs3025058 5A 6A 0.50 Candid. -1676 Promoter 1.09 (0.92 - 1.28) 0.33
rs522616 A G 0.21 GWAS -772 Promoter 1.03 (0.83 - 1.27) 0.80
rs679620 A G 0.50 Candid. 657 Coding exon 1.07 (0.90 - 1.26) 0.46
rs3025066 A G 0.06 GWAS 3794 Intron 1.09 (0.78 - 1.54) 0.61
rs566125 C T 0.15 GWAS 3806 Intron 0.89 (0.69 - 1.15) 0.38
rs646910 T A 0.13 Candid. 4755 Intron 1.06 (0.83 - 1.35) 0.67
rs595840 T C 0.48 GWAS 9380 Downstream 1.03 (0.86 - 1.24) 0.72
rs527832 C T 0.12 GWAS 12393 Downstream 0.94 (0.72 - 1.23) 0.67
rs1010698 A C 0.48 GWAS 13256 Downstream 1.03 (0.86 - 1.24) 0.72
rs1034375 A C 0.07 GWAS 18805 Downstream 1.23 (0.90 - 1.67) 0.19
SNP, single nucleotide polymorphism; MAF, minor allele frequency; Rel., relative; HR, hazard ratio;
CI, confidence interval; candid., candidate approach; GWAS, genome wide association scan.
Cox regression analysis with additive model with correction for sex, age and ethnicity in the GWAS
SNPs and also correction for diabetes, total occlusion, stenting and type C lesions in the candidate SNPs.
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Figure 1. Linkage disequilibrium structure of 19 MMP2 SNPs on chromosome 16








Figure 2. Linkage disequilibrium structure of 11 MMP3 SNPs on chromosome 11
Values shown in D’, * SNP from GWAS, + SNP from candidate approach
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approaches strengthened our findings of the lack of association between the two MMP 
genes and coronary restenosis after successful PCI.
Previously, Hojo et al. reported a significant association of increased serum level of 
MMP2 four hours after PCI and the occurrence of restenosis.4 Their study population 
was however very small and the patient characteristics of the 29 patients with follow-up 
were not well described. Recently, Katsaros et al. reported that in a  population of 85 
patients with sTable angina pectoris receiving DES, increased MMP2 serum activity 
was associated with dramatically increased restenosis rates.9 Although these results look 
promising for possible identification of patients prone to develop restenosis, larger stud-
ies are needed to replicate these results. In our, much larger patient population, we could 
not confirm their results with genotypic data.
Table 4. Haplotype analysis of MMP2
  Haplotype Frequency HR 95% CI p-value
Block 1 AG* 54.56%      
CG 28.12% 1.00 (0.85 – 1.17) 0.99
  AT 17.28% 0.91 (0.75 – 1.11) 0.37
Block 2 AA 57.67%      
GA* 23.89% 0.87 (0.72 – 1.05) 0.15
  AT 18.05% 0.82 (0.66 – 1.02) 0.08
Block 3 CTCTATAC 35.77%      
CGCCACAT 35.42% 0.88 (0.73 – 1.06) 0.18
CGTTGCGT 15.43% 0.90 (0.72 – 1.12) 0.35
  TGCTATAC 7.11% 1.08 (0.81 – 1.44) 0.61
Block 4 TTA 45.60%      
CGG 44.40% 0.89 (0.76 – 1.05) 0.16
  CGA* 9.47% 1.10 (0.86 – 1.42) 0.44
* wild type; HR, hazard ratio; CI, confidence interval.
Table 5. Haplotype analysis of MMP3
Haplotype Frequency HR 95% CI p-value
AACTTCAAAAA* 42.43%
ACTCTCAGGCG 12.84% 1.157 (0.84 – 1.59) 0.37
ACCCATAGACG 11.99% 0.994 (0.80 – 1.24) 0.95
ACCCTCAGGCG 9.35% 1.112 (0.87 – 1.42) 0.40
CCCCTCAGACG 7.71% 1.212 (0.93 – 1.58) 0.16
ACCCTCAGACG 5.72% 1.059 (0.78 – 1.44) 0.72
AACTTCGAAAA 5.59% 1.105 (0.87 – 1.41) 0.42
* wild type; HR, hazard ratio; CI, confidence interval.
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The increased risk of restenosis with the 6A6A MMP3 genotype was described by de 
Maat et.al. and Humphries et.al. in patients after balloon angioplasty without stenting.3, 5 
The latter study also analyzed a subpopulation of patients who received an intracoronary 
stent and they could not identify an association with the 6A6A MMP3 genotype and re-
stenosis. This difference probably indicates that different processes are involved in these 
two patient groups. However, since balloon angioplasty without stenting becomes more 
rare, the clinical relevance of this finding is decreasing. In the GENDER no significant 
association with TVR of any of the SNPs was detected in neither of the subpopulations. 
Also, the 5A6A polymorphism was also not related to restenosis, not in the total popula-
tion nor in the one of the subgroups.
In the GENDER study all patients that were stented received one or more bare-metal 
stents (BMS). It could be argued that a possible role of investigated MMPs might be 
ascribed in restenosis in a patient group receiving drug-eluting stents (DES). This is 
however highly unlikely since DES are associated with a reduction in the development of 
restenosis, which would more likely diminish a possible genotype-dependent difference 
in neointima formation. Definite data on this topic is however lacking.
A limitation of our study is that the patients included in the GENDER study were 
mostly patients with a Caucasian ancestry (96.9%). Different results may be obtained 
in other ethnic groups. Furthermore, we did not test all known polymorphisms in the 
two genes of interest, but since SNPs were selected taking into account the LD measure-
ments, all haplotype blocks were covered. Moreover, no significant associations were 
obtained by means of haplotype analysis. We therefore think it is valid to conclude that 
no major effects are to be expected from these genes. Also, our findings are based on one 
single study. However, since the GENDER study is a large prospective follow-up study 
and taken in account that the previous reports are heterogeneous and in smaller patients 
groups, the power of these results is large enough to draw these conclusions.
In conclusion, with this study we provide evidence that, with regard to restenosis, a 
solid association with genetic variation of MMP2 and MMP3 is absent. Although we did 
not test all the known polymorphisms of the MMP2 and MMP3 genes, using tagging 
analyses we examined those SNPs covering all known haplotypes of MMP2 and MMP3 
to conclude that genetic variation of these genes does not correlate with a genetic risk of 
coronary restenosis after successful PCI. As the search for genetic factors involved in the 
process of restenosis continues, we merely exclude genetic variation in two previously 
proposed candidate genes for involvement in the increased risk for restenosis, so future 
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Introduction: The mRNA binding protein Quaking (Qk) is a key regulator of neuron 
myelination, while more recent data point to a pivotal role in embryonic arteriogenesis. 
Therefore, we hypothesized that Qk might exert regulatory functions in vascular pa-
tency responses responses such as restenosis, a frequent complication of percutaneous 
coronary intervention (PCI).
Methods and results: We addressed the role of Qk in in-stent restenosis by analysis for 
association of single nucleotide polymorphisms (SNPs) throughout the Qk gene and the 
risk of restenosis in the prospective GENetic DEterminants of Restenosis (GENDER) 
study (N=3,104 patients). Seven out of twelve tested SNPs associated with risk for or 
protection against restenosis. The strongest associations were found for SNPs located 
close to the Qk transcriptional start site (2786 T/C: HR: 2.14, 95%CI: 1.24-3.68, P=0.006) 
and in intron 3 (57896 A/G: HR: 0.74, 95%CI: 0.6-0.92, P=0.005 and 65752 A/G: HR: 
1.5, 95%CI: 1.14-1.98, P=0.003). Importantly, patients carrying the 65752G risk allele 
but lacking the protective 57896G allele were at a high risk to develop restenosis (HR: 
1.8, 95%CI: 1.3-2.5, P<0.001). In vitro characterization of Qk deficient vascular smooth 
muscle cells (VSMC) revealed severely compromised cell viability, as evidenced by a de-
creased resistance to stress, decreased cellular proliferation, migration and extracellular 
matrix production. In keeping with this notion, Qk deficient Qkv mice showed markedly 
decreased neointima formation in a mouse model of in-stent restenosis.
Conclusions: We are the first to identify a link between Qk and the risk for in-stent 
restenosis after PCI, which may be attributable to its regulatory role in VSMC function. 
Therefore, Qk could serve as a marker for TVR risk prediction as well as a novel target 
to reduce restenotic risk.
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INTRODUCTION
The mRNA-binding protein Quaking (Qk) is a member of the signal transduction and 
activation of RNA (STAR) family of transcription factors. It is located on chromosome 
6 in humans and chromosome 17 in mice and is highly conserved during mammalian 
evolution.1 As a result of alternative splicing, Qk has three main isoforms derived from 
mRNA transcripts of 5, 6 and 7 kb, notably Qk-5, Qk-6 and Qk-7.2 Qk-5 is the most 
abundantly expressed isoform and is essential during embryogenesis,2 whereas Qk-6 
and Qk-7 are primarily expressed post-natally.3 Qk has been found to play a critical 
role in driving oligodendrocyte differentiation, positioning Qk as a central regulator 
of myelination of both the central and peripheral neural network.4 Illustratively, the 
Qk viable mouse mutant (Qkv), which carries a 1 MB deletion in the promoter region 
resulting in Qk-knockdown, displays severe  developmental defects, characterized by a 
phenotype of seizures and movement-dependent tremors.4 However, its high expression 
levels in heart, brain, lung and testis as well as its broad range of putative Qk response 
genes points to a more general regulatory function of Qk, including vascular function.3 
Support for this notion came from a study showing a pivotal role of Qk in embryonic 
vascular development, as N-ethyl-N-nitrosourea (ENU) induced Qk as well as Qk-null 
mouse mutants were seen to die during development because of a lack of embryonic 
vascular remodelling.5, 6 This lethality was found to be due to a lack of local pericyte 
differentiation into vascular smooth muscle cells (VSMC), preventing the maturation 
of the yolk sac vasculature. Furthermore, Qk expression has been detected in murine 
VSMC of the aorta and coronary arteries,6, 7 suggesting that Qk may also influence 
VSMC function after gestation.
In-stent restenosis after percutaneous coronary intervention (PCI) is largely de-
pendent on VSMC proliferation. This process, harbouring potentially serious clinical 
consequences, is characterized by proliferation of cellular components of the vascular 
wall, in particular VSMCs in response to vascular injury, leading to re-occlusion of the 
stented arterial segment.8, 9 Previous studies have established the significant contribu-
tion of various genetic factors to the occurrence of restenosis.8, 10 Given the proposed 
regulatory role of Qk in arteriogenesis and VSMC function, we hypothesized that single 
nucleotide polymorphisms (SNPs) in both the promoter and coding region of the Qk 
gene could influence Qk expression and function, and could therefore potentially in-
fluence the occurrence of restenosis in patients who underwent PCI. Furthermore, we 
assessed the effects of reduced Qk expression on neo-intimal hyperplasia in vivo and 
studied the specific effects of Qk abrogation in aortic-derived VSMCs of Qkv mice in 
vitro. We demonstrate strong two-directional associations of various Qk SNPs with the 
risk of restenosis after PCI and also, based on direct in vivo and in vitro data, propose a 




GENDER project study design
The present study population has been described previously.11 In brief, the GENDER 
project was designed to study the association between various gene polymorphisms and 
clinical restenosis, defined by target vessel revascularization (TVR). Patients eligible for 
inclusion were treated successfully for stable angina, non-ST-elevation acute coronary 
syndromes or silent ischemia by PCI in 4 out of 13 referral centers for interventional 
cardiology in the Netherlands. Patients treated for acute ST elevation myocardial infarc-
tion were excluded. Patients suffering from events occurring within 1 month after PCI 
were also excluded from analysis, as these events were attributable predominantly to 
sub-acute stent thrombosis or occluding dissections, rather than to restenosis.
PCI procedure
Experienced operators, using a radial or femoral approach, performed standard angio-
plasty and stent placement. Before the procedure, patients received aspirin (300mg) and 
heparin (7500 IU). The use of intracoronary stents and additional medication, such as 
glycoprotein IIb/IIIa inhibitors, were carried out at discretion of the operator. In case 
a stent was implanted, patients received either ticlopidin or clopidogrel for at least 1 
month following the procedure depending on local practice. During the study, no drug-
eluting stents were used.
Follow-up and study end points
Follow-up lasted for at least 9 months, except when a coronary event occurred. TVR, 
either by PCI or coronary artery bypass grafting (CABG), was designated the primary 
end point. An independent clinical events committee evaluated the clinical events. The 
study protocol meets the criteria of the Declaration of Helsinki and was approved by the 
Medical Ethics Committees of each of the participating institutions. Written informed 
consent was obtained from all participating patients before the PCI procedure.
Genotyping
Blood was collected in EDTA tubes upon admission to hospital and genomic DNA was 
extracted following standard procedures. Validated polymorphisms in the promoter and 
in each linkage disequilibrium (LD)-block in the Qk gene, as defined by the algorithm of 
Gabriel et al. 12, were selected using the program Haploview with genotype data from the 
International HapMap Consortium. The -7528 C/T (rs3857503), -4539 T/C (rs3904720), 
-2616 C/T (rs3857504), 2786 A/G (rs3763197), 34084 C/A (rs2759393), 57896 A/G 
(rs1737603), 65752 A/G (rs6937072), 71659 T/C (rs1016502), 106999 A/G (rs9458849), 
120103 G/A (rs9364692), 150256 C/T (rs715020) and 161241 G/T (rs1047944) poly-
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morphisms were selected on the basis of their high minor allele frequency (>5%) and 
measured using the Sequenom Massarray genotyping platform (Sequenom, San Diego, 
CA, USA). A multiplex assay was designed using Assay designer software (Sequenom). 
All PCR reactions had a final volume of 5 μl and contained standard reagents and 5 ng 
of genomic DNA. After PCR a primer extension reaction was performed to introduce 
mass-differences between alleles and, after removing salts by adding resin, approxi-
mately 15 nl of the product was spotted onto a target chip with a 384 patches containing 
matrix. Mass differences were detected by matrix-assisted laser desorption/ionisation 
time-of-flight mass spectrometry (MALDI-TOF; Autoflex; Bruker Daltonics, Billerica, 
MA, USA) and genotypes were assigned real-time using Typer 4.0 software (Sequenom). 
As quality controls, 5-10% of the samples were genotyped in duplo. Cluster plots were 
made of the signals from the low and the high mass allele. Scoring was performed by 
two independent researchers. Disagreements or vaguely positioned dots produced by 
Genotyper 4.0 (Sequenom) were left out of the results.
Femoral cuff induced vascular hyperplasia
Male Qkv mice (N=6) on a C57Bl6-J background together with wild-type age and 
sex-matched C57Bl6-J mice (N=6) were used (Jackson Laboratories, Bar Harbor, ME, 
USA). Mice were fed with water and chow diet ad libitum. At the age of 12 weeks, mice 
were anaesthetized with an intraperitoneal injection of 5 mg/kg Midazolam (Roche, 
Basel, Switzerland), 0.5 mg/kg Medetomidine (Orion, Helsinki, Finland) and 0.05 mg/
kg Fentanyl (Janssen, Geel, Belgium). The femoral artery was dissected from its sur-
roundings and sheathed with a non-constrictive cuff.13 Animals were sacrificed 21 days 
after cuff placement. Preparation for histological analyses was performed as described 
previously.13, 14 All animal work was approved by institutional regulatory authority and 
carried out in compliance with guidelines issued by the Dutch government.
Temporal gene expression cuff model
15 C57Bl6-J mice were maintained and provided with a femoral cuff as described above. 
At 0, 1, 2, 3, 7 and 14 days after placement of the femoral cuff, the mice were sacrificed 
and cuffed arteries were dissected and stored in liquid nitrogen. Trizol (Invitrogen) was 
used to extract total RNA from the femoral arteries, and the samples were subjected 
to DNAse I treatment (Promega, Madison, WS) to ensure that the samples were rid of 
genomic DNA. Subsequently, cDNA was generated using RevertAid M-MuLV reverse 
transcriptase (Fermentas, Burlington, Canada) according to manufacturer’s protocol.2 
Semi-quantitative expression of the QKI gene was performed using the Assays-on-De-
mand primer and probe set for QKI (Mm 01318927_m1) and SYBR-Green (Eurogentec, 
Liege, Belgium) on a Bio-Rad iCycler (Bio-Rad, Hercules, CA). GAPDH was utilized as 
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housekeeping gene. Relative gene expression was calculated by determining the ΔΔCt 
value of QKI versus GAPDH.
Histological analysis and quantification of cuffed femoral artery lesions
All samples were routinely stained with hematoxylin-phloxine-saffron (HPS). Weigert´s 
elastin staining was used to visualize elastic laminae. VSMCs were visualized with 
α-SM actin staining (DakoCytomation, Glostrup, Denmark). Collagen content was 
determined using a 0.1% (w/v) solution of Sirius Red F3B dye (BDH Laboratory Sup-
plies, Poole, UK) in aqueous picric acid for 1h. Unbound dye was removed by washing 
the sections with 0.01M HCl. Subsequently, the collagen-bound dye was dissolved by 
incubating the sections with 0.1M NaOH for 30 minutes. The amount of medial VSMC 
and collagen content was determined by morphometry (Leica Qwin, Wetzlar, Germany) 
and expressed as the percentage of total medial area consisting of α-SM actin- or Sirius 
red-positive area in six equally spaced serial cross-sections in all animals. Monocytes 
were detected with the use of an anti-CD45 antibody (Pharmingen, San Diego, CA, 
USA). Incorporation of 5-bromo-2´-deoxyuridine (BrdU, Sigma) into DNA as a marker 
of DNA synthesis was used to determine the rate of cell proliferation in cuffed vessel 
segments. Mice were injected intraperitoneally with 25 mg/kg BrdU three times at 72, 
48, and 24 hours prior to sacrifice. Sections were incubated with a mouse monoclonal 
anti-BrdU antibody (DakoCytomation). Apoptotic cells were identified by terminal 
deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining ac-
cording to manufacturers protocol (Roche). The number of labeled nuclei per cuffed 
artery were counted in six equally spaced cross-sections and expressed as a percentage 
of the total number of nuclei. For all immunohistochemical stainings, sections were 
incubated with an isotype-matched IgG at an equal titer as the primary antibody to serve 
as a control.
VSMC isolation and culture
Experiments were performed using primary mouse vascular smooth muscle cells 
(mVSMCs) derived by outgrowth from fragments of mouse aorta from C57Bl/6-J and 
Qk(v) mice seeded on fibronectin-coated plates (1 mg fibronectin dissolved in 10 mL 
PBS; solution left on culture dish for approximately 15 minutes). The tissue fragments 
and outgrowth cells were maintained in DMEM culture medium containing 20% fetal 
calf serum and penicillin/streptomycin (0.01 Units/ml and 0.01 μg/mL, respectively), 
at 37°C and 5% CO2 unless specified otherwise. The purity of VSMC outgrowth was 
assessed immunohistochemically using anti-mouse smooth muscle α-actin and 
peroxidase-conjugated goat-anti-mouse immunoglobulins, generally yielding 90-95% 
smooth muscle α-actin positive cells. In designated experiments, VSMCs were treated 
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with freshly isolated oxLDL (20 μg/mL), VLDL (50 μg/mL), and lipopolysaccharide (50 
ng/mL) for the specified times. Experiments were performed with cells at passages 3-4.
Extracellular matrix production assay
Primary wild-type and Qkv mVSMCs were seeded at a density of 1.5x104 cells/cm2 and 
grown for 24h in culture medium described above. Subsequently, the cells were cultured 
in DMEM containing 1% FCS and P/S and Gln for 16h. Next, the cells were extensively 
washed with PBS and fixed for 30 minutes using Formalfix (Thermo Scientific, Waltham, 
MA, USA). To assess total cellular collagen production, the cells were stained with Sirius 
Red F3B dye as described above. Concomitantly, a calibration curve was prepared by 
plating increasing concentrations of gelatin in PBS, which were air-dried and fixed in 
Formalfix. Total collagen content was determined spectrometrically at an optical density 
of 550nm on a microplate reader.
DNA synthesis assay
To quantify DNA synthesis, explant-derived mVSMCs from wild-type and Qkv aortic 
explants were seeded at a density of 1x104 cells/cm2 and cultured in medium described 
above, after which the cells were cultured for 24h in serum-free DMEM. Subsequently, 
the cells were incubated for 12h with [3H]-thymidine (10μCi/mL) in DMEM containing 
10% FCS, after which cell associated [3H]-thymidine was determined by assaying the 
trichloroacetic acid precipitable counts with Aquasol-2 (PerkinElmer, Waltham, MA, 
USA) on a Beckman LS3801 scintillation counter (Beckman, Fullerton, CA, USA).
Cellular migration assay
Primary mMVSMCs were cultured in medium described above, and 24h prior to seed-
ing into a transwell plate, cells were incubated in culture medium containing 1% FCS 
and Gln. DMEM containing 10% FCS, P/S, Gln as well as the chemotactic peptide n-
formyl-methionine-leucine-phenylalanine (fMLP; 0.1nM) was added to the basolateral 
side of a semi-permeable membrane with a pore size of 12 μm (ChemoProbe, UK). 
Subsequently, the cells were detached from the culture dish using trypsin-EDTA and 
2x104 cells were seeded onto the membrane and allowed to migrate for 24h. After cen-
trifugation, adherent mVSMCs were fixed, stained with Mayer’s hematoxylin, and the 
number of cells that had completely migrated to the basolateral side of the chamber was 
assessed microscopically and scored manually.
Cellular outgrowth assay
Aortas were harvested from both wild-type and Qkv mice after sacrificing. The aortas 
were excised from the base of the aortic arch until the iliac bifurcation. Subsequently, 
the aortas were cut longitudinally to expose the luminal portion of the vessel and the 
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endothelial cells were removed by gently scraping. After this, the aortas were cut into ap-
proximately 0.5 cm2 pieces, and placed on fibronectin-coated culture dishes. The explants 
were cultured in DMEM containing 20% FCS, P/S and Gln. After 7 days, phase-contrast 
photomicrographs of cellular outgrowth from individual pieces of aortic tissue were 
taken. Using Leica QWin software, the photomicrographs were used to quantitate both 
the total area of the designated piece of tissue and its corresponding cellular outgrowth 
was calculated based on: (Aoutgrowth = (Total Area (Aoutgrowth + Atissue)) - Atissue).
Western blot analysis
Protein expression was assessed by Western blot analysis with chemiluminescence 
detection. Qk-5 was detected using a rabbit polyclonal anti-human Qk antibody (Bethyl 
Laboratories, Montgomery, TX, USA).  As a reference α-tubulin was detected using a 
monoclonal antibody (Clone B-5-1-1, Sigma).  Horseradish peroxidase conjugated anti-
rabbit and anti-mouse IgG F(ab')2 (Amersham Pharmacia, Roosendaal, the Netherlands) 
were used as secondary antibodies. Bound Fab fragment was detected with enhanced 
chemiluminescent reagents (Boehringer, Ingelheim, Germany) and exposed on Kodak 
X-Omat blue XB-1 film.
Statistics
Allele frequencies were determined by gene counting. The Chi-squared test was used 
to test whether genotype frequencies at the SNP locus complied with Hardy-Weinberg 
equilibrium. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated 
using a Cox-proportional hazards model. All analyses were adjusted for clinical and 
procedural risk factors for restenosis, such as diabetes, smoking, hypertension, stenting, 
total occlusion and residual stenosis >20%. All polymorphisms were also assessed using 
dominant and recessive models, and the model with the lowest Akaike information cri-
teria was used in the multivariable regression analysis 15. SPSS software (version 12.0.1, 
SPSS Inc, Chicago, IL, USA) was used for all GENDER analyses. All in vitro and in vivo 
results were analysed via a 2-tailed Student’s t-test and ANOVA when appropriate using 




Characteristics of the GENDER cohort have previously been described in detail 11. In 
brief, a total of 3,146 patients had a complete follow-up (99.3%) with a median duration 
of 9.6 months (interquartile range 3.9 months). Out of 3,146 patients, 42 had an event 
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in the first 30 days. These patients were excluded from further analysis, according to the 
protocol. Baseline characteristics of the population are shown in Table 1. Bare metal 
stents were used in 2309 patients (74.4%), whereas the rest of the population was treated 
with plain balloon angioplasty. Of all patients, 304 patients (9.8%) underwent TVR dur-
ing follow-up, 51 patients (1.6%) died and 22 (0.7%) had a myocardial infarction.
Quaking genotyping
Due to lack of genomic DNA or inconclusive genotyping (vaguely positioned dots or 
genotyping errors), not all 3,104 patients could be successfully genotyped. For each SNP, 
genotype counts and minor allele frequencies are presented in Table 2 an figure 1A. 
There were no significant deviations from Hardy-Weinberg equilibrium. Out of the 12 
SNPs we assessed, 4 were found to significantly increase the risk of TVR using multiple 
regression analysis: -2616 T/T (promoter region; HR 1.91, 95% CI 1.11-3.28), 2786 G/G 
(intron 1; HR 2.14, 95% CI 1.24-3.68), 65752 G/G (intron 3; HR 1.57, 95% CI 0.87-2.8) 
and 106999 G/G (intron 3; HR 1.51, 95% CI 1.15-1.98) (Table 2 and figure 1A).
Table 1. Demographic, clinical and lesion characteristics of patients with TVR and without TVR during follow-up.
TVR (n=304) No TVR (n=2800) Total (n=3104)
Age (years) 61.7 ± 10.1 62.2 ± 10.8 62.1 ± 10.7
BMI (kg.m-2) 26.9 ± 3.7 27.0 ± 3.9 27.0 ± 3.9
Male sex 220 (72.4%) 1996 (71.3%) 2216 (71.4 %)
Diabetes 63 (20.7%) 390 (13.9%) 453 (14.6%)
Hypercholesterolemia 188 (61.8%) 1702 (60.8%) 1890 (60.9%)
Hypertension 138 (45.4%) 1121 (40.0%) 1259 (40.6%)
Current smoker 62 (20.4%) 700 (25.0%) 762 (24.5%)
Family history of MI 121 (39.8%) 977 (34.9%) 1098 (35.4%)
Previous MI 109 (35.9%) 1130 (40.4%) 1239 (39.9%)
Previous PCI 64 (21.1%) 493 (17.6%) 557 (17.9%)
Previous CABG 36 (11.8%) 340 (12.1%) 376 (12.1%)
Stable angina 198 (65.1%) 1881 (67.2%) 2079 (67.0%)
Multivessel disease 148 (48.7%) 1284 (45.9%) 1432 (46.1%)
Peripheral vessel disease 12 (3.9%) 92 (3.3%) 104 (3.4%)
Lipid lowering medication 171 (56.3%) 1516 (54.1%) 1687 (54.3%)
Restenotic lesions 27 (8.9%) 181 (6.5%) 208 (6.7%)
Total occlusions 56 (18.4%) 372 (13.3%) 428 (13.8%)
Type C lesion 94 (30.9%) 708 (25.3%) 802 (25.8%)
Proximal LAD 70 (23.0%) 619 (22.1%) 689 (22.2%)
RCX 75 (24.7%) 764 (27.3%) 839 (27.0%)


















































































































































Additive 0.91 (0.76-1.09) 0.30
Values are corrected for diabetes, smoking, hypertension, stenting, total occlusion and residual stenosis >20%. TVR = target vessel 
revascularization; HR = hazard ratio; CI = confidence interval
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In contrast, three SNPs were seen to significantly protect against TVR: 34084 A/A 
(intron 1; HR 0.68, 95% CI 0.52-0.88), 57896 G/G (intron 2; HR 0.74, 95% CI 0.6-0.92) 
and 71659 C/C (intron 3; HR 0.76, 95% CI 0.61-0.94). Only 5 SNPs were not significantly 
associated with TVR in the multiple regression analysis model. Importantly, analysis of 
the sub-cohort of patients who received one or more coronary stents did not reveal 
any major differences compared to results the total population (table 3 and figure 1B). 
Therefore, our findings can be extrapolated to the current PCI era in which plain balloon 
angioplasty is hardly being used anymore.
Interestingly, patients who carry the 65752 A/G and G/G alleles together with the 
57896 A/A allele were at high risk of restenosis compared to the rest of the population 
(HR 1.77, 95% CI 1.29-2.44; P<0.001) during 15 months of follow-up (figure 1C). This 










Hazard ratio distribution for all 12 Qk SNPs for the total GENDER cohort (N=3.104) as well as for a sub-cohort of all stented patients (N=2.309). 
Three SNPs are located within the promoter region and 9 within the coding region. Panel A shows the hazard ratio’s (HR) for all 12 SNPs in the 
total population with multivariate regression analysis. Four SNPs are associated with a significant increased HR for TVR, whereas three SNPs 
have a protective effect. The highest hazard ratio’s are located within the promoter region and the first intron. Panel B shows HRs for all 12 
SNPs in stented patients. The same distribution of risk per SNP is observed, although with larger 95% CI. Patients who carry the 65,752 A/G and 
G/G alleles together with 57,896 A/A allele are at higher risk of restenosis compared to the rest of the study population (C). This genotype is 
observed in 10% of the total population.  TVR = target vessel revascularisation. 95% CI = 95% confidence interval.
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Table 3. Distribution and multivariate analysis of 12 Qk polymorphisms in association with TVR in the stented subgroup.











































































































































Values are corrected for diabetes, smoking, hypertension, stenting, total occlusion and residual stenosis >20%. TVR = target vessel 
revascularization; HR = hazard ratio; CI = confidence interval
91
Quaking SNPs associate with restenosis and induce VSMC dysfunction
specific combinations of protective and hazardous genotypes can have additive effects 
on outcome in this high risk patient group.
Effect of Qk abrogation on VSMC function
Since post-operative restenosis is a fibrocellular hyperplastic response to vascular 
injury mediated by VSMC dedifferentiation, migration and proliferation, we sought 
to determine whether altered Qk expression could affect VSMC function. For this, we 
utilized Qkv mice, which contain a 1 Mb deletion in the Qk promoter region resulting 
in ablated transcription. Primary mouse VSMC cultures were established by aortic out-
growth and shown to be SM-a-actin positive by immunohistochemistry. Western blot 
analysis revealed a marked decrease in Qk-5 expression, the most prominent isoform 
(figure 2A). Next, we assessed the effect of sereum starvation as well as proatherogenic 
stimuli on Qk-5 expression. We observed a striking down-regulation of Qk-5 in 1% 
FBS, suggesting that a shift to a non-proliferative phenotype is accompanied by reduced 
Qk-5 expression (figure 2B). Treatment of VSMC for 24h with either oxLDL, VLDL or 
LPS did not influence Qk-5 expression, whereas remarkably that of Qk-6 was markedly 
decreased upon stimulation with oxLDL and VLDL, suggesting differential responses of 
VSMC Qk isoforms to pro-inflammatory stimuli (figure 2C).
Primary WT and Qkv VSMCs displayed pronounced phenotypic differences even 
under non-stimulated conditions. Qkv cells were characterized by a flattened, enlarged 
morphology with prominent stress-fibers as opposed to WT cells which displayed 
a healthy phenotype (figure 3A,B). To gain further insight into the consequences of 
decreased Qk-5 expression for VSMC phenotype, we assessed cellular proliferation, 
migration and extracellular matrix production in primary WT and Qkv VSMC. Qkv 
cells displayed a 45% decrease in outgrowth from aortic explants 7d after plating (WT 
 
 







Qk protein expression analysis in primary mVSMCs. Decreased Qk-5 expression is confirmed in Qkv cells (A). In primary WT mVSMCs, Qk-5 
protein expression is markedly reduced upon serum starvation, suggesting a decreased Qk-5 functionality in non-proliferative  mVSMCs (B). No 
differences are observed for Qk-5 expression upon incubation with pro-atherogenic stressors such as oxLDL, VLDL and LPS, but incubation with 
oxLDL and to a lesser degree VLDL caused a decrease in the Qk-6 isoform protein expression (C). α-tubulin is used as housekeeping control.
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1.8x106 ± 5.6x105 µm2 vs. Qkv 1.0x106 ± 6.0x105 µm2 VSMC area; N=34; P<0.001; figure 
3D). The proliferation rate of primary Qkv VSMC was 3.5 fold lower than that observed 
in WT mice as assessed by [3H]-thymidine incorporation (WT 2,149 ± 806 vs. Qkv607 
± 292 DPM/well; N=25;P<0.001;figure 3E). Moreover, transwell cellular migration was 
significantly decreased with Qkv cells (WT 116 ± 32 vs. Qkv 40 ± 7 migrated cells; N=5; 
P<0.001; figure 3C). Finally, Qkv cells showed a 50% reduction in extracellular matrix 
production than their WT counterparts (36 ± 1 vs. 18 ± 5 µm/ml; N=6; P<0.05; figure 
3F). Altogether, these data point to a significant role of Qk-5 in VSMC homeostasis, 
underscoring a causal relationship of Qk SNPs and the occurrence of clinical restenosis.
Restenosis in vivo model analyses
As a next step we have studied the implication of Qk dependent impairment of VSMC 
function on restenosis in vivo. Firstly, total vessel area of cuffed femoral arteries  in Qkv 
and WT mice did not differ at 2 weeks post surgery (WT 19,458 ± 4,942 vs. Qkv 17,593 
± 4,433 µm2; P=0.42; figure 4A). However, in keeping with our in vitro finding that both 
the proliferative capacity and production of ECM is reduced in Qkv VSMC, both medial 






Cultured primary mVMSCs, derived from WT-mice, display a healthy spindle-shaped VSMC-like phenotype, whereas Qkv derived mVSMCs display 
the cobblestone morphology typically seen in disturbed VSMC homeostasis (A,B). Primary Qkv mVSMCs show a marked, 3-fold decrease in 
migratory response (C). Qk mVSMC outgrowth form aortic tissue is nearly 50% reduced as compared to controls (D). Qk mVSMC show a 3.5-fold 
decrease in proliferative response (E). Decreased viability of primary Qkv mVSMCs also affects the synthesis of extracellular matrix, as witnessed 
by a 50% reduction in collagen production (E). Results are mean ± SEM, * P<0.001, ** P<0.05
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3,537 1,147 ± vs. Qkv 1,779 ± 758 µm2; P<0.05; figure 4B,D) were significantly lower in 
cuff induced femoral artery lesions of Qkv mice.  Of note, luminal stenosis of the cuffed 
femoral artery segment was considerably lower in Qkv than in WT mice (20% and 34%, 
respectively P<0.05; figure 4C,E). These findings suggest that attenuation of Qk gene and 
protein expression not only affects VSMC function but also results in a clinically rel-
evant decreased fibroproliferative response upon vascular injury. Immunohistochemical 
analysis of the VSMC content of the neointimal lesions revealed that lesions in Qkv mice 
contained a significantly lower percentage of SM-α-actin staining (WT 62.5 ± 4.7% vs. 
Qkv 46.5 ± 4.1%; P<0.05; figure 4F). Although not significant, Qkv mice also tended to 
display a decreased neo-intimal proliferative response, as assessed by cellular BrdU 
incorporation (WT 1.30 ± 0.5% vs. Qkv 0.45 ± 0.15%; P=0.14). No significant differences 
were seen in apoptosis (TUNEL staining), nor in collagen and CD45+ leukocyte content 
in Qkv vs. WT lesions (data not shown).
To asses normal Qk gene expression development following cuff placement in WT 
mice, we performed a temporal Qk gene profile analysis as shown in figure 5. Following 
 




























Morphometric analyses of murine femoral artery lesions 3 weeks after non-constricting cuff placement in WT and Qkv mice. No difference is seen 
in vessel surface area (A). Interestingly, Qkv mice show decreased medial expansion, with an even more attenuated intimal hyperplasia (B,C). 
This results in reduced luminal stenosis in the Qkv group (D,E). VSMC content is significantly decreased in Qkv mice (F). Representative pictures of 
control en Qkv femoral artery sections, stained with Weigert´s elastin staining (G,H) and  α-SM actin (I,J). Magnification 200x . Results are mean 
± SEM, * P<0.01, ** P<0.05
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cuff placement, Qk gene expression is unchanged the first 2 days. However, starting 
at day three until day seven, a significant increase in Qk expression was observed in 
femoral arteries, coinciding with neointimal hyperplasia. Two weeks later, Qk expres-
sion falls back to basal levels. These data indicate that Qk has a regulatory role in VSMC 
differentiation in response to neointimal proliferative triggers.
DISCUSSION
In the present study we demonstrate the association of Qk SNPs with clinical restenosis 
and suggest that this association is the result of Qk regulated VSMC dysfunction.
To date, the majority of studies pertaining to Qk have assessed its role in central ner-
vous system development, studies that have primarily been performed in a murine set-
ting. More recently, human studies and clinical data have started to emerge, and provide 
links between Qk and human diseases such as Canavan disease and schizophrenia.16, 
17 In the latter case, SNPs in the Qk gene were seen to associate with the occurrence of 
schizophrenia in a Swedish cohort, possibly caused by abberent Qk splicing.17, 18 Further-
more, previous work has identified that alterations in Qk isoform expression are linked 
to the development of glioblastoma multiforme and ataxia.19, 20 Our study is the first 
to assess the impact of Qk SNPs on clinical restenosis and cardiovascular disease. We 
have identified 7 SNPs that conferred enhanced risk of or protection against TVR, with 
the most significant associations for SNPs located in the promoter region and introns 
1,2 and 3 of Qk. Importantly, these analyses included a correction for possible con-
founding factors, thereby increasing the strength of the current analysis. Furthermore, 
separate analysis of the stented population revealed similar significant outcomes, which 
 




























Temporal Qk gene expression in femoral arteries following cuff placement. A significant increase in vascular Qk expression is observed during 
neointimal hyperplasia, peaking 7 days post cuff placement. Results are mean ± SEM, * P<0.01, ** P<0.001.
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is particularly relevant for current clinical practice in which plain balloon angioplasty 
is only rarely employed because of the higher risk of restenosis of this procedure. Of 
note, only bare metal stents were applied, thereby excluding bias due to interference of 
Qk with the activity of stent-coated drugs. Remarkably, subjects with both the 57896AA 
protective allele and 65752AG and GG risk alleles, a genotype prevalent in 10% of the 
total population, exhibited a 2 fold enhanced risk for restenosis, the strongest of all as-
sociations observed before in previous analyses of the GENDER study. Cloning and 
functional characterization of individual SNPs in vitro will likely clarify the effects of 
each SNP. Further studies are needed to examine wether protective SNPs confer reduced 
Qk expression or activity and if deleterious SNPs enhance Qk expression or vice versa.
The in vitro analyses point to a causal involvement of Qk in restenosis. In fact reduced 
Qk expression results in VSMC dysfunction. Qk-5 protein expression was significantly 
reduced in Qkv derived VSMCs, whereas expression of Qk-6 and Qk-7 did not appear to 
be affected in Qkv mice. It has previously been shown that Qk isoforms show differential 
patterns of temporal expression during differentiation in various cell types.3, 21 Interest-
ingly, Qk-/- mice have previously been found to be embryonically lethal, an effect that 
was attributed to a loss of Qk-5 expression during vascular development and matura-
tion.5, 6, 22 Our findings suggest that as a result of decreased Qk-5 expression, Qkv VSMCs 
lose their capacity to function properly, displaying many of the hallmarks of stressed 
cells, highlighted by a senescent morphology. This was substantiated in four functional 
assays, all pointing to decreased VSMC function as indicated by altered phenotype and 
decreased migration, proliferation, outgrowth and extracellular matrix production, 
features of the cobble-stone shaped synthetic phenotype. Therefore, Qk is likely to have 
a critical regulatory role in VSMC function and/or differentiation. Li et al. demonstrated 
that vitelline arteries of Qk null mice, which die at day 10 after gestation, are essentially 
devoid of α-actin+ VSMCs, a feature that was attributed to an inability of endothelial 
cells to differentiate into VMSCs pointing to a vital role of Qk in VSMC differentiation.6 
The defective VSMC phenotype could be rescued in vitro by adding Qk and PECAM-1 
positive cells to a culture of para-aortic splanchopleural cells derived from Qk-/- mice, 
suggesting the presence of a paracrine factor mediating the differentiation of endothelial 
cells into VSMCs.6 In addition, Bohnsack et al. demonstrated the paracrine effects of 
Qk-mediated release of retinoic acid regulating visceral endoderm survival and endo-
thelial cell function.22 We extend these observations by showing that even decreased, 
not completely abrogated Qk expression has serious implications on VSMC function in 
vitro, without requiring paracrine effects of neighboring endothelial cells.
Although we observed both protective and enhanced risk ratio’s of restenosis within 
our Qk SNP analysis, Qkv mice displayed a decreased neo-intimal response after femoral 
cuff placement which was in line with our in vitro observations. This is likely to be caused 
by decreased VSMC migration and proliferation, as SM-α-actin and, to a lesser extent, 
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BrdU staining was decreased in neo-intimal lesions of Qkv mice. The temporal Qk gene 
expression analysis strengthens this hypothesis, while Qk expression was significantly 
raised seven days following femoral cuff placement in wild type mice. Therefore, Qk is 
imperitive for the physiological neo-intimal proliferative response. It should be noted 
that the 1-MB deletion in the Qk gene in Qkv mice not only affects Qk expression, but 
also that of Parkin as well as of the Parkin co-regulate gene (Pacrg).23 Although we have 
solid evidence that underscores a direct relationship of Qk with VSMC function, and 
while others have previously shown that expression of Qk-6 rescues the dysmyelination 
phenotype of Qkv mice,22 it cannot be excluded that parkin or Pacrg are partly responis-
ible for VSMC dysfunction and/or restenosis as well.
The actual downstream effectors in this regulatory role of Qk on VSMC function are 
hitherto unknown. Recently, Galarneau and Richard, based on a computational analysis 
for Qk response elements, composed a list of 1,433 putative downstream targets of Qk.3 
These targets included genes involved in development, cell adhesion, morphogenesis, 
organogenesis, transport, cell differentiation, cell growth and/or maintenance, and cell 
communication, implicating Qk proteins as regulators of cell fate and proliferation. 
Many of these putative targets are implicated in cancer, a disease process heavily depen-
dent on (neo)vascularization. Extending these observations, we hypothesize based on 
these putative targets that Qk has additional functions in cardiovascular disease next to 
restenosis, such as atherogenesis, vascular and cardiac remodeling.
Finally, our observations strengthen the hypothesis that proteins which are originally 
associated with central nervous system development and maintenance also play a crucial 
role in vascular homeostasis.24 In this regard, Nogo-B, a protein involved in the inhibi-
tion of axonal growth and repair, was shown to regulate VSMC as well as endothelial cell 
migration in vitro and vascular remodeling in vivo.25 Furthermore, Nogo-B overexpres-
sion was recently shown to reduce neo-intima formation following vascular injury.26 
Although these effects are opposite to the effects of Qk, it shows that genes involved in 
neural cell maintenance may have substantial influence on vascular cells as well.
In conclusion, Qk SNPs are associated with the occurrence of restenosis in a large 
prospective cohort. As in this study decreased Qk activity could be linked to VSMC 
dysfunction, we propose that Qk may serve as a future genetic marker for restenotis risk, 
as well as a target for anti-restenosis therapy. The development of compounds which 
directly target the Qk transcriptional route responsible for regulation of VSMC function 
would be a feasible next step towards direct in vivo therapeutic targeting.
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Variation in the NOS3 gene has been related to the development of restenosis. The 
Glu298Asp polymorphism has previously been investigated for its effect on NO levels 
and the development of restenosis. However, the variability of findings gave rise to the 
hypothesis that the functional significance of this polymorphism may only become 
manifest under conditions of endothelial dysfunction. Since patients with the metabolic 
syndrome are known to have endothelial dysfunction, we aimed to investigate if the 
significance of NOS3 polymorphisms may depend on the presence of the metabolic 
syndrome.
We examined the impact of the -949 A/G, the -716 C/T and the Glu298Asp poly-
morphisms in the NOS3 gene on the risk of clinical restenosis in a previously described 
subpopulation of the GENDER-study, a multicenter prospective study design that 
enrolled consecutive patients after successful PCI. This subpopulation consisted of 
901 patients of whom sufficient data were available to establish absence or presence of 
the metabolic syndrome. Of these patients, 448 had the metabolic syndrome. Clinical 
restenosis, defined as target vessel revascularization (TVR), was the primary endpoint.
We demonstrated that the minor -949G, -716T and 298Asp alleles were associated 
with a significantly increased risk of TVR in patients with the metabolic syndrome (HR: 
1.58 [95%CI: 1.04-2.40], HR: 1.95 [95%CI: 1.02-3.70] and HR: 1.67 [95%CI: 1.09-2.54], 
respectively). In the group without the metabolic syndrome we observed no association 
between the three polymorphisms and TVR.
We suggest that the metabolic alterations present in patients with the metabolic 
syndrome influence the functional significance of these polymorphisms and increase 
the susceptibility of carriers of one of these variations in the NOS3 gene to develop 
restenosis after PCI.
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INTRODUCTION
The frequent occurrence of restenosis is a major limitation to percutaneous coronary 
intervention (PCI) in patients with coronary artery disease. Patients at increased risk for 
restenosis could benefit from alternative treatment options such as drug-eluting stents 
or coronary artery bypass surgery. To be able to stratify patients with regard to their risk 
of developing restenosis, it is important to determine both inherited and clinical factors 
influencing this complex and multifactorial process.
Nitric oxide (NO) is a vasodilatory molecule known to inhibit adhesion of platelets1 
and leukocytes2 to the vessel wall and to decrease proliferation and migration of vascular 
smooth muscle cells (VSMCs),3 which are all processes known to play an important role 
in the development of restenosis,4 Due to its favourable actions in these processes, NO 
is likely to play a protective role in the formation of restenosis. Restenosis has already 
been related to alterations in nitric oxide synthase (NOS) expression5 and impaired 
NO-dependent endothelial vasodilation.6 In support of these observations, Piatti et al. 
showed a lack of NO release after an oral glucose tolerance test (OGTT) in patients 
with restenosis.7 Since endothelial NOS catalyses the formation of NO from L-arginine 
in endothelial cells, polymorphisms in the NOS3 gene could influence NO formation 
and thereby play a role in the process of restenosis. The Glu298Asp polymorphism in 
the NOS3 gene has previously been investigated.  However, data on its influence on NO 
levels and the development of restenosis are still conflicting. Sofowora et al. suggested 
that the functional significance of this polymorphism may only become manifest under 
conditions of endothelial dysfunction.8 Since endothelial dysfunction is an important 
characteristic of the metabolic syndrome, we hypothesize that the metabolic alterations 
present in patients with the metabolic syndrome may influence the functional signifi-
cance of NOS3 polymorphisms. Therefore, the aim of this study was to examine whether 
the -949 A/G, the -716 C/T and the Glu298Asp polymorphisms in the NOS3 gene are 
related to the risk of restenosis after PCI in patients with and without the metabolic 
syndrome. The GENDER protocol was designed to allow separate analyses in a prespeci-
fied subgroup of patients with the metabolic syndrome.
PATIENTS AND METHODS
The present study population has been described previously.9 In brief, the GENetic 
DEterminants of Restenosis project (GENDER) was designed to study the association 
between genetic polymorphisms and clinical restenosis. Patients were eligible for inclu-
sion if they were successfully treated for stable angina, non-ST-elevation acute coronary 
syndromes or silent ischemia by PCI. Patients treated for acute ST elevation myocardial 
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infarction were excluded. All patients were treated in 4 of the 13 referral centers for 
interventional cardiology in the Netherlands. The overall inclusion period lasted from 
March 1999 until June 2001. We determined the lipid profile (serum triglycerides, serum 
total cholesterol, serum HDL-cholesterol) and fasting serum glucose in a subpopula-
tion of patients of whom plasma was collected. The study protocol conforms to the 
Declaration of Helsinki and was approved by the Medical Ethics Committees of each 
participating institution. Written informed consent was obtained from each participant 
before the PCI procedure.
PCI procedure
Standard angioplasty and stent placement were performed by experienced operators us-
ing a radial or femoral approach. Before the procedure, patients received aspirin 300 mg 
and heparin 7500 IU. The use of intracoronary stents and additional medication, such 
as glycoprotein IIb/IIIa inhibitors, was at the discretion of the operator. In case of stent 
implantation, patients received either ticlopidin or clopidogrel for at least one month 
following the procedure depending on local practice. During the study, no drug-eluting 
stents were used.
Follow-up and study endpoints
Follow-up lasted at least nine months, except when a coronary event occurred. Patients 
were either seen in the outpatient clinic or contacted by telephone. Restenosis was de-
fined by target vessel revascularization (TVR), either by PCI or coronary artery bypass 
grafting (CABG). An independent clinical events committee adjudicated the clinical 
events.
Events occurring within the first month were excluded from the analysis, since these 
events were attributable mainly to sub-acute stent thrombosis or occluding dissections, 
and less likely to restenosis. Data were collected with standardized case-report forms 
that were completed by the research coordinator at each site. Representatives from the 
data-coordinating center monitored all sites.
Genotyping
Blood was collected in EDTA tubes at baseline and DNA was extracted following standard 
procedures. The NOS3 -949 A/G (rs1800779), -716 C/T (rs3918226) and the 5219 G/T 
(rs1799983) polymorphism, resulting in the amino acid substitution Glu298Asp, were 
determined by a validated multilocus genotyping assay (Roche Molecular Systems).10 
The Glu298Asp polymorphism has already been implicated in coronary artery disease11 
and restenosis.12, 13 The -949 A/G polymorphism was selected on the basis of its involve-
ment in atherosclerotic disease14 and the -716 C/T polymorphism is located between the 
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cAMP regulatory element (nt -726 to -732) and an activator protein-1 binding domain 
(nt -655 to -661),15 which suggests a potential involvement in gene regulation.
In short, each DNA sample was amplified in a multiple polymerase chain reaction 
(PCR) using biotinylated primers. The PCR product pool was then hybridized to a 
matching panel of sequence-specific oligonucleotide probes, immobilized in a linear 
array on nylon membrane strips. A colorimetric detection method based on incuba-
tion with streptavidin-horseradish peroxidase conjugate, using hydrogen peroxide and 
3,3’,5,5’-tetramethylbenzidine as substrates, was used. Operators blinded to restenosis 
status performed genotyping.
To confirm genotype assignments, the PCR-procedure was performed in replicate 
on 10% of the samples. Two independent observers carried out scoring. Disagreements 
(<1%) were resolved by further joint reading, and when necessary, genotyping was 
repeated.
Definitions
Patients were defined as having metabolic syndrome by presence of three or more of 
the following criteria: 1) triglyceride level ≥1.7 mmol/l (150 mg/dl); 2) HDL cholesterol 
level <1.04 mmol/l (40 mg/dl) in men and  <1.3 mmol/l (50 mg/dl) in women; 3) systolic 
blood pressure  ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg; 4) obesity, 
defined as BMI >28.8 kg/m2, which was equivalent to a waist circumference of 102 cm 
in a cross-sectional study and similar to the BMI value (28.2 kg/m2) calculated in a 
regression of BMI on waist circumference in a large population of Scottish men;16, 17 
and 5) fasting glucose level ≥5.55 mmol/l (100 mg/dl), above which patients have either 
pre-diabetes (impaired fasting glucose) or diabetes. This level was established by the 
American Diabetes Association and suggested as the new cut point for identifying the 
lower boundary to define an elevated glucose level as one criterion for the metabolic 
syndrome.18-20
Statistical methodology
Allele frequencies were determined by gene counting, the 95% confidence intervals 
of the allele frequencies were calculated from sample allele frequencies, based on the 
approximation of the binominal and normal distributions in large sample sizes. Con-
tinuous variables are expressed as mean ± standard deviation and were compared by 
means of an unpaired, two-sided t test. Discrete variables are expressed as counts or 
percentages and were compared with a chi-square test.
The association between each of the 3 polymorphisms and TVR was determined using 
a Cox proportional regression model. If less than 10 patients were homozygous for a 
particular allele, the homozygotes and heterozygotes were combined. Polymorphisms 
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with independent prognostic value were selected in a multivariable regression model, 
also containing clinical and procedural risk factors.
To investigate possible additive effects of haplotypes of the NOS3 polymorphisms on 
TVR risk, we analyzed haplotype effects using the THESIAS program (www.genecanvas.
org), which implements the stochastic-EM (Expectation–Maximization) algorithm and 
allows the use of Cox proportional hazards survival regression.21 Statistical analyses 
were carried out using SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
The characteristics of this patient sample have been described previously.9 In summary, 
a total of 3,146 patients had complete follow-up (99.3%) with a median duration of 9.6 
months (interquartile range 3.9 months). Out of 3,146 patients 42 experienced an event 
in the first 30 days and were therefore excluded from further analysis, according to the 
protocol. In a previously described subpopulation of 901 patients,22 data were sufficient 
to establish absence or presence of metabolic syndrome. Of these patients, 448 (49.7%) 
had metabolic syndrome (≥ 3 of the 5 characteristics). The prevalence of metabolic syn-
drome characteristics in patients with and without the metabolic syndrome, as well as 
demographic, clinical and lesion characteristics, are presented in table 1. The presence of 
one or more components of the metabolic syndrome was common in both sexes: 16.3% 
had one component, 29.6% had two components, 26.9% had three components, 15.9% 
had four components, and 7.0% had all five components. Except for the presence of 
diabetes, the prevalence of factors that were previously found to be related to restenosis 
did not differ between the two groups. However, patients with the metabolic syndrome 
had higher insulin levels and were more frequently treated with statins or insulin.
At follow-up 47 patients (10.5%) with the metabolic syndrome versus 45 (9.9%) without 
the metabolic syndrome underwent TVR. On multivariable Cox regression, there was 
no significant increase in risk of TVR in patients with the metabolic syndrome (HR: 1.03 
[95%CI: 0.68- 1.57]).
Genotyping of the -949 A/G, the -716 C/T and the Glu298Asp (G/T) polymorphisms 
was successful in 96.9%, 96.7% and 96.9% of patients with the metabolic syndrome 
and in 98.7%, 98.2% and 98.2% of those without the metabolic syndrome, respectively. 
Results of the remaining patients were missing due to lack of DNA or inconclusive ge-
notyping. In both groups, the frequencies of the minor -949G, -716T and 298Asp alleles 
were 0.37, 0.09 and 0.31, respectively. The genotype distributions were consistent with 
Hardy-Weinberg equilibrium and did not differ significantly between patients with the 
metabolic syndrome and controls (p>0.05).
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Univariate Cox regression in patients with the metabolic syndrome revealed a signifi-
cant association between the -949 A/G, the -716 C/T and the Glu298Asp polymorphisms 
and the rate of TVR (HR: 1.58 [95%CI: 1.04-2.40] p=0.034, HR: 1.95 [95%CI: 1.02-3.70] 
p=0.042 and HR: 1.67 [95%CI: 1.09-2.54] p=0.018, respectively) (Table 2). TVR oc-
curred more often in -949 GG homozygotes (18.2%) than in AG heterozygotes (11.0%) 
or AA homozygotes (7.6%). Since only one patient was homozygous for the -716T allele, 
we combined homozygous and heterozygous patients for this polymorphism. This com-
bined group had an increased risk of TVR (17.6%) when compared to the group with 
the -716 CC genotype (9.2%). Homozygotes and heterozygotes for the 298Asp allele 
also had a higher risk of TVR (21.1% and 11.5%, respectively) when compared to the 
Glu/Glu genotype (7.8%). In contrast, in patients without the metabolic syndrome, the 
-949 A/G, -716 C/T and the Glu298Asp polymorphisms were not associated with TVR 
(HR: 0.90 [95%CI: 0.57-1.43] p=0.65, HR: 0.33 [95%CI: 0.10-1.08] p=0.067 and HR: 
1.02 [95%CI: 0.66-1.59] p=0.93, respectively). For each polymorphism, TVR-risks were 
equal in the different genotype groups (Table 2).
Table 1. Baseline and metabolic syndrome characteristics by metabolic syndrome status (N=901)
Metabolic syndrome
Absent Present P valuea
Baseline Characteristics: N=453 N=448
Age (y± SD) 63 (±10) 61 (±11) 0.003
BMI (kg/m2 ± SD) 25.4 (±3.0) 28.7 (±4.1) <0.001
Female Sex (%) 127 (28) 131 (29) 0.69
Diabetes Mellitus (%) 32 (7) 108 (24) <0.001
Current Smoking (%) 80 (18) 94 (21) 0.21
Stent placement (%) 376 (80) 373 (83) 0.92
Residual stenosis (%) 51 (11) 44 (10) 0.52
Total occlusion (%) 32 (7) 41 (9) 0.27
Total cholesterol (mmol/L, ±SD) 4.91 (±1.05) 5.01 (±1.12) 0.32
Statins (%) 231 (51) 265 (59) 0.014
Insulinb (mU/l, IQR) 12 (9) 20 (20) <0.001
Insulin Therapy (%) 13 (3) 32 (7) 0.003
Metabolic Syndrome Characteristics
BMI >28.8 kg/m2 37 (8.2%) 207 (46.2%)
Triglycerides ≥ 1.7 mmol/L 128 (28.3%) 370 (82.6%)
HDL cholesterol < 1.04 mmol/L men and < 1.3 
mmol/L women
128 (28.3%) 324 (72.3%)
Systolic BP ≥130 and diastolic BP ≥85 mm Hg 273 (60.3%) 383 (85.5%)
Fasting glucose ≥ 5.55 mmol/L 115 (25.4%) 329 (73.4%)
a   p-value of the nonparametric Mann-Whitney test, or chi-square test
b  Insulin levels are presented as median with interquartile range (IQR)
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After adjustment for patient and intervention-related characteristics that were pre-
viously described to be related to TVR risk, such as age, sex, hypertension, diabetes, 
current smoking, stenting, total occlusion and residual stenosis>20%, the -949 A/G, 
the -716 C/T and the Glu298Asp polymorphisms were predictors of TVR (HR: 1.55 
[95%CI: 1.01-2.37] p=0.043, HR: 2.05 [95%CI: 1.05-4,00] p=0.034 and HR: 1.68 [95%CI: 
1.09-2.59] p=0.019, respectively).
As determined with haploview, the -949 A/G and -716 C/T polymorphisms revealed 
significant linkage disequilibrium (D’: 0.95) and were combined into haplotypes for 
further analysis. The Glu298Asp polymorphism was excluded from this analysis due 
to the lack of linkage disequilibrium between this polymorphism and the -949 A/G 
polymorphism (D’: 0.45). In both groups, frequencies of the -949A/-716C, -949G/-
716C and -949G/-716T haplotypes were 0.62, 0.29 and 0.08, respectively. Due to its low 
Table 2. Cox regression of NOS3 polymorphisms in association with TVR in patients with and without 
the metabolic syndrome
Metabolic Syndrome Polymorphisms Number of 
patients
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frequency (0.007 in patients with the metabolic syndrome and 0.008 in patients without 
the metabolic syndrome), the -949A/-716T haplotype was excluded from the analysis. 
A haplotype-based risk analysis in patients with the metabolic syndrome revealed a sig-
nificant association of the -949G/-716T haplotype with the risk for TVR when compared 
to -949A/-716C, the most frequent reference haplotype (HR: 2.89 [95%CI: 1.45-5.76], 
p=0.0026 (Figure 1)).
DISCUSSION
To test our hypothesis that the functional significance of NOS3 polymorphisms may 
depend on the presence of the metabolic syndrome, we studied the relationship between 
these polymorphisms and the risk of restenosis in a subpopulation of patients with the 
metabolic syndrome that took part in a large follow-up study of unselected, consecu-
tive patients undergoing PCI. We demonstrated that the   -949G, -716T and 298Asp 
variants in the NOS3 gene were associated with a highly increased risk of TVR after 
PCI in patients with the metabolic syndrome, but not in patients without the metabolic 
syndrome.
Of the -949 A/G, -716 C/T and Glu298Asp polymorphisms, only the Glu298Asp 
polymorphism has previously been investigated for its involvement in restenosis. Suzuki 




NOS3 haplotype effects on the risk for target vessel revascularization (TVR) in patients with (circles) and without (triangles) the metabolic 
syndrome. Hazard ratios by reference to the most frequent haplotype were calculated using the THESIAS software. The -949G/-716T promoter 
haplotype showed a strong association with TVR (HR: 2.89 [95%CI: 1.45-5.76], p=0.0026), which indicates that both polymorphisms contribute 
separately to the risk of TVR.
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oping angiographic restenosis after stent placement (OR: 3.9 [95%CI: 1.09-13.95], after 
multivariate analysis).12 However, their population was very small (n=85) and consisted 
of relatively many patients with diabetes (27%). In support of their results, Gomma et 
al. demonstrated in a still relatively small and selected group of 205 stented patients, 
that possession of one or more alleles of the 298Asp variant was associated with an 
increased rate of angiographic restenosis after adjusting for clinical factors (OR: 2.47 
[95% CI: 1.22-5.00]).13 However, Gorchakowa et al. could not confirm these findings and 
demonstrated in a similar study, with a much larger patient number (n=1850), that rates 
of angiographic restenosis or TVR did not differ significantly between the Glu298Asp 
genotypes.23
The mechanism by which this polymorphism would promote neointima formation 
remains subject to discussion. It was originally suggested that NO would protect against 
restenosis because of its inhibitory role in VSMC proliferation, adhesion of leukocytes 
to the vessel wall and coagulation,1-3 processes known to be involved in restenosis.4 In 
addition, NO has been shown to suppress the production of the potent vasoconstrictors 
endothelin and angiotensin II, that also induce VSMC proliferation.24, 25 Its role in reste-
nosis was further established by the observation that L-arginine, the precursor to NO, 
decreases restenotic lesion formation in the rat,26 whereas L-NAME (NG-nitro-L-arginine 
methyl ester), a non-selective NOS-inhibitor, stimulates neo-intimal hyperplasia in the 
rabbit after balloon angioplasty.27 In humans, intramural administration of L-arginine 
has been shown to reduce neointimal hyperplasia at 6 months after stent placement.28 
Furthermore, patients with in-stent restenosis had impaired endothelial vasodilation 
and a lack of NO-release after an OGTT when compared to patients without restenosis.7
Although several in vitro29 and in vivo8, 30 studies showed reduced levels of NO in 
Glu298Asp homozygotes, data on the functional significance of this polymorphism are 
still conflicting. The 298Asp variant has been shown to result in protein with twofold less 
activity31 and an increased susceptibility to proteolytic cleavage.32 However, Sessa et al. 
demonstrated that the observed fragmentation was an artifact of sample preparation for 
gel electrophoresis33 and several authors reported similar activity of NOS3 in the different 
Glu298Asp genotypes.34,35 Studies examining vasodilation in response to intrabrachial 
injection of acetylcholine produced conflicting results.36, 37 Furthermore, flow-mediated 
dilation of the brachial artery was not affected by the Glu298Asp polymorphism,38,39 
whereas Naber et al. demonstrated a higher coronary vascular resistance in 298Asp 
homozygotes compared to that of 298Glu homozygotes at rest.40 These discrepancies 
might reflect the impact of interactions with environmental factors, such as smoking.11
To explain this variability, Sofowora et al. put forward an interesting hypothesis. In 
spite of the observed reduction in urinary excretion of NO in 298Asp homozygotes, 
they could not demonstrate differences between 298Asp homozygotes and 298Glu ho-
mozygotes as to vascular responses to acetylcholine, glyceryl trinitrate or phenylephrine 
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in a healthy population.8 Since, in contrast to their results, 298Asp homozygous patients 
with ischemic heart disease were found to be more sensitive to the vasoconstrictive ef-
fects of phenylephrine, they suggested that the functional significance of the Glu298Asp 
polymorphism may only become manifest under conditions of endothelial dysfunction. 
In support of this possibility, Leeson et al. demonstrated that 298Asp homozygotes had 
significantly lower flow-mediated dilation than 298Glu homozygotes, only in smokers, 
a group known to have endothelial dysfunction.38 Recently, smoking carriers of the 
298Asp allele were also found to have an increased risk of coronary heart disease relative 
to nonsmokers carrying two 298Glu alleles.41
Endothelial dysfunction is an important characteristic of the metabolic syndrome. 
A study by Lteif et al. showed that insulin resistance and systolic blood pressure seem 
to be the most important determinants of endothelial dysfunction in patients with the 
metabolic syndrome.42 Furthermore, high glucose levels are also known to determine 
endothelial dysfunction. A recent study showed that glucose downregulates NOS3 
mRNA and protein expression through regulation of mitochondrial production of reac-
tive oxygen species (ROS) with subsequent activation of AP-1.43 The inhibitory effect of 
glucose on NOS3 gene transcription was reversed by mutation of the AP-1 binding site 
in the promoter region. These findings indicate a mechanism by which hyperglycemia 
could increase the significance of NOS3 promoter polymorphisms.
Thus, if we assume that the functional significance of NOS3 polymorphisms depends 
on the presence of endothelial dysfunction, an explanation of our results may be that 
patients with the metabolic syndrome which carry the -949G, -716T or 298Asp alleles 
produce less NO than patients without the metabolic syndrome or carriers of the -949C, 
-716C or 298Glu alleles. Since the -949G/-716T haplotype showed a stronger association 
with TVR than both polymorphisms individually, these alleles could even interact to 
reduce NOS3 activity in patients with the metabolic syndrome. Further research has to 
be performed to test these hypotheses.
LIMITATIONS OF THE STUDY
One of the limitations of our study is that we did not have waist circumference as per 
criteria of ATP-III. We therefore substituted waist circumference with variable of obesity 
as defined by BMI of >28.8 kg/m2, this cutoff was equivalent to a waist circumference of 
102 cm in a cross-sectional study and similar to the BMI value (28.2 kg/m2) calculated 
in a regression of BMI on waist circumference in a large population of Scottish men.16, 17
In our study we lack data on NOS3 activity or NO concentration. Abundant data is 
present on the functionality of the Glu298Asp polymorphism. However, little is known 
about a difference of NOS3 activity between patients with and without the metabolic 
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syndrome. We would like to promote research that compares NOS3 activity and local 
NO concentrations between patients with the metabolic syndrome and controls having 
specific genotypes of the -949 A/G, -716 C/T and Glu298Asp polymorphisms.
Conclusions
In conclusion, we have demonstrated that the variant alleles of the -949 A/G, -716 C/T 
and Glu298Asp polymorphisms in the NOS3 gene increase the risk of TVR in patients 
with the metabolic syndrome, but not in patients without the metabolic syndrome. 
We suggest that the metabolic alterations in these patients influence the functional 
significance of the three NOS3 polymorphisms and increase the susceptibility of carriers 
of these variations in the NOS3 gene to develop restenosis after PCI. Genotyping for 
these polymorphisms may lead to better risk stratification and more tailored therapy in 
patients with the metabolic syndrome to prevent TVR after PCI.
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Late acquired stent malapposition (LASM) is a common finding after sirolimus-eluting 
stent (SES) implantation and may be the cause for late stent thrombosis. Inflammation 
may play a pivotal role in LASM just as it plays in stent restenosis. We have therefore 
investigated 7 polymorphisms involved in inflammatory processes, related in previous 
reports to restenosis, on the risk of LASM in SES patients. Patients with ST-elevation 
myocardial infarction who underwent SES implantation and had intravascular ultra-
sonography (IVUS) data available for both immediate post-intervention and 9-month 
follow-up were included in the present study. In total, 104 patients from the MISSION! 
intervention study were genotyped for the caspase-1 5352 G/A, eotaxin 1382 A/G, CD14 
260 A/G , colony stimulating factor 2 1943 C/T, IL10 -1117 C/T , IL10 4251 C/T  and 
the tumor necrosis factor alpha 1211 C/T polymorphisms. LASM occurred in 26/104 
(25%) of patients. We found a significantly higher risk for LASM in patients carrying 
the caspase-1 (CASP1) 5352 A allele (RR= 2.32; 95% CI 1.22-4.42). In addition, mean 
neointimal growth was significantly lower in patients carrying this LASM risk allele 
(1.6 vs 4.1%, p=0.014). The other 6 polymorphisms related to inflammation were not 
significantly related to the risk of LASM. In conclusion, carriers of the 5352 A allele in 
the caspase-1 gene are at increased risk of developing LASM after SES implantation. If 
this is confirmed in larger studies, screening for this polymorphism in patients undergo-
ing percutaneous coronary interventions could eventually help cardiologists to better 
select between commercially available stents.
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INTRODUCTION
Over the past years concerns were raised with regard to the long-term safety of coronary 
stents, mostly related to the fearful complication of late stent thrombosis. Several stud-
ies reported stent thrombosis to occur more frequently after drug-eluting stents (DES) 
than bare-metal stents (BMS) implantation1-3 and to be associated with underlying stent 
malapposition.4-6 Stent malapposition, as detected by intravascular ultrasonography 
(IVUS), represents a separation of the stent struts from the intimal surface of the arterial 
wall (in the absence of a side branch) with evidence of blood speckles behind the struts.7 
Stent malapposition may be acute (present immediately after implantation), persistent 
(present both immediately after implantation and at follow-up) or late acquired (present 
only at follow-up).
Intravascular ultrasonography (IVUS) studies have repeatedly identified positive ves-
sel remodeling as the main mechanism of late acquired stent malapposition (LASM).6,8-10 
Positive remodeling is a complex process characterized by a regional increase in the 
vessel wall diameter.7 A hypersensitivity reaction to the polymer coating of DES9 and 
induction of apoptosis by sirolimus may lead to positive remodeling.11,12
In the GENDER study,13 7 polymorphisms located in the caspase-1,14 eotaxin, CD14, 
colony stimulating factor 2 (CSF2),15 interleukin 10 (IL10)16 and tumor necrosis fac-
tor alpha (TNFα) genes,17 were found significantly associated with clinical restenosis 
after a  percutaneous coronary intervention (PCI) for stable angina pectoris. Besides its 
established role in restenosis, inflammation may also play an important role in LASM 
after DES implantation. On the long term, stent malapposition may be the consequence 
of chronic inflammation and delayed healing, resulting in tissue necrosis and erosion 
around the stent.18
In the present study we aimed at investigating these 7 inflammatory polymorphisms 
with regard to LASM and neointimal growth in a population of ST-elevation myocardial 
infarction patients treated by primary PCI with sirolimus-eluting stents (SES) in the 
prospective MISSION! Intervention Study.19
METHODS
IVUS measurements
Details about the MISSION! protocol and the MISSION! Intervention Study have been 
published elsewhere.19,20 In brief, MISSION! Intervention Study was a single center, 
single blind, randomized prospective study to evaluate clinical, angiographic and IVUS 
results in documented acute STEMI patients treated with either BMS (Vision™, Guidant 
Corp. Indianapolis, Indiana, USA) or SES (Cypher™, Cordis Corp. Miami Lakes, Florida, 
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USA). The study protocol was approved by the institutional ethical committee. Patients 
and operators performing the follow-up angiography were blinded to the treatment 
assignment. The study was conducted from February 2004 to October 2006. Patients 
had an IVUS examination immediately after the stent deployment and at nine-month 
follow-up. LASM at 9 months was common after SES implantation (26/104 patients, 
25.0 %) but rare after BMS implantation (4/80 patients, 5.0%).6 As a consequence, in the 
present study an analysis on LASM was conducted only for the SES group.
IVUS images were analyzed off-line, using quantitative IVUS analysis software (QCU-
CMS 4.14, Medis, Leiden, The Netherlands).21 After determining vessel, stent and lumen 
contours, their volumes were automatically calculated.
LASM was defined as stent malapposition present at 9-month follow-up IVUS exami-
nation but absent at immediate post-intervention IVUS examination. We have therefore 
examined first the follow-up IVUS images in order to identify cases of stent malapposi-
tion. After identification, IVUS images of follow-up and immediate post-intervention 
procedures were analyzed side-by-side in order to discriminate the late-acquired stent 
malapposition cases.
The neointima growth (%) at nine months was calculated with the formula: [stent 
volume(mm³) – lumen volume(mm³)  in the stented region]/stent volume(mm³) and 
represents the amount of new intimal tissue growth inside the stent as a fraction of the 
stent volume.
All patients gave informed consent before the procedure. An additional informed 
consent was obtained for follow-up angiography and IVUS at nine months. Patients 
were considered to have dislipidemia, hypertension and diabetes if they had been di-
agnosed such by a physician previous to the present myocardial infarction admission. 
IVUS imaging was performed with motorized pull-back (0.5mm/s) starting at least 10 
mm distal to the stent and ending at the coronary ostium, using a 2.9F 20MHz catheter 
and a dedicated IVUS console (Eagle Eye, Volcano Corp. Rancho Cordova, California, 
USA).22 Each angiogram and ultrasound sequence was preceded by 200-300μg of intra-
coronary nitroglycerin. After the initial procedure aspirin (100 mg/day) was prescribed 
indefinitely and clopidogrel (75 mg/day) for twelve months. During follow-up, patients 
were treated with beta-blockers, statins and ACE-inhibitors or ATII-blockers, according 
to current guidelines.20
Genotyping
Blood was collected in EDTA tubes upon admission to hospital and genomic DNA was 
extracted following standard procedures. A multiplex assay which included the caspase 
1 (CASP1) 5352 A/G (rs580253), eotaxin (CCL11) -1382 A/G (rs4795895), CD14 -260 
A/G (rs2569190), colony stimulating factor 2 (CSF2)1943 C/T (rs25882), IL10 -1117 C/T 
(rs1800896), IL10 4251 C/T (rs3024498) and the tumor necrosis factor alpha (TNFα) 
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-1211 C/T (rs1799964) polymorphisms, was designed using Assay designer software 
(Sequenom). All PCR reactions had a final volume of 5 μl and contained standard re-
agents and 5 ng of genomic DNA. After PCR a primer extension reaction was performed 
to introduce mass-differences between alleles and, after removing salts by adding resin, 
approximately 15 nl of the product was spotted onto a target chip with a 384 patches 
containing matrix. Mass differences were detected using an Autoflex (Bruker) matrix-
assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF) 
and genotypes were assigned real-time using Typer 4.0 software (Sequenom). Cluster 
plots were made of the signals from the low and the high mass allele. Two independent 
researchers carried out the scoring. There were neither disagreements nor vaguely posi-
tioned dots produced by Genotyper 3.0 (Sequenom Inc.).
Data analysis
Allele frequencies were determined by gene counting. The Chi-squared test was used to 
test the consistency of the genotype frequencies at the SNP locus with Hardy-Weinberg 
equilibrium. Relative risks (RR) with 95% confidence intervals (CI) were calculated with 
the Chi-Square test. If less than 10 patients were homozygous for a particular allele, the 
homozygotes and heterozygotes were combined. Differences in neointima formation, 
as measured by IVUS, were calculated and compared using a Student’s t-test. Differ-
ences in baseline characteristics between genotypes were assessed with Student’s t-test 
(for continuous variables) and Chi-Square test (for categorical variables). Population 
attributable risk was calculated as [f(RR-1)]/[1+f(RR-1)], where f is the frequency of 
the genotype(s) of interest in the present SES population and RR is the relative risk 
for LASM. A p-value <0.05 was considered statistically significant.The SPSS software 
(version 15.0, SPSS Inc, Chicago, IL) was used for all statistical analyses.
The authors had full access to the data and take responsibility for its integrity. All 
authors have read and agree to the manuscript as written.
RESULTS
A total number of 104 SES patients with complete IVUS data were analyzed from our 
MISSION! Intervention Study database. The baseline characteristics are presented in 
Table 1. Of all clinical and procedural factors analyzed, only the absence of diabetes 
seemed to predict LASM: none of the 10 diabetic patients and 26 of the 93 non-diabetic 
patients presented LASM. The 10 diabetic patients in our SES population also had more 
neointimal growth when compared to non-diabetics (8.9 vs. 2.7%, p=0.014).
The RR for LASM of all 7 polymorphisms are presented in table 2. The CASP1 5352 
G/A polymorphism was significantly associated with the risk for LASM: carriers of the 
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Table 1. Baseline clinical and angiographic characteristics. Adapted from van der Hoeven et al.6
Characteristic Sirolimus-eluting stents (N=104)
Age (yrs) 58.6±11.5
Male sex – No.(%) 76 (73.1)
Diabetes mellitus – No.(%) 10 (9.6)
Current smoker – No.(%) 62 (59.6)
Hypercholesterolemia – No.(%) 22 (21.2)
Hypertension – No.(%) 36 (34.6)
Family history of CAD – No.(%) 45 (43.3)
Prior myocardial infarction – No.(%) 5 (4.8)
Prior PCI or CABG – No.(%) 2 (1.9)




Multivessel disease – No.(%) 37 (35.6)
TIMI flow – No.(%)
0-1 73 (70.2)
2-3 31 (29.8)
Vessel reference diameter (mm) 2.81±0.56
Minimal luminal diameter (mm) 0.23±0.36
Diameter stenosis (%) 92.0±12.4
Values are means (±SD) or numbers (percentages). CABG = coronary artery bypass graft; CAD = coronary artery disease; LAD = left anterior 
descending, LCX = left circumflex, PCI = percutaneous coronary artery, RCA = right coronary artery.
Table 2. Relative risk for late aquired stent malapposition in sirolimus-eluting stent patients.
SNP N LASM N (%) RR (95%CI) for LASM
CASP1 5352 G/A
     GG
     GA
     AA
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CASP1 A allele were at clearly higher risk of developing LASM than homozygous wild 
type patients (41.9% vs 18.1, RR=2.3, 95%CI: 1.22-4.42). They also had less neointimal 
growth than patients not carrying the CASP1 A risk allele (1.6 vs. 4.1%, p=0.014). Only 
Table 2. Continued.
CSF2 1943 C/T
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*A dominant model was used. LASM = late-acquired stent malapposition. NA = not applicable. RR = relative risk. SNP= single nucleotide 
polymorphism.
Table 3. Baseline characteristics by CASP1 5352 G/A genotype
Characteristic GG (%) GA+AA (%) p-value
Male sex 73.6 71 0.78
Caucasians 83.3 90.3 0.63
Age (yrs) 57.4±11.7 60.7±10.7 0.18
BMI (Kg/m²) 26.9±3.6 28.6±5.6 0.11
Diabetes 9.7 9.7 0.99
Current smokers 61.1 58.1 0.77
Hyperlipidemia 18.1 29 0.21
Hypertension 31.9 38.7 0.51
Family history of CAD 44.4 41.9 0.81
Previous MI 4.2 6.5 0.62
Previous PCI 1.4 0 0.51
Previous CABG 0 3.2 0.13
Values are percentages or means (±SD). BMI = body mass index (kg/m²), CAD = coronary artery disease, CABG = coronary artery bypass graft, 
MI = myocardial infarction, PCI = percutaneous coronary intervention
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one patient was homozygous for the CASP1 A allele and was included in the heterozy-
gous group in all analyses.
There were no significant differences in baseline characteristics in the GG vs. (AA+AG) 
genotypes of the CASP1 5352 G/A polymorphism (Table 3). In the present sirolimus-
eluting stent population the frequency of the AA+AG genotypes was (31/103) =30%. 
Population attributable risk (PAR) in sirolimus-eluting stent population was therefore 
[0.3*(2.3-1)]/[1+0.3*(2.3-1)]=28 %.
DISCUSSION
In this study we investigated the influence of 7 polymorphisms involved in inflam-
matory processes on LASM and neonitimal growth in SES patients. We found that of 
these polymorphisms, the caspase-1 5352 G/A polymorphism was a strong predictor of 
LASM. Moreover, there was a clear inverse relation between LASM risk and the amount 
of neointimal growth. This polymorphism has previously been identified to play a role 
in clinical restenosis after PCI.14
The caspase family of cysteine proteases is a key component in signal transduction 
cascades leading to inflammatory responses.23 Caspase-1 (CASP1 or interleukin-1β-
converting enzyme, ICE) transforms immature IL-1β to the mature form which can 
then be secreted by monocytes and macrophages.23 CASP1 is also required for the 
production of IL-1α and activation of IL-18.23 The other members of the caspase family, 
namely caspases 2, 3, 6-10 are mainly involved in apoptosis. Because caspases share 
similarities in structure and substrate specificity,23 CASP1 was initially thought to have a 
pronounced apoptotic effect. Initial studies showed that overexpression of CASP1 could 
promote apoptosis in rat fibroblasts.24 However, other studies showed that CASP1 null 
mice exhibit defects in IL-1 and IL-18 production but did not clearly present defects in 
the regulation of apoptosis.25,26
One previous study14 found the 5352 AA genotype of CASP1 to be associated with 
the higher risk for target vessel revascularization (TVR) and angiographic restenosis 
in patients undergoing percutaneous transluminal coronary intervention (PTCA) and 
BMS deployment.
In the present study we found that patients carrying the 5352 A allele had a significantly 
higher risk for LASM. Furthermore, with IVUS analysis we found the 5352 A allele to be 
associated with significantly less neointimal growth at 9-month follow-up.
In the above mentioned study,14 authors investigated the role of the CASP1 5352 G/A 
polymorphism in patients treated by PTCA, in the majority followed by BMS implanta-
tion. In our study all patients received SES. Sirolimus (rapamycin) was initially described 
as a cytostatic anti-tumoral and immunosuppressant agent.27 Experiments on various 
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cell lines showed that in some cases they may develop resistance and continue to grow 
while in others sirolimus may even induce apoptosis.27-29 In current practice, SES per-
form better than BMS (and some other DES30) in respect to restenosis but are frequently 
associated with LASM.6,31 Conversely, LASM is mostly absent after BMS implantation.6,32 
It is not clear to date whether sirolimus-induced apoptosis is the main mechanism for 
LASM or local inflammation plays the major role. Ozer et al.33 showed that systemic 
inflammatory markers display different patterns according to the type of implanted 
stent: SES associate with a lower plasma increase in high-sensitivity C-reactive protein 
(hsCRP) when compared with BMS, but with a  slightly higher interleukin 6 (IL-6) 
increase; tumor necrosis factor alpha (TNF-α) showed a similar trend in DES and BMS. 
Although the precise mechanism remains to be revealed, we speculate that sirolimus is 
responsible for the differential effect of the CASP 1 5352 G/A polymorphism in the BMS 
and SES population.
In our sirolimus-eluting stent population with a frequency of approximately 30% for 
5352 AA/AG we calculated a population attributable risk for LASM of 28% In other 
words if the 5352 AA/AG genotypes could hypothetically be eliminated, then this would 
reduce LASM risk with 28% in the sirolimus-stented patients.
According to existing data, in case of the patients with one or two A allele of the CASP1 
5352 G/A polymorphism, cardiologists might need to chose between a greater risk of 
LASM potentially triggering stent thrombosis (in SES) or a greater risk of stent reste-
nosis (in BMS). Therefore, cardiologists may need to carefully assess risks and benefits 
related to patient’s condition, previous coronary interventions and associated pathology 
before making this choice. In future, a better tailored dual-antiplatelet therapy as well 
as the new generation of stents may drastically decrease the risks associated with DES 
implantation.. At the same time, further research is needed to optimize the approach of 
patients with documented stent thrombosis34.
In our study, none of the 10 diabetic patients and 26 of the 93 non-diabetic presented 
LASM. Diabetes is a predictor of restenosis after PCI in general35 and higher glucose 
levels have been associated with diminished efficacy of sirolimus on smooth muscle cell 
proliferation in particular36. This may explain a lower incidence of LASM in diabetic 
compared to non-diabetic SES patients. In the larger DIABETES trial37, IVUS analysis 
with a 40 MHz catheter identified at 9 month LASM in 11 out of the 75 (14.7%) SES 
treated lesions in diabetes patients.
The present study investigated inflammatory polymorphisms in STEMI patients. 
Although late (acquired) stent malapposition incidence is higher in STEMI versus non-
STEMI patients, inconclusive data are available about the incidence of late (acquired) 
stent malapposition in STEMI patients receiving SES. Results from previous studies38-41 
vary according to the DES type, the length of the follow-up and the use of either IVUS 
or of the much higher resolution optical coherence tomography (OCT) for assessment. 
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It is therefore unclear to what extent the present findings may be extrapolated to the 
wide category of non-STEMI patients, including those who receive SES during elective 
procedures or to patients receiving a different type of DES.  To date there is no relation 
known between unstable plaque and CASP1. Moreover, there are yet no arguments for 
a differential effect of CASP1 in SES versus non-SES which may limit the outcome of 
this study.
Our findings do not prove a causal relationship between CASP1 polymorphism 
and stent malapposition. The relation between 5352 G/A polymorphism and cytokine 
expression needs further investigation. In a subset of 69 patients, Monraats et al.14 
examined the functional role of the 5352 G/A polymorphism by measuring mature 
IL-1β levels. IL-1β levels were found numerically higher in individuals with the 5352 
AA genotype compared with 5352 GA and 5352 GG genotypes but the difference did 
not reach statistical significance. In our analysis, a policy of not making adjustments 
for multiple comparisons was preferred since, in our view leads to fewer errors of data 
interpretation42.
Conclusions
Our findings sustain the important role of inflammation (and possibly apoptosis) in the 
mechanism of LASM. The A allele of the 5352 G/A polymorphism is associated with 
higher risk of LASM in SES. If this is confirmed in larger studies, genotyping for CASP1 
5352 G/A polymorphism may help cardiologists to make a better decision between SES 
and BMS implantation and may guide the (duration of) anti-platelet therapy in the 
future.
125
The 5352A allele of the Caspase-1 gene predicts late acquired stent malapposition
REFERENCES
 1.  Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent 
thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092
 2.  Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinua-
tion may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-
metal stents. J Am Coll Cardiol 2006;48:2584-2591
 3.  Watanabe Y, Asano R, Hata N, et al. Late stent malapposition with marked positive vascular remodel-
ing observed only at the site of drug-eluting stents after multivessel coronary stenting. Heart Vessels 
2009;24:308-312
 4.  Bergheanu SC, Van der Hoeven BL, Hassan AK, et al. Post-intervention IVUS is not predictive for very 
late in-stent thrombosis in drug-eluting stents. Acta Cardiol 2009;64:611-616
 5.  Hassan AKM, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk is higher after drug-eluting 
stent compared to bare-metal stent implantation and associates with late stent thrombosis. Eur Heart 
J 2009;31:1172-80
 6.  van der Hoeven BL, Liem SS, Dijkstra J, et al. Stent Malapposition after Sirolimus-Eluting and Bare-
Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction: Acute and 
9-Month Intravascular Ultrasound Results of the MISSION! Intervention Study. J Am Coll Cardiol Intv 
2008;1:192-201
 7.  Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus 
Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound 
Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Con-
sensus Documents. J Am Coll Cardiol 2001;37:1478-1492
 8.  Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition after sirolimus-eluting stent implan-
tation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 2005;46:1002-1005
 9.  Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis 
secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-705
 10.  Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of late stent malapposition. 
Circulation 2003;107:2660-2663
 11.  Giordano A, Avellino R, Ferraro P, Romano S, Corcione N, Romano MF. Rapamycin antagonizes NF-
kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and 
enhances apoptosis. Am J Physiol Heart Circ Physiol 2006;290:H2459-H2465
 12.  Perlman H, Maillard L, Krasinski K, Walsh K. Evidence for the rapid onset of apoptosis in medial 
smooth muscle cells after balloon injury. Circulation 1997;95:981-987
 13.  Agema WR, Monraats PS, Zwinderman AH, et al. Current PTCA practice and clinical outcomes in 
The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 2004;25:1163-1170
 14.  Monraats PS, de Vries F, de Jong LW, Pons D, et al. Inflammation and apoptosis genes and the risk of 
restenosis after percutaneous coronary intervention. Pharmacogenet Genomics 2006;16:747-754
 15.  Monraats PS, Pires NM, Agema WR, et al. Genetic inflammatory factors predict restenosis after 
percutaneous coronary interventions. Circulation 2005;112:2417-2425
 16.  Monraats PS, Kurreeman FA, Pons D, et al. Interleukin 10: a new risk marker for the development of 
restenosis after percutaneous coronary intervention. Genes Immun 2007;8:44-50
 17.  Monraats PS, Pires NM, Schepers A, et al. Tumor necrosis factor-alpha plays an important role in 
restenosis development. FASEB J 2005;19:1998-2004
 18.  Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late 
thrombotic risk. J Am Coll Cardiol 2006;48:193-202
Chapter 8
126
 19.  van der Hoeven BL, Liem SS, Jukema JW, et al. Sirolimus-eluting stents versus bare-metal stents in 
patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular 
ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J 
Am Coll Cardiol 2008;51:618-626
 20.  Liem SS, van der Hoeven BL, Oemrawsingh PV, et al. MISSION!: optimization of acute and chronic 
care for patients with acute myocardial infarction. Am Heart J 2007;153:14-11
 21.  Koning G, Dijkstra J, von Birgelen C, et al. Advanced contour detection for three-dimensional intra-
coronary ultrasound: a validation--in vitro and in vivo. Int J Cardiovasc Imaging 2002;18:235-248
 22.  Oemrawsingh PV, Mintz GS, Schalij MJ, et al. Intravascular ultrasound guidance improves angio-
graphic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a 
randomized comparison with angiographic guidance (TULIP Study). Circulation 2003;107:62-67
 23.  Creagh EM, Conroy H, Martin SJ. Caspase-activation pathways in apoptosis and immunity. Immunol 
Rev 2003;193:10-21
 24.  Miura M, Zhu H, Rotello R, Hartwieg EA, Yuan J. Induction of apoptosis in fibroblasts by IL-1 beta-
converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 1993;75:653-
660
 25.  Kuida K, Lippke JA, Ku G, et al. Altered cytokine export and apoptosis in mice deficient in interleu-
kin-1 beta converting enzyme. Science 1995;267:2000-2003
 26.  Li P, Allen H, Banerjee S, et al. Mice deficient in IL-1 beta-converting enzyme are defective in produc-
tion of mature IL-1 beta and resistant to endotoxic shock. Cell 1995;80:401-411
 27.  Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001;4:378-391
 28.  Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human 
cancer cells. Mol Pharmacol 1998;54:815-824
 29.   Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and 
induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-894
 30.  Cirillo P, De Rosa S, Di Palma V, et al. Different vascular response to concurrent implantation of 
sirolimus- and zotarolimus-eluting stents in the same vessel. Heart Vessels 2009;24:313-316
 31.  Takano M, Inami S, Jang IK, et al. Evaluation by optical coherence tomography of neointimal coverage 
of sirolimus-eluting stent three months after implantation. Am J Cardiol 2007;99:1033-1038
 32.  Xie Y, Takano M, Murakami D, et al. Comparison of neointimal coverage by optical coherence to-
mography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation. Am J 
Cardiol 2008;102:27-31
 33. Ozer N, Tangurek B, Firat F, et al. Effects of drug-eluting stents on systemic inflammatory response in 
patients with unstable angina pectoris undergoing percutaneous coronary intervention. Heart Vessels 
2008;23:75-82
 34. Karakurt O, Cagirci G, Kilic H, Akdemir R. Resolution of late sirolimus-eluting stent thrombosis after 
tirofiban treatment. Heart Vessels 2009;24:388-390
 35. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary inter-
ventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 
1997;95:1366-1369
 36. Patterson C, Mapera S, Li HH, et al. Comparative effects of paclitaxel and rapamycin on smooth 
muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol 
2006;26:1473-1480
 37. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, et al. Vascular effects of sirolimus-eluting versus bare-
metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-
Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006;47:2172-2179
127
The 5352A allele of the Caspase-1 gene predicts late acquired stent malapposition
 38. Chechi T, Vittori G, Biondi Zoccai GG, et al. Single-center randomized evaluation of paclitaxel-eluting 
versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007;20:282-
291
 39. Gonzalo N, Barlis P, Serruys PW, et al. Incomplete stent apposition and delayed tissue coverage are 
more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention 
for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/
unstable angina: insights from optical coherence tomography. J Am Coll Cardiol Intv 2009;2:445-452
 40. Maehara A, Mintz GS, Lansky AJ, et al. Volumetric intravascular ultrasound analysis of Paclitaxel-
eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revas-
cularization and stents in acute myocardial infarction intravascular ultrasound substudy. Circulation 
2009;120:1875-1882
 41. Takano M, Inami S, Jang IK, Yamamoto M,  et al. Evaluation by optical coherence tomography of 
neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol 
2007;99:1033-1038
 42. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46

Part 2
Epigenetic determinants in vascular disease

Chapter 9
Epigenetic histone acetylation modifiers  
in vascular remodeling  – new targets  
for therapy in cardiovascular disease
Douwe Pons, Florentine R. de Vries, Peter J. van den Elsen,  
Bastiaan T. Heijmans, Paul H.A. Quax and J. Wouter Jukema




Significant progress has been made in the clinical management of a variety of cardiovas-
cular diseases. Nevertheless, the therapeutic efficacy of the current treatment modalities 
for atherosclerosis and restenosis is not fully sufficient in a large proportion of patients. 
One of the major contributing factors is the clinical and biological heterogeneity of these 
still life-threatening diseases, which involve processes that we do not fully understand 
at the moment. Over the past decades it has become increasingly clear that part of the 
gene-environmental interactions relevant for complex diseases is regulated by epigenetic 
mechanisms such as histone acetylation and DNA methylation. Epigenetic processes 
modulate gene expression patterns without modifying the actual DNA sequence and 
have profound effects on the cellular repertoire of expressed genes. They contribute to 
the expression of genes that play a key role in extracellular matrix formation, inflam-
mation and proliferation, processes involved in cardiovascular pathologies such as 
atherosclerosis and restenosis.
Therefore, in this review we argue that epigenetic regulators involved in histone 
acetylating and deacetylating activities, contribute to the pathogenesis of atherosclerosis 
and restenosis. Furthermore, as alterations in chromatin structure are reversible, these 
epigenetic modifications are amendable to pharmacological intervention, which may 
prove to be an effective treatment modality for management of cardiovascular diseases.
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1. INTRODUCTION
1.1 Atherosclerosis and restenosis
Atherosclerosis and restenosis are multifactorial processes, which have several corre-
sponding features and share some risk factors such as diabetes and hypertension. Both 
processes are in a significant part characterized by an inflammatory response to injury 
of the endothelium, which causes reshaping of the vessel wall in size and composition, 
called vascular remodeling. Furthermore, they share proliferation and migration of 
vascular smooth muscle cells (VSMCs) and elaboration of extracellular matrix, leading 
to accumulation of collagen and proteoglycans.
Despite these similarities, there also are important differences in the cause and pro-
gression of atherosclerosis and restenosis. Atherosclerosis develops partly in response 
to elevated lipoprotein levels and cigarette smoke, whereas restenosis is mainly an 
overshooting wound healing response to vascular injury by balloon dilatation or stent 
placement. This restenotic process is not particularly sensitive to circulating lipids and 
smokers even seem to have a reduced risk for restenosis.1 Furthermore, atherosclerosis 
is, in contrast to restenosis, characterized by accumulation of oxidized lipoproteins, 
both within foam cells and extracellularly. While development and progression of ath-
erosclerosis is associated with aging, the restenotic process is relative rapidly induced 
after revascularization interventions such as balloon dilatation or stent placement.
Currently, atherosclerosis and restenosis are still serious health problems, which we 
do not yet fully understand. It is therefore important to search for factors that cause and 
contribute to the development of the processes involved in these diseases. Investiga-
tion into the exact mechanisms of the disturbed lipoprotein metabolism, inflammation, 
proliferation and migration of smooth muscle cells and vascular remodeling, will offer 
us more opportunities for prediction, diagnosis and finally treatment.
Because clinical risk factors do not fully predict the development of atherosclerosis 
and restenosis, it is important to search for genes that determine susceptibility to these 
risk factors.  A positive family history is a major risk factor for cardiovascular disease 
and twin studies have shown that death from coronary artery disease at an early age of 
one twin is a strong predictor of the risk in the other twin.2
As reviewed by Nordlie et al., many genes in lipid metabolism, vascular homeostasis, 
hemostasis and inflammation have been found to be related to coronary artery disease.3 
Although observed associations were not always replicated by other studies, their review 
emphasizes the importance of genetics in atherosclerotic disease. Moreover, the multi-
factorial nature of the disease suggests a role for many other, yet uninvestigated genes.
Previous research from our department has demonstrated the importance of genet-
ics in restenosis after percutaneous coronary interventions (PCI). Polymorphisms in 
several inflammatory genes, such as tumour necrosis factor α (TNF-α), eotaxin, CD14, 
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granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin 10 (IL-10), 
caspase-1, but also non-inflammatory genes, such as lipoprotein lipase (LPL), stromely-
sin-1 (MMP3) and the β adrenergic receptor have been found to be associated with the 
risk for restenosis.4-7
In the past decade, research into cardiovascular diseases has been focused on the 
identification of these genetic factors. It has become clear, however, that part of the 
gene-environmental interactions relevant for complex diseases in which inflammation, 
proliferation and remodeling play an important role, is regulated by epigenetic mecha-
nisms such as histone acetylation and DNA methylation.
Epigenetics, the study of non-DNA sequence-related heredity, can help to explain 
the relationship between an individual’s genetic background, the environment, aging 
and disease. Thus, a review of the possible role of epigenetics in complex diseases like 
atherosclerosis and restenosis seems appropriate and is presented here.
1.2 Epigenetics
Epigenetic processes modulate gene expression patterns without modifying the actual 
DNA sequence and have profound effects on the cellular repertoire of expressed genes.8 
It is well known that epigenetic processes can lead to meiotically and mitotically heritable 
changes in gene expression and play an important role in control of cell identity. Two 
well-known examples of epigenetic mechanisms are methylation of DNA at CpG di-
nucleotides and modification or rearrangement of nucleosomes, which include covalent 
post-translational modifications of histone tails.9, 10 Both processes can be influenced by 
environmental factors and affect gene function without changing the DNA sequence.
In contrast with classical mendelian views on inheritance, epigenetics also focuses on 
heredity of environmental effects which lead to DNA modifications other than DNA 
sequence variation, a phenomenon which is called ‘epigenetic inheritance’. An increas-
ing number of findings from both human and animal studies support the existence 
of epigenetic inheritance, and show that DNA-methylation is the main responsible 
mechanism.11, 12 Inheritance of DNA-methylation is regulated by the enzyme DNA 
methyltransferase 1 (Dnmt I), which is known to copy methylation patterns during 
semiconservative DNA replication.13
Although a similar mechanism has not yet been discovered for post-translational 
histone modifications, they are likely to be maintained through cell-division. Not only 
methylation of DNA, but also acetylation of histones, has been shown to accumulate 
in time.8 Older monozygotic twins were found to have larger differences in DNA 
methylation and histone acetylation when compared to younger twin pairs. This finding 
also demonstrates that post-translational histone modifications can be influenced by 
environmental factors.
135
Histone acetylation modifiers in vascular remodeling – new targets for therapy in CVD
Despite the lack of an evident mechanism of maintaining post-translational histone 
modifications during cell division, modification of histone tails is by many considered 
an epigenetic process.14, 15
Epigenetic modifications of histone tails include acetylation, methylation, ubiqui-
tination and SUMOylation of lysine residues, phosphorylation of serine residues and 
methylation of arginines. The various histone modifications form a code which is read 
by non-histone proteins and have varying effects on chromatin structure and gene ac-
cessibility.9 As a rule of thumb, conformationally relaxed chromatin (euchromatin) is 
a hallmark of potentially active genes and is associated with hypomethylation of CpG 
dinucleotides in DNA and acetylated histones. Compact chromatin (heterochromatin) is 
associated with transcriptionally silent genes and is associated with DNA hypermethyl-
ation at CpG dinucleotides and nonacetylated histones. These chromatin modifications 
are exerted by epigenetic regulators such as DNA methyltransferases (Dnmts), histone 
(lysine) acetyltransferases (KATs) and histone methyltransferases (HMTs), which are 
increasingly being implicated as direct or indirect components in the regulation of 
expression of vascular, immune, and other (tissue)-specific genes.
A great promise of epigenetics is that it offers new targets for therapy in cardiovas-
cular disease. Epigenetic processes are reversible by nature, which is underscored by 
the counterbalancing action of KATs and KDACs (lysine deacetylases), and of HMTs 
and HDMs (histone demethylases), and is required for fine-tuning of gene expression 
for fundamental cellular processes such as cell proliferation and differentiation. This 
offers the prospect of pharmacological inhibition of the various enzymatic activities 
involved in epigenetic DNA and histone modifications, which is aimed at the induction 
or silencing of transcription of disease relevant genes. In addition to the possibility of 
modifying the effects of deleterious genes, it might be possible to influence the effects of 
environmental risk factors.
Since KATs and KDACs are involved in fundamental processes that regulate the 
expression of multiple genes, they most likely play an important role in the multifacto-
rial processes that lead to atherosclerosis and restenosis. Therefore, it is important to 
identify those KATs and KDACs that play a role in the transcriptional regulation of 
genes, the products of which contribute to the processes involved in neointima forma-
tion and atherogenesis, such as inflammation, smooth muscle cell proliferation and 
matrix formation.
Single gene disorders in the histone acetylation machinery have already been shown 
to cause clinical syndromes. For example, patients with Rubinstein-Taybi syndrome 
are known to have mutations in the gene encoding CREB binding protein (CBP), a 
transcriptional coactivator with KAT-activity.16 Therefore it seems likely that also poly-
morphisms in genes encoding
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KATs or KDACs, provided that they have functional implications, may influence 
cardiovascular disease susceptibility by affecting the fidelity of these enzymes. This 
hypothesis was recently confirmed by research from our department showing that the 
-2481 G/C polymorphism in the promoter of the gene encoding p300/CBP-associated 
factor (PCAF), a KAT with an important role in inflammatory gene activation, is sig-
nificantly associated with all-cause mortality in the PROSPER-study (n=5804) and with 
clinical restenosis after a percutaneous coronary intervention in the GENDER-study 
(n=3104). Genetic epidemiology may lead to the identification of more risk markers 
in genes encoding KATs or KDACs and provide new insights into the pathophysiology 
of atherosclerosis and restenosis, which could contribute to the development of better 
therapy.
In this review we will discuss the role of KATs and KDACs in the transcriptional 
regulation of genes that play a critical role in inflammation, proliferation and matrix 
formation, processes which are thought to be pathognomonic for atherosclerosis and 
restenosis development.
2. KATS AND KDACS
Gene expression is regulated by acetylation of core histones through the action of KATs 
by transfer of an acetyl group to the ε-portion of lysine residues. Hyperacetylation of 
histones results in an open modification of chromatin structure and affects gene tran-
scription through accessibility of DNA to the basal transcription initiation machinery 
(figure 1).17-19 Conversely, gene repression is mediated via KDACs and other corepres-
sors, which remove the acetyl groups from hyperacetylated histones and counteract the 
activity of KATs resulting in a closed chromatin structure. These  nuclear enzymes have 
been shown to regulate the expression of inflammatory genes by modifying chromatin 
structure.20 KATs are recruited to promoters by gene regulatory proteins that interact 
with specific recognition sequences in DNA, and in this way control gene transcrip-
tion. This is exemplified by the transcriptional control of MHC-II genes in which the 
class II transactivator (CIITA), a component of the promoter assembled enhanceosome, 
provides the platform for recruitment of KAT and KDAC activities.21-23
At the moment a large variety of KATs have been identified, which can be divided in 
several families, including the PCAF/Gcn5, p300/CBP, MYST, SRC, TAFII250, KAT1 and 
ATF-2 families. The KATs within these families show high sequence similarity, but there 
is poor similarity between these families.24 All KAT proteins vary in their KAT-domains 
and their substrate-specificity, but have the common feature that they require the as-
sembly of multiprotein complexes for nucleosomal acetylation.25 Their precise substrate-
specificity even depends on the context of these multisubunit KAT-complexes.26
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The KDAC enzymes are zinc-dependent aminohydrolases which can be grouped into 
different classes. 27 Class I KDACs (KDAC 1-3 and 8) are widely expressed, reside almost 
exclusively in the nucleus and are known to modulate cell proliferation and survival. 
Class II KDACs (KDAC 4-7, 9 and 10) have a more restricted distribution, are able to 
move between the nucleus and cytoplasm in response to certain cellular signals and 
may be involved in cellular differentiation.27, 28 Class II KDACs can be further divided in 
subclasses IIa (KDAC 4, 5, 7 and 9) and IIb (KDAC 6 and 10). Class IIa members form 
a distinct group because of the presence of an extended N-terminal regulatory domain, 
29 whereas KDAC 6 and 10 contain an extra catalytic domain. 30 The most recently dis-
covered isoform is KDAC11, which constitutes class IV.31 A different NAD+-dependent 
family consists of sirtuins (SIRT 1-7) which are thought to be involved in apoptosis of 
mononuclear cells.32, 33
The different KDACs are likely to be regulated differently. KDACs interact with core-
pressor molecules, such as nuclear receptor corepressor and ligand-dependent corepres-
sor, NuRD and mSin3, all of which aid KDACs in gene repression and may provide 
specificity by selecting which genes are switched off by KDACs.34, 35 Furthermore, KDAC 
activity is associated with the action of Polycomb Group Proteins,36 which play a key role 
in gene silencing and maintenance of cellular identity.
Besides their role in histone acetylation, KATs are also found to act as factor acetyl-






Figure 1. Histone acetylation
Acetylation of histone-tails is mediated by histone (lysine) acetyltransferases (KATs) and results in an open modification of chromatin structure. 
It allows transcriptions factors to access the DNA and initiate gene transcription. Conversely, gene repression is mediated via lysine deacetylases 
(KDACs), which remove the acetyl groups from the histone-tails, resulting in a closed chromatin structure.
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is directly acetylated by PCAF,38, 39 CREB binding protein (CBP) and p300,40, 41 and 
nuclear factor kappa B (NFκB), which is acetylated by CBP and p300.42, 43 Acetylation 
of these proteins often results in increased DNA-binding and transcriptional activity.37 
Accumulating evidence suggests that many KDACs can deacetylate these non-histone 
proteins. For example, KDAC3 is known to deacetylate the p65 subunit of NFκB, pro-
moting association with IκBα, which leads to IκBα-dependent nuclear export of NFκB.44 
Furthermore, KDAC1 has been shown to deacetylate p53 in vitro and in vivo.45 As many 
other non-histone proteins are also known to be targeted by KATs and KDACs, their 
influence on gene expression is not necessarily dependent on chromatin remodeling. 
Changes in gene expression which are caused by alterations in the activity of KATs or 
KDACs can therefore not automatically be regarded as epigenetic.
 Over the past years several KAT and KDAC inhibitors have been identified. These 
inhibitors mechanistically affect the action of KATs and KDACs. The large variety of 
KDAC-inhibitors that have been discovered or developed can be divided in structural 
classes (table 1).27, 46, 47 Early phase clinical trials have demonstrated that inhibitors from 
all different classes seem to be well tolerated and exhibit clinical activity against several 
human neoplasms.27
In the next paragraphs we will discuss the role of KATs and KDACs in inflammatory, 
proliferative and remodeling processes associated with atherosclerosis and restenosis. 
Furthermore, we will discuss the potential applicability of KAT and KDAC inhibitors in 
disease management.
Table 1. Structural classes of KDAC inhibitors
Short-chain fatty acids Sodium butyrate, Sodium phenylbutyrate, Valproic acid (VPA), Pivaloyloxy-
methylbutyrate (AN-9)
Hydroxamic acids Trichostatin A (TSA), Suberoylanilide hydroxamic acid (SAHA), Azelaic bishydroxamic 
acid (ABHA), Aroyl pyrrolyl hydroxy-propenamides (APHA), carboxycinnamic acid 
bishydroxamide (CBHA), Suberoyl bishydroxamic acid (SBHA), Oxamflatin, Scriptaid, 
Pyroxamide, Tubacin, ITF2357, LBH589, NVP-LAQ824, 3-Cl-UCHA, A-161906, 
JNJ16241199, CRA-024781, PXD101
Benzamides MS-275  (MS-27-275), MGCD0103, CI-994
Epoxyketone-containing cyclic 
tetrapeptides
Trapoxins, Chlamydocin, 2-Amino-8-oxo-9,10-epoxydecanoic acid (AOE)
Non-epoxyketone-containing 
cyclic tetrapeptides
Depsipeptide, FR901228 (FK228), Apicidin
Hybrid molecules Cyclic hydroxamic acid-containing peptides (CHAPs): CHAP31, CHAP50
Adapted from: Santini et al. (2007), Drummond et al. (2005) and Monneret et al. (2005).2
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3. INFLAMMATION, THE ROLE OF KATS AND KDACS
3.1 Nuclear Factor kappa B
Atherosclerosis and restenosis are for a major part determined by inflammation.5, 48 The 
expression of multiple inflammatory genes is regulated by pro-inflammatory transcrip-
tion factors, such as NFκB. The transcription factor NFκB plays a role in the orchestration, 
amplification and perpetuation of the inflammatory response and forms the molecular 
basis of chronic inflammation.49-51 KATs and KDACs have been implicated in modu-
lating NFκB activity. In unstimulated cells NFκB is found in the cytoplasm associated 
with its inhibitor protein called IκB, which masks the nuclear translocation signal and 
prevents NFκB from entering the nucleus.52 Upon cell stimulation with various NFκB 
inducers, including reactive oxygen species (ROS) and lipid peroxidation products, IκB 
is rapidly phosphorylated and thereby targeted for ubiquination.53, 54 The released NFκB 
dimer is translocated to the nucleus and activates target genes by binding with high 
affinity to κB elements in their promoters.55, 56 This process is known to be activated by 
KATs and repressed by KDACs.57 IL-1β and TNF-α have been shown to stimulate the 
binding of the NFκB p65 subunit to CBP and to induce histone acetylation, thus leading 
to an increase in NFκB-mediated expression of inflammatory genes, such as GM-CSF 
and IL-8 (figure 2).58, 59 Furthermore, p300 has been shown to enhance angiotensin II-
induced IL-6 expression in rat VSMCs, a process which is also mediated by NFκB.60 
Also PCAF is known to be required to coactivate p65-dependent transcription and 
has been shown to activate the transcription of several NFκB-regulated genes known 
to be involved in cardiovascular disease. Spermidine/Spermine N1-Acetyltransferase 2 
(SSAT2) has been found to cooperate with CBP and PCAF to enhance TNF-α-induced 
NFκB activity.61 Furthermore, Miao et al. demonstrated that PCAF could enhance the 
p65 mediated increase in TNF-α promoter activity and that high glucose increased the 
recruitment of PCAF to the TNF-α and cycloöxygenase 2 (COX-2) promoters.62 They 
demonstrated concomitant acetylation of specific lysine residues of histone H3 and H4 
at these promoters. Since TNF-α and COX-2 have been implicated in the development 
of  both atherosclerosis63, 64 and restenosis,4, 65 PCAF may play a role in the development 
of these diseases. A role for PCAF in vascular disease was recently confirmed by findings 
from our department showing that the -2481 G/C polymorphism in the promoter of the 
PCAF gene is significantly associated with all-cause mortality in the PROSPER-study 
(manuscript in preparation, abstract published in Circulation, Oct 2007; 116: II_40). 
The minor C allele was associated with a significant survival advantage, while this al-
lele was also found to protect against clinical restenosis after a percutaneous coronary 
intervention in the GENDER-study.
In line with the findings showing a role for KATs in NFκB-mediated transcriptional ac-
tivation, KDACs have been shown to reverse this process and to repress NFκB-mediated 
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gene expression.66, 67 Furthermore, KDAC-inhibition by trichostatin A (TSA) was found 
to increase basal and TNF-α-induced expression of the NFκB-regulated IL-8 gene, 
whereas expression of KDAC1 and KDAC2 repressed TNF-induced NFκB-dependent 
gene expression.67
In addition to its ability to associate with KATs and KDACs, the p65 component of 
NFκB is also a direct target for acetylation and deacetylation. PCAF and CBP/p300 
appear to acetylate specific lysine residues on the p65 subunit of NFκB, increasing its 
DNA binding and causing transcriptional activation (figure 2), whereas KDAC3 has 
been shown to deacetylate NFκB and promote its association with the inhibitor IkBα 
within the nucleus, in order to promote export into the cytoplasm and thus terminate 
the activity of NFκB.42, 44, 68, 69
3.2 Granulocyte Macrophage – Colony Stimulating Factor
Several findings indicate the importance of GM-CSF in atherosclerosis and restenosis. 






Figure 2. The role of PCAF in the activation of NFκB-mediated transcription.
The figure illustrates the dual role of p300, CBP and PCAF in the activation of NFκB-mediated transcription upon cell stimulation with 
NFκB-inducers, such as Reactive Oxygen Species (ROS), TNF-α or IL-1β. These coactivators act as lysine acetyltransferases (KATs) at the site of 
NFκB-regulated genes. Furthermore, they act as factor acetyltransferases (FATs) and appear to acetylate the p65 subunit of NFκB, increasing its 
DNA-binding and causing transcriptional activation also by this mechanism.
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sclerosis in WHHL (Watanabe heritable hyperlipidemic) rabbits.70 Furthermore, in a 
rabbit model of restenosis, GM-CSF injections have been shown to reduce neointima 
formation.71 In further support of a role for GM-CSF in the development of restenosis, 
variation in the GM-CSF gene has been shown to be related to the risk of restenosis in 
a large patient population undergoing PCI.5 Because of its role in atherosclerosis and 
restenosis it is of interest to note that the NFκB-mediated, inflammatory signalling 
induced hyperacetylation of histone H4 also correlated with an increased expression of 
GM-CSF. The KDAC inhibitor TSA was found to lead to an increased expression of GM-
CSF and IL-8 in alveolar macrophages and airway epithelial cell lines after activation 
with inflammatory stimuli.58, 72, 73
3.3 Eotaxin
Eotaxin, an eosinophil chemoattractant important in inflammatory responses, has 
already been shown to play a role in atherosclerotic disease. Eotaxin plasma levels 
were found to be associated with angiographic coronary artery disease74 and human 
atherosclerotic plaques were found to express increased quantities of eotaxin mRNA.75 
Furthermore, the A23T polymorphism in the eotaxin gene is associated with the risk 
for myocardial infarction76 and the -1328 A allele was found to decrease the risk for 
restenosis after PCI.5
Inflammatory signalling by TNF-α induces selective histone H4 acetylation and bind-
ing of p65 to the eotaxin promoter as determined by chromatin immunoprecipitation 
(ChIP), resulting in eotaxin gene transcription.77 Notably ChIP analysis also revealed 
that Beta(2)-agonists and glucocorticoids were able to reduce transcription of eotaxin 
by inhibiting both TNF-α-induced histone H4 acetylation and recruitment of p65 to the 
eotaxin promoter, without altering the capability of NFκB to translocate to the nucleus.
3.4 Cycloöxygenase-2
Several proteins that have been implicated in the development of cardiovascular disease 
have been studied more extensively in cancer and inflammatory diseases. This is exempli-
fied by Cox-2, a protein that may be associated with the development of atherosclerosis64 
and restenosis,65 which plays an important role in colon carcinogenesis and inflamma-
tion.78 Cox-2 expression can be induced by several cytokines, including TNF-α, and 
the KDAC-inhibitors sodium butyrate (NaBu) and TSA were found to repress Cox-2 
mRNA and resulting protein synthesis in a colon cancer cell line (HT-29).79 Although 
KDAC inhibition by NaBu is known to suppress cytokine-induced NFκB activation, and 
NFκB binding sites exist within the Cox-2 promoter, this repression of Cox-2 expression 
in HT-29 cells was not mediated by a lower Cox-2 promoter activity, but was related 
to mRNA stabilization.79 These observations infer that besides a direct effect of KDAC 
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inhibitors on gene promoter activity, additional cellular mechanisms exists which con-
tribute to modulation of mRNA expression and protein levels of Cox-2.
3.5 Reactive Oxygen Species
Activated inflammatory cells and a perturbation of lipoprotein metabolism are key fac-
tors in atherogenesis. The oxidative modification of lipids is involved in the recruitment 
of mononuclear leukocytes to the arterial intima. Furthermore, activated leukocytes, as 
well as endothelial mitochondria, can produce reactive oxygen species (ROS) that are as-
sociated with endothelial dysfunction.80 Elevated intracellular ROS are generated under 
various physiological and pathological conditions involving oxidative stress, including 
inflammation, ischemia, reperfusion, and sepsis. The biological effects resulting from 
oxidative stress are in part mediated by modifications in KAT and KDAC activities, 
which lead to alterations in histone acetylation levels and resulting NFκB activation.28, 
52, 81 Several in vitro experiments have shown that hydrogen peroxide increases KAT-
activity73 and decreases KDAC-activity,57, 82 leading to an increase in histone acetylation 
and expression of inflammatory mediators.
The role of ROS in chromatin remodeling is further illustrated by the observed imbal-
ance in expression levels of KATs and KDACs in bronchial biopsies from patients with 
asthma, when compared with airways of non-asthmatic subjects.83 Notably, treatment 
with inhaled steroids resulted in increased KDAC activity and reduced KAT activity 
in subjects with asthma thereby influencing this imbalance. This is in accordance with 
other studies describing that recruitment of KDAC activity to activated transcriptional 
complexes was required for glucocorticoid repression of inflammatory genes.58, 84 In ad-
dition, the glucocorticoid receptor also acts as a direct inhibitor of CBP-associated KAT 
activity.58 This could be a mechanism that explains the effectiveness of glucocorticoids in 
suppressing inflammation in asthma.
Together there are several lines of evidence that suggest an important role of altered 
histone acetylation levels in inflammatory processes, which are associated with athero-
sclerosis and restenosis.
4. PROLIFERATION OF (V)SMCS AND HISTONE ACETYLATION
4.1 Serum Response Factor
Precise control of smooth muscle cell (SMC) gene transcription plays a major role in 
vascular development and pathophysiology. Vascular SMCs undergo profound changes 
in their phenotype during neointima formation in response to vessel injury or within 
atherosclerotic plaques.85 Serum Response Factor (SRF) is an important mediator in 
transcriptional activation of genes that exhibit SMC-restricted expression. SRF exerts 
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its activation through binding to CArG box DNA sequences found within regulatory 
elements of these genes. Recent findings indicate that binding of this factor is influenced 
by chromatin structure. In vitro and in vivo experiments have shown that SRF-binding 
is associated with patterns of posttranslational histone modifications that are specific 
to the SMC lineage, including di-methylation of lysine residues 4 and 79 in histone 
H3, acetylation of lysine 9 in histone H3 and acetylation of histone H4. In particular, 
deacetylation of histone H4 was coupled with loss of SRF binding to CArG box DNA 
during suppression of SMC differentiation in response to vascular injury.86 SRF-medi-
ated transcriptional activation is enhanced by myocardin, which acts as a co-activator, 
through interaction with the MADS box of SRF. Myocardin is specifically expressed in 
cardiac and smooth muscle cells, and plays a critical role in the differentiation of SMCs 
through activation of SMC-specific genes by tethering to CArG boxes with SRF.87 The 
promyogenic activity of myocardin is enhanced by p300, a lysine acetyltransferase that 
associates with the transcription activation domain of myocardin.87 Conversely, class II 
lysine deacetylases interact with a domain of myocardin distinct from the p300-binding 
domain and suppress smooth muscle gene activation by myocardin.
4.2 Hyper nuclear acetylation
Hyper nuclear acetylation (HNA) plays a role in proliferation, differentiation and 
apoptosis.88 Using an antibody against ε-acetylated lysine, increased histone acetyla-
tion was observed in VSMCs in coronary atherosclerotic lesions, whereas it was not 
present in normal coronary arteries. Furthermore, thrombin, a humoral factor known 
to cause activation and proliferation of VSMCs, strongly potentiates HNA in cultured 
VSMCs. In thrombin-induced HNA of VSMCs, the MAP kinase pathway and the CREB 
binding protein (CBP) are implicated.89 It suggests that coactivators cooperating with 
signal-dependent transcription activators play a role in atherosclerogenesis via HNA in 
VSMCs.
4.3 Cell-cycle regulators
Because KDACs also modulate histone acetylation levels at the site of genes involved 
in cell cycle control, they have also been implicated in the proliferation of SMCs.90, 91 
This is illustrated by the observation that TSA was found to inhibit SMC proliferation 
via induction of p21waf1.92 Activity of p21waf1 is known to induce cell-cycle arrest in 
vascular smooth muscle cells,93-96 and A20, a NFκB-dependent gene that has been shown 
to inhibit proliferation of VSMCs via increased expression of p21waf1, has been shown 
to prevent neointima formation after balloon angioplasty in a rat model of carotid artery 
stenosis.97
Also PCAF could play a role in the suppression of VSMC proliferation by its ability 
to directly acetylate p53.38, 39 PCAF has been shown to activate p53-responsive enhancer 
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elements within the p21waf1 promoter.39 Moreover, KDAC8 was found to be exclusively 
expressed in cells showing smooth muscle differentiation, including visceral and vascu-
lar smooth muscle cells, myoepithelial cells and myofibroblasts, and is mainly detected 
in their cytosol.98 Until recently, it was thought that its activity was restricted to the 
nucleus, with histones as a unique substrate.
5. REMODELING: EXTRACELLULAR MATRIX FORMATION AND CHROMATIN 
DYNAMICS
Inappropriate remodeling of the vessel wall in response to a variety of stimuli, including 
hemodynamic changes, inflammation and tissue injury, is currently thought to be caus-
ative to the development of atherosclerosis and restenosis. The matrix metalloproteinases 
(MMPs) comprise a family of structurally related proteins, which includes collagenases, 
stromelysin and gelatinases. They have the collective capability to degrade components 
of the extracellular matrix and to act as mediators in a variety of cell signalling pathways 
through degradation of non-matrix proteins. MMP expression is strongly enhanced 
in vascular pathologies and is therefore thought to contribute to the disease process. 
This is illustrated by the observation that enhanced expression of MMP2 and MMP9 
(also referred to as Gelatinase A and Gelatinase B) is noted in vulnerable regions of 
human carotid plaques in association with macrophages.99 Furthermore, as reviewed by 
Newby, induction of MMP9 and activation of MMP2 occur rapidly after balloon injury 
in multiple animal models.100 Additional evidence for an important role of MMP2 and 
MMP9 in vascular remodeling comes from knockout mouse-models of these gelatinases 
which showed reduced VSMC migration and less neointima formation after arterial 
injury.101-104 Increased MMP3 (also referred to as stromelysin-1) expression has been 
linked to plaque rupture.99, 105 In addition, several studies investigating the MMP3 5A/6A 
promoter polymorphism have shown that the risk of myocardial infarction is higher in 
patients carrying the 5A allele, which is associated with increased MMP3 levels.106-110 
MMP1 and MMP13 are also associated with cardiovascular disease. MMP1 was found 
expressed in human atherosclerotic lesions and not in unaffected blood vessel walls.111 
Moreover, the MMP1 1G/2G polymorphism at position -1607 of the transcriptional 
start site, which is associated with a higher promoter activity, reduces the risk for coro-
nary artery disease.111 Likewise, the MMP13 -77 A/G polymorphism is associated with 
atherosclerosis in the abdominal aorta of black males.112
Due to their essential role in vessel wall remodeling, MMPs could become prime 
targets for pharmacological interference in various pathological conditions that exhibit 
increased or decreased MMP levels and resulting excessive or reduced matrix degrada-
tion.
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In the next sections we will discuss the role of the chromatin environment in expres-
sion of the various MMPs in vascular pathologies.
5.1 MMP2 and MMP9 (Gelatinase A and Gelatinase B)
Epigenetic mechanisms have been implicated in regulation of transcription and/or 
functional expression of MMP2 and MMP9. This is underscored by several observa-
tions showing modulation in expression levels of MMPs following exposure of cells to 
different KDAC inhibitors in various cell types. Treatment of different tumour cell-lines 
with NaBu resulted in modulation of secreted expression levels of MMP2 and MMP9, 
which was accompanied by global histone H4 hyperacetylation.113 On the other hand it 
was demonstrated that increased histone acetylation by TSA-treated 3T3 cells decreases 
mRNA as well as zymographic activity of MMP2.114 This TSA-induced inhibition of 
MMP2 activation is mediated via upregulation of the glycoprotein RECK.115 With re-
spect to MMP9, it has been demonstrated that IFN-γ induced a reduction in MMP9 
expression, which is mediated by CIITA. CIITA is induced by IFN-γ through the JAK/
Stat signalling pathway and downregulation of MMP9 is exerted by CIITA through 
sequestering of CBP from the MMP9 promoter, effectively reducing histone H3 acetyla-
tion, explaining the inhibition in MMP9 transcription by IFN-γ.116 Further support for 
a role of epigenetic mechanisms in the regulation of MMP9 expression comes from the 
observation that the metastases associated gene MTA1 represses MMP9 expression, in 
part by the recruitment of KDAC2 to the distal MMP9 promoter-region117 and modula-
tion of the activity of MMP9 by depsipeptide in uveal melanoma cells.118
5.2 MMP3 (Stromelysin-1)
Besides MMP2 and MMP9, several findings also indicate the involvement of epigenetic 
mechanisms in the expression of MMP3. Overexpression of the TEL (Translocation-
ETS-Leukemia)-protein, which specifically associates with KDAC3, represses transcrip-
tion of the stromelysin-1 gene. A role for KDAC3 in the TEL-mediated repression 
was supported by the observations that histone H3 was underacetylated near the TEL 
binding sites in the stromelysin-1 promoter and that administration of TSA impaired 
TEL-dependent repression of the stromelysin-1 promoter.119 A role for histone acety-
lation in MMP3 expression is further supported by the finding that NaBu selectively 
enhanced protein production and mRNA expression of stromelysin-1 in TNF-α or IL-
1β stimulated mesenchymal cells.120 Furthermore, it has been demonstrated that the 
transcription factors Ets-1 and Ets-2 recruit p300 and CBP to the human stromelysin-1 
promoter to activate transcription.121
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5.3 MMP1 and MMP13 (Collagenase 1 and collagenase 3)
Histone acetylation modifications are also implicated in the expression of MMP1 and 
MMP13. This notion is derived from studies in chondrocytes which revealed that 
exposure of cells to TSA or NaBu blocks the induction of MMP1 and MMP13 by pro-
inflammatory cytokines at both the mRNA and protein level.122 Furthermore, NaBu 
treatment of liver cancer cells results in decreased transcription of MMP1.123 Additional 
evidence for a role of histone acetylation modifications in the control of MMP1 expres-
sion is derived from the observation that the co-activator p300 has been shown to relieve 
the Smad-mediated inhibitory effect of TGF-β in cytokine-induced MMP1 expression 
in dermal fibroblasts.124 Expression of MMP1 is also indirectly affected by TSA and 
SAHA (Suberoylanilide hydroxamic acid) through inhibition of c-jun.125
Together, histone acetylation modifications have been shown to play a direct and indi-
rect role in the regulation of MMP expression, critical mediators in vascular remodeling 
and as such implicated in the pathology of atherosclerosis and restenosis.
6. CONCLUSIONS AND FUTURE DIRECTIONS
Besides genetic control, epigenetic mechanisms contribute to expression at the tran-
scriptional level of genes, the products of which play a key role in extracellular matrix 
formation, inflammation and proliferation as discussed in this review. Altered expression 
levels of these genes have been observed in cardiovascular pathologies and therefore it 
is thought that these aberrant expression patterns contribute to the processes associated 
with atherosclerosis and restenosis. As the nucleotide composition of genes is not al-
tered by these epigenetic processes and alterations in chromatin structure are reversible, 
these epigenetic modifications are amendable to pharmacological intervention, which 
may prove to be an effective treatment modality for the management of cardiovascular 
diseases.
Although chromatin modifications exist at the level of DNA methylation at CpG di-
nucleotides and a variety of post-translational histone modifications, we have focussed 
on the role of histone acetylation modifications exerted by KATs and KDACs in cardio-
vascular disease.  Besides accumulation of epigenetic modifications in aging, histone 
acetylation modifications are also dynamic: rapid alterations in the levels of histone 
acetylation modifications can be measured after cell activation by a variety of external 
stimuli. It can therefore be envisioned that similar alterations in histone acetylation 
modifications are induced in the response to cellular injury such as inflicted by e.g. flow 
shear stress or by balloon angioplasty. As detailed in the various preceding sections of 
this review, there is ample experimental evidence from different cellular models that 
indeed the activities of KATs and KDACs are key elements, either directly or indirectly, 
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in the transcriptional control of vascular disease-associated genes. Aberrant expression 
of these chromatin modifying activities therefore has a profound effect on the overall 
level of transcription of disease-associated genes and function of their products in the 
processes involved in extracellular matrix formation, inflammation and proliferation.
Clinical feasibility of applying drugs which inhibit the activity of KATs and KDACs is 
demonstrated in the application of these compounds in the treatment of cancer and neu-
rological disorders.27 However, it should be realized that application of these compounds 
can also result in non-specific activation of genes and other genomic elements not only 
in diseased cells but also in normal cells. Especially the use of non-specific inhibitors 
that target many different KATs or KDACs can be expected to have broad effects on 
gene expression and may inflict potential harmful side-effects. It is therefore important 
to identify those KATs and KDACs that play a role in the transcriptional regulation 
of cardiovascular disease-associated genes and to develop specific inhibitors that target 
these KATs and KDACs. As also a single KAT or KDAC family-member can be involved 
in the transcription of multiple genes, even specific inhibitors could have unwanted 
effects on gene expression. However, each of these family-members could have some 
degree of specificity to a set of genes acting together in a vascular disease-associated 
process. Although KATs and KDACs are known to be substrate-specific, it is thus far not 
known if they can also be specific to certain processes.
Nevertheless, many KDAC-inhibitors appear to be well tolerated in patients and local 
application of these epigenetic modifiers would overcome the side-effects which are 
inheritably linked with systemic application.
Several recent investigations indeed indicate that KDAC-inhibition may be beneficial 
in vascular disease-associated processes. Transcription of the CYP7A1 gene encoding 
cholesterol 7α-hydroxylase, an enzyme involved in the intra-hepatic conversion of 
cholesterol to bile acids, is known to be repressed by bile acids as part of a feedback 
regulatory mechanism. Recent findings demonstrate that the bile acid-mediated repres-
sion of this gene was caused by an increase in the nuclear concentration of KDAC7, 
which promoted the assembly of a repressive complex at the CYP7A1 promoter.126 
Notably, treatment of LDL-receptor knockout mice with the KDAC-inhibitors TSA 
and valproic acid elevated Cyp7a1 mRNA levels and consequently reduced total plasma 
and LDL-cholesterol dramatically. In addition to these findings, in vitro experiments 
showed that TSA strongly inhibited SMC proliferation and TNF-α production by ac-
tivated macrophages, processes with an important role in atherogenesis.127 Interesting 
in this context is the recent finding that also statins inhibit KDAC-activity. Lovastatin 
was found to induce p21 expression through dissociation of KDAC1/2 and association 
of CBP, leading to histone-H3 acetylation at the site of the p21 promoter.128 Therefore, 




Recent findings from Granger et al. also identify KDACs as possible targets for therapy 
in cardiovascular disease. They showed, utilizing a standard murine model of ischemia-
reperfusion, that ischemia induces KDAC activity in the heart resulting in deacetylation 
of histones H3 and H4.129 Within a treatment window from 1 hour before ischemia 
until 45 minutes after reperfusion, the KDAC inhibitors TSA and Scriptaid were able 
to reverse the induction of ischemia-induced KDAC activity in vivo and to reduce 
myocardial infarct size by approximately 50%. Furthermore, a 5 hour period of hypoxia 
induced a strong decrease in acetylated histones H3 and H4 in mouse cardiomyocytes 
in vitro, which could be completely blocked by TSA. The finding that KDAC-inhibition 
can reduce the size of myocardial infarction in mice by half, even when treatment is 
applied after reperfusion, has important implications for the potential application of 
these compounds in the context of acute coronary syndromes.
In conclusion, over the past years it has become increasingly clear that besides ge-
netic also epigenetic components contribute to the etiology of cardiovascular disease. 
Dynamic interactions of the environment and the epigenome determine accessibility 
of genes which have profound effects on their transcription and function. A further 
understanding on the role of epigenetic processes in cardiovascular disease processes 
such as atherosclerosis and restenosis might provide novel opportunities to understand 
disease pathology. This would provide the necessary knowledge platform for design 
of alternative treatment strategies, which are aimed at interfering in these epigenetic 
processes for the management of atherosclerosis and restenosis.
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Aims: A major influence on gene expression is attributed to the counterbalancing ac-
tion of lysine acetyltransferases (KATs) and lysine deacetylases (KDACs). This study 
was designed to investigate the influence of genetic variation in the promoter of the 
gene encoding P300/CBP associated factor (PCAF), a lysine acetyltransferase (KAT) on 
coronary heart disease (CHD) and mortality.
Methods and results: We investigated the association of genetic variation in the pro-
moter region of the PCAF-gene on CHD and mortality in two statin trials (PROSPER 
and WOSCOPS) and on restenosis risk in a third study of percutaneous coronary inter-
vention (GENDER). We combined the results from these cohorts to examine 1) overall 
effects on CHD mortality and on 2) restenosis risk and determined the contribution of 
PCAF in an animal model of reactive stenosis. Compared with the homozygous -2481G 
allele in the PCAF promoter, we observed a significant reduction in CHD mortality risk 
with the homozygous -2481C PCAF promoter allele in PROSPER (risk reduction 22%; 
2% to 37%), a non-significant trend towards reduction in WOSCOPS (risk reduction 
17%; -14% to 39%), and a significant reduction of restenosis in GENDER (20%; 3% to 
33%). A combined risk reduction for CHD death/ restenosis for the three studies was 
21% (15%-26%; p= 8.1 x 10-4). In elderly patients (>58 years) the effects were stronger 
and significant in all three studies. Furthermore, this PCAF allele was significantly as-
sociated with all cause mortality in PROSPER (p=0.001). Functional analysis showed 
that nuclear factors interact in vitro with the oligonucleotides encompassing this -2481 
G/C polymorphism and that this interaction might be influenced in some cell types by 
this polymorphism in the PCAF promoter, and modulation of PCAF gene expression 
was detectable upon cuff-placement in an animal model of reactive stenosis.
Conclusion: We showed in three large prospective studies that the -2481C allele in 
the PCAF promoter is associated with a significant survival advantage in elderly pa-
tients while also protecting against clinical and angiographic restenosis after PCI. Our 
observations promote the concept that epigenetic processes are under genetic control 
and that, other than environment, genetic variation in genes encoding KATs may also 
determine susceptibility to CHD outcomes and mortality.
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INTRODUCTION
Investigations into the pathogenetic mechanisms of human complex disease, such as 
cardiovascular disease and cancer, may lead to better risk prediction, treatment and new 
targets for future therapy. Cell proliferation regulatory pathways and pro-inflammatory 
transcription factors, such as NFκB, have been associated with progression of these dis-
eases.1 In the past decade, research into cardiovascular diseases such as atherosclerosis 
and restenosis, has been focused on the identification of genetic factors that determine 
disease risk. Several genes involved in inflammation and cell proliferation appeared to be 
common denominators of these diseases.2-4 It has become clear, however, that part of the 
gene-environmental interactions relevant for complex diseases is regulated by epigenetic 
mechanisms such as histone acetylation and DNA methylation.5 Epigenetic processes 
modulate gene expression patterns without modifying the actual DNA sequence and 
have profound effects on the cellular repertoire of expressed genes.6 Evidence is growing 
that epigenetic mechanisms also regulate the expression of genes in the inflammatory 
and cell proliferation pathways7,8 and may therefore also play a role in cardiovascular 
disease.9-11
A major influence on gene expression is attributed to the counterbalancing action 
of lysine acetyltransferases (KATs) and lysine deacetylases (KDACs).12 KATs acetylate 
histones by transfer of an acetyl-group to the ε-portion of lysine residues, which results 
in an open modification of chromatin structure and in accessibility of DNA to transcrip-
tion factors and recruitment of the basal transcription initiation machinery. Conversely, 
gene repression is mediated via KDACs, which remove acetyl groups and counteract the 
activity of KATs resulting in a closed chromatin structure. Thus far, the main focus has 
been to investigate the environmental influence on epigenetic processes. Research in 
this field has shown that epigenetic differences arise during the lifetime of monozygotic 
twins.6 Furthermore, oxidative stress has been shown to influence the balance between 
KATs and KDACs in favour of KATs, leading to an increase in inflammation.13 Notably, 
genetic variations in the genes encoding KATs and KDACs, which affect the activities 
of the enzymes they encode, have a bearing on the global and gene-specific levels of 
histone acetylation. As such, these genetic variations in the genes encoding KATs and 
KDACs could also be important determinants contributing to susceptibility to major 
human diseases.
P300/CBP associated factor (PCAF) is a transcriptional co-activator with intrinsic 
KAT-activity. Besides its role in lysine acetylation of histones at the site of  NFκB-
regulated genes and the resultant inflammatory gene activation,14,15 PCAF is also found 
to act as a factor acetyltransferase (FAT) that acetylates non-histone proteins, including 
several tumor-suppressor proteins, such as p5316,17 and the phosphatase and tensin ho-
molog (PTEN).18 Because PCAF is involved in proliferation and inflammation, common 
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denominators of the major diseases determining human mortality, with clear evidence 
for inflammatory factors predicting incident CVD events,19,20 incident cancers21 and 
mortality, we hypothesized that the PCAF-gene could be of major importance in the 
development of cardiovascular disease and cancer, and death from such disease.
We investigated the impact of genetic variation in the promoter region of the PCAF-
gene on all-cause mortality and mortality due to coronary heart disease and cancer in 
the PROSPER-study, a randomized controlled trial in which 5804 elderly patients (age 
70-82) at risk for vascular disease were randomized to pravastatin or placebo.22 In order 
to validate the observed effects and to be able to extrapolate our findings to a younger 
population, we investigated the PCAF gene in the WOSCOPS study, a randomized con-
trolled trial similar to the PROSPER-study, designed to determine the effect of pravas-
tatin in middle-aged men with hypercholesterolemia without a history of cardiovascular 
disease. Finally, in order to further test the validity of results in the two statin trials, and 
to get insights in the mode of action, we investigated these variants in another large 
prospective study, the GENDER-study, a prospective follow-up study that included 3104 
patients undergoing percutaneous coronary intervention (PCI).23 The primary endpoint 
in this study was clinical restenosis, a process that is known to be mainly determined by 
inflammation and proliferation.2
All participants in these three study groups were analyzed for 2 polymorphisms (SNPs) 
in the promoter region of the PCAF-gene. Of these polymorphisms, the -2481G/C SNP 
was found significantly associated with CHD mortality in elderly patients in PROSPER 
and WOSCOPS, and, in addition, with differential risk for restenosis in the GENDER 
study.
METHODS
Study design and follow-up of the PROSPER study
The protocol of PROSPER has been described elsewhere.24 PROSPER is a prospective 
multicenter randomized placebo-controlled trial to assess whether treatment with 
pravastatin diminishes the risk of major vascular events in elderly individuals. Be-
tween December 1997 and May 1999, we screened and enrolled subjects in Scotland 
(Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men and women aged 70-82 
years were recruited if they had pre-existing vascular disease or increased risk of such 
disease because of smoking, hypertension, or diabetes. A total number of 5804 subjects 
were randomly assigned to pravastatin or placebo. In this genetic sub-study, we evalu-
ated the predefined endpoints all-cause mortality and mortality due to vascular events 
and cancer. Mean follow-up was 3.2 years (range 2.8-4.0) and 604 (10.4%) patients died 
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during the study.22 Of these patients, 292 (48%) died from vascular disease and 206 
(31%) from cancer.
Study design and follow-up of the WOSCOPS study
The WOSCOPS study (the West of Scotland Coronary Prevention Study), a primary 
prevention trial, included 6595 men, aged between 45 and 64 years old, who had LDL 
cholesterol levels between 174 and 232 mg/dL (4.5 and 6.0 mmol/L), who had no history 
of myocardial infarction, but were considered to be at enhanced risk for developing 
CHD.25 The first patient was enrolled on February 1, 1989, and the study ended on May 
15, 1995. Mean follow up duration was 4.9 years. All participants were randomly as-
signed to receive 40 mg of pravastatin or placebo daily.
The present genetic study was performed in a previously described nested case-control 
cohort.26 In brief, the prospective nested case-control study included all of the 580 
on-trial CHD events (death from CHD, nonfatal MI, or revascularization procedures) 
from the WOSCOPS cohort as case subjects and 1,160 control subjects matched to case 
subjects by age and smoking. In the present genetic study we used death from coronary 
heart disease as our primary endpoint.
Study design and follow-up of the GENDER study
The present study sample has been described previously.23 In brief, the GENetic DEter-
minants of Restenosis project (GENDER) was a multicenter follow-up study designed 
to study the association between various gene polymorphisms and clinical restenosis. 
Patients eligible for inclusion in the GENDER-study were treated successfully for stable 
angina, non-ST-elevation acute coronary syndromes or silent ischemia by PCI in four 
out of 13-referral centers for interventional cardiology in the Netherlands. Patients 
treated for acute ST-elevation myocardial infarction were excluded. Experienced op-
erators, using a radial or femoral approach, performed standard angioplasty and stent 
placement. During the study, no drug-eluting stents were used. Follow-up lasted for at 
least nine months, except when a coronary event occurred. Clinical restenosis, defined 
as TVR, either by PCI or coronary artery bypass grafting (CABG), was the primary 
endpoint. Median follow-up duration was 9.6 months (interquartile range 3.9) and 
304 (9.8%) patients underwent TVR during follow-up. A prespecified subpopulation 
of 478 patients was scheduled for re-angiography at 6 months, according to standard 
procedures as described previously.27 Identical projections were used before, during and 
6 months after the PCI for all assessed angiograms. Quantitative Computer Analyses 
(QCA) were independently performed by Heartcore (Leiden, the Netherlands).
For all three studies, all endpoints were adjudicated by independent clinical events 
committees. The protocols meet the criteria of the Declaration of Helsinki and were 
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approved by the Medical Ethics Committees of each participating institution. Written 
informed consent was obtained from all participating patients.
Genotyping
Blood was collected in EDTA tubes at baseline and genomic DNA was extracted follow-
ing standard procedures. As a first step to investigate this gene, we selected 2 validated 
polymorphisms in the PCAF-promoter. The -4556 C/T (rs2623074) and the -2481 G/C 
(rs2948080) polymorphisms were selected on the basis of their high minor allele 
frequency (>5%) and measured using the Sequenom Massarray genotyping platform. 
A multiplex assay was designed using Assay designer software (Sequenom). As qual-
ity controls, 5-10% of the samples were genotyped in duplo. No inconsistencies were 
observed. Cluster plots of the signals from the low and the high mass allele were drawn. 
Two independent researchers carried out scoring. Disagreements or vaguely positioned 
dots produced by Genotyper 4.0 (Sequenom Inc.) were left out of the results.
Cells and cell culture
The cell lines (HeLa, U251, Raji) used in this study were obtained through the ATCC 
(Rockville, MD, USA) and were cultured in Iscove’s modified Dulbecco’s medium 
(IMDM; BioWhittaker Europe, Verviers, Belgium) supplemented with 10% (v/v) heat-
inactivated fetal calf serum (FCS; Greiner, Alphen a/d Rijn, The Netherlands), 100 IU/
mL streptomycin and 100 IU/mL penicillin. For interferon-γ (IFN-γ) induction, cells 
were treated with 500U/mL of IFN-γ (Boehringer-Ingelheim, Alkmaar, The Nether-
lands) for 4 hours, hereafter nuclear extracts were prepared (see below). HUVECs were 
cultured in Medium 199 with Earl’s salt and L-glutamine (Life Technologies, Breda, The 
Netherlands), supplemented with 20% (v/v) FCS (PAA, Pasching, Austria), 100 IU/mL 
streptomycin and 100 IU/mL penicillin, 10 IU/mL heparine (Leo Pharma, Breda, The 
Netherlands) and 25 mg bovine pituitary extract (BPE; Life Technologies).
Transcription factor binding site search
Potential transcription factor binding sites were identified using the TFSEARCH pro-
gram (http://www.cbrc.jp/research/db/TFSEARCH.html), which searches the TRANS-
FAC database28. Cutoff was set at 75% of the consensus TF binding site.
Nuclear extracts and electrophoretic mobility shift assay (EMSA)
Nuclear extracts and EMSAs were performed as described previously.29 In brief, 2 µL of 
nuclear extracts (HeLa, HUVEC, U251, Raji) in binding buffer were incubated for 30 
min on ice, with 2 ng of a [33P]-labeled dsDNA probe. The probe sequences were similar 
to either the C or G promoter variants of the PCAF-gene (PCAF-C:
5’-GCAATAAGCCTCCTCAATCCTTTGCCCTTG-3’; PCAF-G:
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5’-GCAATAAGCCTCCTGAATCCTTTGCCCTTG-3’). Probe sequences for tran-
scription factors MZF1 and GATA1-3 were similar to their previously described con-
sensus sequence (MZF1 (zinc fingers 1-4): 5’- GATCTAAAAGTGGGGAGAAAA-3’; 
MZF1 (zinc fingers 5-13): 5’- GATCCGGCTGGTGAGGGGGAATCG-3’; GATA:
5’- GGACCTTGATCTTATCTT-3’).30;31
For competition assays, nuclear extracts from IFN-γ stimulated HeLa cells were in-
cubated with unlabelled oligonucleotides in 100- and 200-fold excess for 30 min on ice, 
prior to incubation with the labeled probe. In case of IFN-γ treated samples, cells from 
five different cell types were stimulated with IFN-γ (500U/mL; Boehringer-Ingelheim) 
for 4-hours prior to preparing nuclear extracts. Samples were run on a 6% polyacryl-
amide gel in 0.25x TBE-buffer. Gels were densitometrically analyzed using the ImageJ 
software.32
Mouse model for reactive stenosis
The institutional committee on animal welfare approved all animal experiments. For all 
experiments hyperlipidemic male ApoE*3-Leiden mice33 were fed a high-cholesterol diet 
(ArieBlok, Woerden, The Netherlands). Blood samples to determine plasma cholesterol 
were collected at time of surgery. After 3 weeks on diet, a non-constrictive polyethylene 
cuff was placed loosely around one femoral artery and mice were sacrificed at several 
time points after surgery. After sacrifice, at t=0 hours (control, no cuff placement), 6 
hours, 24 hours, 2 days, 3 days, 7 days and 14 days, both femoral arteries were isolated 
and snap-frozen in liquid nitrogen (n=6 mice for each timepoint).
RNA isolation and cDNA synthesis from femoral artery tissue
Per time point, cuffed segments of three femoral arteries were pooled to enable isolation 
of suitable amout of RNA, resulting in 4 pooled RNA samples obtained from n=6 mice, 
cuffed at two limbs. After RNA isolation, cDNA was synthesized and RT-PCR analysis 
was performed as previously described.34
PCAF mRNA quantification
Expression levels of PCAF were measured by virtue of quantitative RT-PCR using Taq-
Man® gene expression assay (Mm00451387_m1). PCR runs were carried out in the ABI 
PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA). 
HPRT was assayed as control gene and its cycle threshold (Ct) was substracted from the 
Ct of the gene of interest, yielding ΔCt. For each timepoint, ΔΔCt was determined by 
substracting the average ΔCt at timepoint 0 hours from the ΔCt at each other timepoint. 




Allele frequencies were determined by gene counting. The Chi-squared test was used to 
test the consistency of the genotype frequencies at the SNP locus with Hardy-Weinberg 
equilibrium. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated 
using a Cox-proportional hazards model. All analyses with PROSPER and WOSCOPS 
data were adjusted for sex, age and pravastatin use. The analyses with PROSPER data 
were additionally adjusted for country. In the GENDER-study, polymorphisms were 
included in a multivariable model containing clinical and procedural risk factors for re-
stenosis, such as diabetes, smoking, hypertension, stenting, total occlusion and residual 
stenosis >20%.
To reach statistical significance with an alpha of 0.05 and a beta of 0.8 in the associa-
tion between the -2481 polymorphism and coronary heart disease death in this popula-
tion, we need 168 cases of coronary heart disease death, for the -4556 we need 379 
cases of coronary heart disease death. A combined-effect analysis was performed to pool 
the results of the effect of the -2481G/C polymorphism on study endpoints (all-cause 
mortality, CHD death and clinical restenosis) and coronary endpoints (CHD death in 
two studies and clinical restenosis in the third study) in the three separate studies at 
old age. The random-effects model was used to consider both the between-study and 
within-study variability. The pooled hazard ratio over the genotypes was assessed with 
ordinary logistic regression. The SPSS software (version 12.0.1, SPSS Inc, Chicago, IL) 
was used for all statistical analyses.
RESULTS
PROSPER study
Participant characteristics are presented in table 1. Genotyping success rates were higher 
than 96% for all polymorphisms and there were no significant deviations from Hardy-
Weinberg equilibrium.
Using a Cox proportional hazards model, which included several clinical variables 
such as sex, age, pravastatin use, and country, we found a significant association of the 
-2481 G/C promoter polymorphism with all-cause mortality in PROSPER. As presented 
in table 2 and figure 1, heterozygotes had a reduced mortality risk by 17% (2% to 30%, 
p=0.03), whereas individuals homozygous for the -2481C allele had a 39% lower mor-
tality (16% to 56%, p=0.003). The effect of PCAF is more profound in the association 
with coronary heart disease (CHD) death (risk reduction 22% (2% to 37%), p=0.03) 
compared to the association with cancer mortality (risk reduction 13% (9% to 30%), 
p=0.22). Due to its proximity to the -2481 G/C polymorphism, we also present the data 
of the -4556 C/T polymorphism (table 2). It shows a small and non-significant trend 
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Continuous variates (mean, SD)
    Age (years) 75.3 (3.4) 56.8 (5.2) 62.1 (10.7)
    Body mass index, (kg/m2) 26.8 (4.2) 26.0 (3.2) 27.0 (3.9)
Categorical variates (%)
    Male sex 48 100 71
    Current smoker 27  54 25
    History of diabetes 11 2 15
    History of hypertension 62 18 40
    History of myocardial infarction 13 0 40
    History of stable angina 27 8 67
    Statins 50 48 55
Genotype, minor allele frequency (%)
    PCAF -4556 C/T 9 9 11
    PCAF -2481 G/C 33 33 33
All data are presented in % unless otherwise stated.
Table 2. Results of the association between two promoter polymorphisms in the PCAF gene and mortality endpoints within the PROSPER and 
WOSCOPS studies.
All cause mortality in PROSPER CHD death in PROSPER CHD death in WOSCOPS
N (%)* HR
(95%CI)
p-value N (%)* HR
(95%CI)
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   C/C


































HR=Hazard ratio. CI=Confidence interval.
All hazard ratios and p-values were assessed with a Cox-proportional hazards model and adjusted for sex, age, country, and use of pravastatin.
*Calculated for 5595 subjects in the PROSPER study and for 1092 in the WOSCOPS study.
Chapter 10
166
towards a decrease in all-cause mortality. The linkage disequilibrium (LD)-coefficient 
between these promoter polymorphisms was 0.79.
WOSCOPS study
To validate the association of the -2481 G/C polymorphism with CHD mortality, and to 
investigate whether its effect is also present in a population largely without established 
vascular disease, we aimed to replicate our findings in a previously described26 nested 
case-control cohort of the WOSCOPS study. Baseline characteristics of the WOSCOPS 
study are presented in table 1.
In this case, the -2481 G/C polymorphism was associated with a non-significant trend 
towards protection against death from coronary heart disease (CHD) (risk reduction 
17% (-14% to 39%), p=0.26) at all ages. Heterozygotes (risk reduction 11% (-39% to 
42%), p=0.62) and homozygotes (risk reduction 37% (-36% to 71%), p=0.24) had a non-
significantly lower mortality risk. Although these data did not reach statistical signifi-





 Figure 1.  Hazard ratios for all-cause mortality in PROSPER, for coronary heart disease death in WOSCOPS, and for clinical restenosis in GENDER 
by PCAF -2481 G/C genotype at all ages.
The PCAF -2481 G/C polymorphism is associated with mortality in the PROSPER study, with coronary heart disease death in the WOSCOPS study, 
and with clinical restenosis in the GENDER study in all age groups
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in the PROSPER study (figure 1). The -4556 C/T polymorphism was not significantly 
associated with the risk of CHD death (risk reduction 20% (-36% to 53%), p=0.40).
GENDER study
To extent the observed results in the PROSPER study, we tested the relevance of the gene 
to clinical conditions in which cell proliferation and inflammation play a role in a large 
patient population included in the GENDER-study. In this study patients were followed 
for at least 9 months after a PCI to determine absence or presence of clinical restenosis, 
as defined by the need for target vessel revascularization (TVR). We considered TVR a 
suitable intermediate endpoint as it is a direct consequence of mainly proliferative and 
inflammatory processes.2
In agreement with the results from the PROSPER and WOSCOPS-study, the -4556 
C/T polymorphism was not associated with the risk for TVR in the GENDER-study, 
whereas the
-2481 G/C polymorphism showed a significant association with TVR (p-trend = 0.02) 
(table 3 and figure 1). Heterozygous patients were at lower risk for TVR (risk reduction 
20% (-2% to 38%), p=0.07), and patients carrying two -2481C alleles had a greater pro-
tection against the development of restenosis (risk reduction 36% (0% to 59%), p=0.05).
Table 3. Results of the association between two promoter polymorphisms in the PCAF gene and clinical and angiographic restenosis within the 
GENDER study.
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a measured in a subgroup of 478 subjects. b measured in a subgroup of 2309 subjects.
HR=Hazard ratio. CI=Confidence interval.




In analogy of the clinical restenosis (TVR) results, carriers of the -2481C allele also 
had less angiographic restenosis in a subpopulation of 478 patients undergoing angiog-
raphy six months after the PCI (risk reduction 44% (4% to 67%), p=0.03) (table 3).
Combined effect analysis
Hazard ratios were almost remarkably equal in all three studies (figure 1). We formally 
test for homogeneity using a standard Olkin-type Q-test and found p-values of 0.91 
and 0.77 for heterozygotic and homozygotic carriers of the minor allele of -2481G/C 
SNP between the three studies. Therefore and since all three studies have comparable 
endpoints, we conducted a combined effect analysis to show the effect of the -2481C on 
the study endpoints (CHD death in PROSPER and WOSCOPS, and clinical restenosis in 
GENDER) at all ages (figure 2, top panel). The pooled hazard ratio for the- 2481C allele 
was 0.79 ((95%CI: 0.74-0.85), p =8.1 x 10-4). Heterozygotes had a reduced risk (HR: 
0.82, 95%CI: 0.68-0.98, p=0.03), and this risk was lower in subjects homozygous for the 




Figure 2. Combined effect estimate of the hazard ratios of the PROSPER, WOSCOPS, and GENDER studies for the PCAF -2481 G/C polymorphism.
This figure represents the hazard ratios for the additive model of the PCAF -2481 G/C polymorphism. Coronary endpoints consist of CHD death 
for the PROSPER and WOSCOPS study, and clinical restenosis for the GENDER study. The top panel is the combined effect analysis for coronary 
endpoints at all ages, the bottom panel in subgroups with age > 58 years.
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Examining for an age effect
We investigated an effect of the -2481C variant allele on vascular mortality in two age 
strata, older and younger than 58 years old. We could however not perform this analysis 
in the PROSPER cohort since all subjects were older than 70 years. In the WOSCOPS 
study, among participants ≥58 years old (median age), we found that the -2481C allele 
significantly reduced the risk of CHD death (risk reduction 39% (3% to 62%), p= 0.035), 
whereas there was no significant effect in the lower age group. We found similar results 
in the GENDER study. We again observed a strong protective effect of the C-allele in old 
patients (≥58 years, n=1800) (risk reduction 30% (12% to 45%), p=0.003) whereas there 
was no significant effect present in young patients (<58 years, n=1052).
We also conducted a combined effect analysis to show the effect of the -2481C allele 
at a high age only (median age >58), shown in figure 2 bottom panel. The pooled hazard 
ratio for the
-2481C allele on coronary events (CHD death or TVR) in this high age group was 0.72 
((95%CI: 0.61-0.84), p=4.9 x 10-5), which is somewhat stronger than the effect at all ages.
Functional involvement: the -2481 region encompassing the C/G PCAF variants
Using the EMSA technique we tested whether the observed polymorphism would lead 
to differential protein binding in vitro. Using nuclear extracts of different cell types, we 
studied complex formation at the -2481 region of PCAF. We could detect constitutive 
protein binding to both PCAF-C and G-variants (figure 3). In both human umbilical vein 




Figure 3. Protein binding to the C- and G-variant of the -2481 region.
(A) EMSA showing binding of protein to the C- and G-variant of the -2481 region using nuclear extracts of various cell-lines. EMSA suggests 
slightly stronger binding of protein to the G-variant of the -2481 region, most pronounced in HUVECs and U251 cells. (B) Competition assay 
with nuclear extracts from HeLa cells stimulated with IFN-γ also suggests slightly increased binding affinity for the -2481 G-variant at high 
concentrations. The difference is best observed when unlabelled probe is added in 200-fold excess, indicating that the observed difference in 
affinity is weak. Shown are representatives of multiple independent experiments
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by IFN-γ stimulation. Densitometric analysis revealed that the PCAF G-variant exhibits 
slightly stronger protein binding in some cell types than the C-variant, although these 
differences are not statistically significant. Competition assays also suggest a modest 
difference in binding affinity (figure 3B).
Using the TFSearch program, we identified possible binding sites for MZF1 and 
GATA1-3 in the PCAF C-variant promoter. However, ds-oligonucleotides representing 
binding sites for MZF1 and GATA1-3 did not compete with factor binding to the PCAF 
C-promoter variant (data not shown).
PCAF mRNA expression in a mouse model of reactive stenosis
Placement of a small non-constrictive cuff around the femoral artery in hyper-choles-
terolemic (13.9 ± 3.6 mmol/L) ApoE3Leiden mice results in induction of neointima 
formation. In the developing neointima a rapid upregulation of the PCAF expression 
was observed after cuff placement in a time dependent manner (figure 4). PCAF expres-
sion showed a peak two days after vascular injury (~1.5 fold increase) and reduces to 
baseline levels of expression after 7 days. PCAF expression at day 3, 7 and 14 differed 
significantly from the 24h measurement (p<0.05).
 
Figure 4. Expression of PCAF mRNA in a cuff-induced reactive stenosis mouse model.
The figure shows PCAF differentially expressed upon activation of the vessel wall in a time dependent manner, with an expression peak 48 hours 
after vascular injury. The data is presented as fold increase compared to the control arteries, using HPRT as an internal control for cDNA input.
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DISCUSSION
Our data indicate that the -2481C allele in the gene encoding PCAF, a protein which 
has been shown to be a key mediator in epigenetics by acetylating histones and several 
non-histone proteins, such as the p53 tumor-suppressor proteins, is associated with a 
significant survival advantage in three independent studies. We found in the PROSPER-
study an advantage in survival mainly due to a significant risk reduction in CHD death. 
In line with this observation we also observed that the -2481C allele was associated 
with a lower death by CHD in the WOSCOPS study in an age dependent manner. 
Furthermore, this allele also protects against clinical and angiographic restenosis in the 
GENDER-study. The effects of the -2481C allele on mortality, CHD death and clinical 
restenosis were more profound at older age (>58 years). The -2481G/C polymorphism 
in the PCAF promoter affects transcription factor binding, as was demonstrated by an 
EMSA band shift analysis. A role for PCAF in vascular disease was further confirmed 
in a mouse model for reactive stenosis, in which modulation of PCAF expression was 
detected during vascular remodeling.
Our observation in the PROSPER-study that this promoter variant associates to lower 
mortality from cardiovascular disease and cancer as well as clinical restenosis after PCI 
in GENDER, may indicate a role of PCAF in inhibiting cell proliferation also in more 
general terms. PCAF has been shown, for example, to activate p53-responsive enhancer 
elements within the p21waf1 promoter17 and activity of p21waf1 is known to induce cell-
cycle arrest in vascular smooth muscle cells.36-39 Furthermore, A20, a NFκB-dependent 
gene that has been shown to inhibit proliferation of VSMCs via increased expression 
of p21waf1, was able to prevent neointima formation after balloon angioplasty in a rat 
model of carotid artery stenosis.40
Apart from its well-described role in cell-cycle regulation, PCAF is also known to 
be required to co-activate p65-dependent transcription and has been shown to directly 
activate the transcription of several NFκB-regulated genes known to be involved in car-
diovascular disease.41 Miao et al. has shown that PCAF could enhance the p65 mediated 
increase in TNF-α promoter activity and that high glucose increased the recruitment 
of PCAF to the TNF-α and COX-2 promoters.14 Furthermore, they demonstrated con-
comitant acetylation of specific lysine residues of histone H3 and H4 at these promoters. 
Since TNF-α and COX-2 have been implicated in the development of atherosclerosis,42;43 
and restenosis,27;44 and also cancer,45;46 our data suggest that PCAF may also play a role in 
the development of these diseases.




-2481C allele was more profound in patients older than 58 years old, whereas it seemed 
not present in young patients (<58 years old) is of particular interest.47 It could reveal the 
combined effect of a life-time dysregulation of expression of the lysine acetyltransferase
-2481C PCAF variant, which affects global levels of histone acetylation, in addition to 
the accumulating effect of exposure to environmental factors which also affects histone 
acetylation profiles during life as observed by Fraga et al.6 In the PROSPER population 
such an age dependent effect was not observed as this trial included only patients >70 
years old. As expected, here the effects on cardiovascular and cancer mortality associ-
ated with the PCAF
-2481 G/C polymorphism were evident for the entire population. After observing 
an age-dependent effect in the WOSCOPS and GENDER study, we suggest that this 
polymorphism in PCAF is associated with an altered tendency to acetylate histones 
and non-histone proteins (such as the tumor-suppressor p53 whose function relies on 
acetylation, reviewed in Spange et al.36) and may therefore become important especially 
in elderly patients, who may have been under the influence of altered PCAF activity for 
many years. This hypothesis needs however further investigation.
Although our findings in the GENDER-study do not directly replicate the effect of 
the -2481 G/C polymorphism on CHD mortality in the elderly, they are of much value 
as this study has a mechanistically linked and better defined concise endpoint. Thus in 
this way patho-physiologic insights would be obtained and not just replication only. 
Restenosis after a PCI is very well investigated and is now known to be mainly the 
consequence of inflammatory and proliferative processes, which is underscored by the 
fact that stents eluting drugs that suppress these processes are highly efficacious in the 
prevention of restenosis. Therefore, we believe that our finding that the -2481C allele 
protects against restenosis in the GENDER-study could possibly confirm its functional 
significance, but could also provide mechanistic insights in its beneficial role in survival 
in the PROSPER and WOSCOPS studies. However this could only explain part of the 
causes by which CHD death risk is decreased in PROSPER and WOSCOPS studies, the 
exact mechanism is not known. We did not find any association between the strongly 
linked -4556C/T polymorphism and survival in any of the three studies. The estimated 
hazard ratio’s were quite similar as expected, however, due to small numbers since the 
minor allele frequency of -4556C/T is three to four times smaller than of -2481G/C, no 
significant results were yielded. This could simply be due to lack of power.
Here we show a strong association between the PCAF locus involved in epigenetic 
control and clinical conditions in three large follow-up studies with a mechanistically 
linked endpoint, however our studies warrant further investigation into the influence 
of the -2481 G/C polymorphism on the activity of the PCAF promoter or expression 
levels of NFκB-regulated genes. Here we hypothesize a new concept that differential 
transcription of the PCAF gene leads to differences in gene expression in various path-
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ways mechanistically linked to CHD events, such as inflammatory regulatory pathways 
or pathways involved in proliferation. Hence, further research has to be performed to 
test this hypothesis.
In a first analysis we were able to demonstrate binding of nuclear factors to the specific 
region flanking the -2481 G/C polymorphism in the PCAF promoter. EMSA analysis 
showed that the G-variant possibly exhibits a slightly higher affinity for nuclear factor 
binding than the C-variant in some cell types tested (e.g. HUVECS and U251), albeit 
that this was not significant. It should also be noted that IFN-γ stimulation slightly in-
creases nuclear factor binding in HUVECs and U251 cells, suggesting a role for IFN-γ 
induced nuclear factors. It remains to be established whether these interacting factors 
play a role in the transcriptional regulation of PCAF. However, provided that this SNP 
influences PCAF transcription and resulting protein levels, this could have a bearing on 
the cellular portrait of expressed genes and might lead to a dramatic different outcome 
if the effects accumulate over years. The fact that nuclear extracts do bind to the same 
region of the promoter in which the polymorphism is situated does strongly suggest that 
the SNP might affect the binding of transcription complexes and thus influences gene 
transcription, however this needs to be confirmed in future studies.
To further illustrate a possible role of PCAF in vascular disease, we quantified PCAF-
transcripts in the stenotic vessel wall in a mouse model of cuff induced reactive stenosis 
in the femoral artery. During the stenotic process, the PCAF gene expression was rapidly 
upregulated, indicating that PCAF gene expression is activated upon vascular injury and 
suggesting that this transcriptional coactivator is involved in the development of reac-
tive stenosis, at least in the early stages. Unfortunately it is not possible to measure the 
PCAF protein levels directly, however the rapid up and down regulation of the mRNA 
levels suggests that PCAF is not stable. The changes in mRNA levels are likely to reflect 
the changes in protein levels.
In conclusion, we showed in three large prospective studies that the -2481C allele in 
the PCAF promoter is associated with a significant survival advantage in elderly patients 
while also protecting against clinical and angiographic restenosis after PCI. Although 
the exact mechanisms of these actions are thus far unknown, we suggest that the effect 
of this allele on these endpoints may be due to the well-known involvement of PCAF 
in inflammatory and proliferative processes. Our observations promote the concept 
that epigenetic processes are under genetic control and that, other than environment, 
genetic variation in genes encoding KATs may also determine susceptibility to CHD 
outcomes and mortality. Therefore epigenetic histone modification, when our results are 
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CARDIOVASCULAR DISEASE?
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There is evidence indicating that altered epigenetic regulation of gene expression in 
inflammatory and vascular cells plays a role in the development of atherosclerosis and 
cardiovascular diseases.1 DNA in the nuclei of eukaryotic cells wraps around histone 
proteins, forming nucleosomes which are further packaged to form chromosomes, and 
the combination of DNA, histone and other proteins in chromosomes is referred to 
as the chromatin. Histones are susceptible to chemical modifications which can alter 
the chromatin structure, consequently increasing or decreasing the accessibility of DNA 
elements to transcription factors that regulate gene transcription.
The most extensively studied histone modification is acetylation by the action of histone 
acetyltransferases.2 P300/CBP associated factor (PCAF) is one of a number of proteins 
with acetyltransferase activity and can acetylate histones as well as many non-histone 
proteins that regulate the expression of genes involved in inflammation and cell prolif-
eration. 3-6 In this issue of Heart, Pons et al. provide evidence of an association between 
a single nucleotide polymorphism (SNP) in the PCAF gene promoter and reduced risk 
of coronary heart disease (CHD) mortality and restenosis.7 The authors studied three 
population cohorts previously recruited in the PROSPER, WOSCOPS and GENDER 
studies, the former two being prospective, randomised placebo-controlled pravasatin 
trails for prevention of cardiovascular events and the latter being a follow-up study of 
clinical restenosis after percutaneous coronary intervention. An association between 
the SNP and reduced CHD mortality was detected in PROSPER and a non-significant 
trend in WOSCOPS, while a relationship between the SNP and reduced risk of clinical 
restenosis was observed in GENDER. A meta-analysis of the three data sets estimated 
that individuals who were heterozygous for the low-risk allele had ~20% lower risk of 
the cardiovascular events (pooled HR of 0.82 (95% CI 0.68 to 0.98)) and individuals who 
were homozygous for this allele had ~40% lower risk (HR 0.61 (95% CI 0.44 to 0.84)). To 
provide a possible explanation for the association, the authors show that PCAF expres-
sion is increased in a mouse model of mechanical injury-induced neointima formation 
and provide some evidence suggesting that the SNP associated with reduced risk of 
cardiovascular events in humans might have an effect on PCAF expression.
A strength of the study of Pons et al. is the replication of the relationship between 
the genetic variation and cardiovascular traits in three independent cohorts. However, 
before the PCAF gene variant can be reliably regarded as a genetic factor for CHD, 
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further replications of the association will still be required. A handful of accepted 
CHD-associated genomic loci have recently been identified via genomewide association 
studies with subsequent confirmation in replication studies.8-11 The PCAF gene does not 
reside at any of these loci. Nevertheless, since the handful of accepted loci identified so 
far only account for a small proportion of the heritability of the disease, it is likely that 
many more CHD-associated loci are still yet to be uncovered, and it is possible that the 
PCAF locus could be one of them.
The SNP (-2481G/C) found to be associated with the cardiovascular traits in the 
study of Pons et al. is located in the promoter region of the PCAF gene. The authors 
provide results from electrophoretic mobility shift assays which suggest that the SNP 
might affect binding of a nuclear protein (whose identity is unknown) to the PCAF 
gene promoter, which could potentially have an effect on PCAF transcription. If this is 
indeed the case, the association between the SNP and cardiovascular events could be 
due to altered expression of PCAF and consequently changes in the expression of genes 
regulated by PCAF. Alternatively, the SNP (-2481G/C) may be just a proxy marker for 
a functional SNP located elsewhere at the PCAF locus due to linkage disequilibrium. If 
this is the case, because the ‘functional SNP’ has not been identified, it is unknown what 
functional effect it exerts -i.e., it is unknown whether it affects the level of PCAF expres-
sion or its acetyltransferase activity, or something else. Despite a number of unanswered 
questions, the study of Pons et al. suggests a potential link between cardiovascular events 
and genetic variation of PCAF whose acetyltransferase activity renders it as having a 
role in epigenetic regulation. If confirmed, the finding will add to the growing evidence 
that altered epigenetic regulation of gene expression plays a part in the development of 
atherosclerosis and cardiovascular diseases.
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SUMMARY AND CONCLUDING REMARKS
This thesis examines the impact of genetic and epigenetic factors on several aspects 
of vascular disease. Part 1 has addressed the influence of genetic variation in genes 
involved in the different processes that lead to the occurrence of adverse events after 
percutaneous coronary intervention (PCI), mainly restenosis after bare metal stent 
(BMS) placement, but also late acquired stent malapposition (LASM) after implantation 
of a drug-eluting stent (DES). The role of a relatively new area of research, which we 
refer to as ‘epigenetic epidemiology’, in restenosis and other aspects of coronary heart 
disease has been discussed in part 2.
Traditionally, angiographic restenosis is defined by 50% occlusion of the lumen 
diameter, which gradually develops in the first year after a PCI. As not all of these angio-
graphic re-occlusions lead to complaints in patients, the clinical definition of restenosis; 
target vessel revascularization (TVR), is currently regarded the most valuable endpoint. 
Since long we are aware of the multifactorial nature of the restenotic process. Initially, 
it develops as a normal wound-healing response after intervention-induced damage to 
the vessel wall. Thrombus formation is followed by an immune response and migration/
proliferation of vascular smooth muscle cells (VSMC’s). Previous research by Monraats 
et al. has demonstrated the importance of the relative overactivity of the immune sys-
tem,1 which we now consider as one of the driving forces in restenosis development. 
Restenosis is also known to be caused by VSMC proliferation and matrix formation, 
although evidence for the influence of genetic polymorphisms in these processes on 
neointima formation is still lacking.
From this point of view it could be stated that the process has some similarities to the 
development of cancer, a process which is also largely determined by inflammation, pro-
liferation and matrix remodeling. However, an important exception to this comparison 
is the self-limiting behavior of the restenotic process, which will never lead to continued 
growth or even invasive tumor formation after complete occlusion of the vessel.
Since the important role of inflammatory genes has been established by the findings 
of Monraats et al., part 1 of this thesis has focused on the other processes of which 
histological and non-genetic findings have shown relevance in neointima-formation, 
such as hemostasis, matrix formation, VSMC proliferation and endothelial function. 
Chapter 3 and 4 discuss new insights in the role of hemostasis in restenosis development 
and describe the influence of established genetic variations in the hemostatic system on 
the risk for TVR. Coagulation seems important as any vascular intervention leads to 
the formation of a thrombus. However, many genetic studies have shown associations 
of only a few polymorphisms in the hemostatic system with the risk for restenosis after 
PCI.2 Furthermore, one strong (Factor V Leiden, chapter 3), and also a more subtle 
(Marburg 1, chapter 4), pro-thrombotic risk factor were even found to reduce this 
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risk.3 The first chapters of this thesis therefore reduce the value of thrombotic factors in 
restenosis after PCI. In contrast with these findings, the PAI-1 4G/5G variant, which is 
known to be associated with higher PAI-1 levels, was found to increase restenosis risk.3 
This might be due to the diverse functional profile of PAI-1, which is also known to have 
a role in inflammatory pathways. Most of the findings in chapter 3 and 4 suggest that 
coagulation is not a main determinant of the long-term remodelling process that leads 
to restenosis. Chapter 4 also describes our finding that the Marburg I polymorphism, 
which leads to less activity of factor VII activating protease (FSAP), increases stroke 
risk and mortality. The observed Marburg I associated increase in mortality was mainly 
due to this increased risk of fatal stroke. Unexpectedly, as mentioned earlier, we also 
observed a strong trend towards a reduced risk for clinical restenosis in Marburg I carri-
ers. This apparent contradiction might be due to the diverse functional profile of FSAP, 
which increases proliferation of VSMCs via cleavage of platelet derived growth factor 
(PDGF), but has also been found to increase activation of matrix metalloproteinases 
(MMPs), and could thereby also reduce plaque-stability.
Due to their importance in vascular remodeling MMPs are expected to play a role in 
several aspects of cardiovascular disease, including restenosis. Nearly all MMPs have 
been found to be elevated in atherosclerotic plaques4 and genetic variations in MMP2 
and MMP3, two well investigated MMPs, were also found to be associated with myocar-
dial infarction.5 The well studied 5A/6A MMP3 promoter polymorphism, of which we 
know that the 6A insertion leads to less MMP3, was even found to be associated with 
restenosis after PCI in some, but not all studies investigating this subject.6-9  In chapter 5 
of this thesis we combined the results of a candidate gene approach and a whole genome 
association scan to investigate the influence of genetic variation in the MMP2 and 
MMP3 genes on restenosis after PCI. In our study we did not find an association of any 
polymorphism in the MMP2 or MMP3 gene with TVR. Some of these polymorphisms, 
especially the MMP3 5A/6A polymorphism and two promoter polymorphisms in the 
MMP2 gene, might still be functional, as was demonstrated in studies investigating their 
role in myocardial infarction.5 Their influence on the risk of myocardial infarction has 
been hypothesized to be due to their tendency to destabilize atherosclerotic plaques. In 
restenosis, in which plaque stability is not a issue, subtle effects of the MMP2 and MMP3 
polymorphisms on MMP function or levels probably lead to minor changes in total 
neointima volume, which are not sufficient to cause clinical restenosis.
Although proliferation of VSMCs is by many regarded as one of the main contributors 
to neointima formation, there is little genetic evidence supporting this hypothesis. Recent 
findings by Van Tiel et al. demonstrated an association of the -838 G/A polymorphism 
in the cyclin-dependent kinase inhibitor p27(kip1), a key regulator of smooth muscle 
cell proliferation, with in-stent restenosis in two different studies.10 In 715 patients 
undergoing coronary angioplasty and stent placement, patients with the p27(kip1) -838 
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AA genotype had a decreased risk of in stent restenosis (HR: 0.28; 95% CI: 0.10–0.77). 
This finding was replicated in another cohort study of 2309 patients (HR: 0.61; 95% CI: 
0.40–0.93). The -838A allele also corresponded to enhanced promoter activity, which in 
turn may explain decreased smooth muscle cell proliferation. Chapter 6 of this thesis 
constitutes an important addition to this field and describes multiple strong associations 
of polymorphisms in the Quaking gene with the occurrence of clinical restenosis after 
PCI. The quaking protein, which was thus far known for its role in myelination, has 
recently gained renewed interest as a possible mediator in vascular disease. Recent work 
by Van der Veer and Kraaijeveld et al., which is also described in chapter 6, revealed an 
important role of the protein in proliferation and migration of VSMCs. Furthermore, 
Quaking viable mice (qkv) mice showed markedly decreased neointima formation in 
a mouse model of in-stent restenosis. In the GENDER-study, investigating the effect 
of SNPs throughout the whole quaking gene, the strongest associations were found 
for SNPs located upstream of the QKI transcriptional start site (-2616 T/C: HR: 2.14, 
95%CI: 1.24-3.68, P=0.006) and within intron 3 (57896 A/G: HR: 0.74, 95%CI: 0.6-0.92, 
P=0.005 and 65752 A/G: HR: 1.5, 95%CI: 1.14-1.98, P=0.003). Though a small amount 
of proliferative genes have yet been investigated, the strength of these associations in 
comparison to those found in other association studies investigating coronary restenosis, 
emphasizes the importance of proliferative genes in neointima formation. A combined 
effect of the 5752 GG and GA genotypes together with the 57896 AA genotype, was 
demonstrated to be even stronger (HR 1.77, 95% CI 1.29-2.44; p<0.001). This particular 
genotype combination was observed in 10% of the total population.
Due to its inhibitory role in VSMC proliferation, adhesion of leukocytes to the vessel 
wall and coagulation,11-13 nitric oxide (NO) has often been suggested to protect against 
the development of restenosis. Its role in restenosis was further established by the obser-
vation that L-arginine, the precursor to NO, reduces neointimal hyperplasia at 6 months 
after stent placement.14 Despite these findings, studies investigating the influence of 
the Glu298Asp polymorphism in the NOS3 gene on restenosis after PCI have yielded 
conflicting results. Especially the larger studies did not find a significant association of 
this polymorphism with TVR.15
After their finding that 298Asp homozygous patients with ischemic heart disease were 
found to be more sensitive to the vasoconstrictive effects of phenylephrine, Sofowora 
et al. suggested that the functional significance of the Glu298Asp polymorphism may 
only become manifest under conditions of endothelial dysfunction.16  In chapter 7 
we confirm this hypothesis and demonstrate that the functional significance of NOS3 
polymorphisms may depend on the presence of the metabolic syndrome, a syndrome 
which is characterized by endothelial dysfunction. We studied the relationship between 
these polymorphisms and the risk of restenosis in a subpopulation of patients with the 
metabolic syndrome that took part in a large follow-up study of unselected, consecutive 
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patients undergoing PCI.17 We demonstrated that the   -949G, -716T and 298Asp vari-
ants in the NOS3 gene were associated with a highly increased risk of TVR after PCI in 
patients with the metabolic syndrome, but not in patients without the metabolic syn-
drome. We suggest that the metabolic alterations present in patients with the metabolic 
syndrome influence the functional significance of these polymorphisms and increase 
the susceptibility of carriers of one of these variations in the NOS3 gene to develop 
restenosis after PCI.
As introduced in chapter 2, stent malapposition (SM), commonly detected by intra-
vascular ultrasonography (IVUS), represents a separation of the stent struts from the 
intimal surface of the arterial wall and has been suggested to be a risk factor for late stent 
thrombosis. Late-acquired stent malapposition (LASM) is a consequence of positive 
remodeling of the vessel wall and/or of plaque volume decrease behind the stent (includ-
ing clot lysis or plaque regression).18-20 The precise mechanisms leading to LASM are 
thus far unknown. Although a hypersensitivity reaction to the polymer coating has been 
suggested to play a role,21 it may very well be a consequence of increased apoptosis22, 23 or 
chronic inflammation.24 In chapter 8 we found support for the possibility that the pro-
cess may be determined by inflammation. We found a significantly higher risk for LASM 
in patients carrying the caspase-1 (CASP1) 5352 A allele (RR: 2.32;95% CI: 1.22–4.42). 
In addition, mean neointimal growth was significantly lower in patients carrying this 
allele (1.6 vs 4.1%; p = 0.014). The caspase 1 protein, also known as IL-1β converting 
enzyme, increases inflammation trough activation of IL-1 β and IL-18.25 However, as 
caspase-1 may also induce apoptosis by the proteolytic cleavage of other caspase family 
members, caspase-1 may have divergent effects on cell survival, depending on which of 
its substrates is preferentially processed.26-28 Therefore, there is a slight possibility that 
caspase-1 could also play a role in LASM through its influence on apoptosis. Further 
research, preferrably in larger patient groups, has to be performed to learn which of 
these processes is predominant in the development of LASM.
Part 2 of this thesis describes a relatively new area of research which we refer to as 
‘epigenetics’, the study of non-DNA-sequence related heredity. Chapter 9 summarizes 
evidence showing that epigenetic mechanisms regulate the expression of genes in the 
inflammatory and cell proliferation pathways29,30 and may therefore play a role in cardio-
vascular disease.31-33 The fact that epigenetic modifications are reversible makes this area 
of research especially interesting. New compounds which are aimed at interfering in 
epigenetic processes may prove to be an effective in the management of cardiovascular 
diseases.
Part 2 has focused on covalent post-translational modifications of histone tails, a well-
studied example of epigenetic change that leads to rearrangement of nucleosomes. Of 
several types of chemical modification, especially acetylation of lysine residues in the 
histone tails is considered a key process in gene regulation. Lysine acetyltransferases 
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(KAT) acetylate histones by transfer of an acetyl-group to the ε-portion of lysine resi-
dues, which results in an open modification of chromatin structure and in accessibility 
of DNA to transcription factors, which leads to gene activation. Gene repression is 
mediated via KDACs, which remove acetyl groups and counteract the activity of KATs 
resulting in a closed chromatin structure. As mentioned in the general introduction, the 
main focus has thus far been to investigate the environmental influence on epigenetic 
processes. Part 2 of this thesis has introduced the concept that epigenetic processes are 
also under genetic control and that, besides the environment, genetic variation in genes 
encoding KATs and KDACs could also be an important determinant of susceptibility to 
complex human diseases such as cardiovascular disease.
Our findings in chapter 10 that the -2481C allele in the gene encoding PCAF, a KAT 
which has been shown to be a key mediator in epigenetics by acetylating histones at 
the site of important inflammory genes such as NFκB, is associated with a significant 
survival advantage in both the PROSPER and the WOSCOPS studies. The finding that 
this allele also protects against restenosis, a process which is mainly determined by in-
flammation and proliferation, supports the hypothesis that the PCAF gene has a role in 
coronary heart disease mortality through its actions in inflammatory and proliferative 
processes. The effects of the -2481C allele on mortality, CHD death and clinical resteno-
sis were more profound at older age (>58 years). This age-dependent effect suggests that 
the polymorphism in PCAF is associated with an altered tendency to acetylate histones 
and may therefore become important especially in elderly patients, who may have been 
under the influence of altered PCAF activity for many years.
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Dit proefschrift beschrijft de invloed van genetische en epigenetische factoren op ver-
schillende aspecten van hart- en vaatziekten. Deel 1 behandelt de invloed van genetische 
varianten op de verschillende processen die kunnen leiden tot complicaties na een 
percutane coronaire interventie (PCI). De meest voorkomende complicatie hiervan is 
restenose na plaatsing van een bare metal stent (BMS). Een andere complicatie die in 
deel 1 besproken wordt is late verworven stent malappositie (LASM) na plaatsing van 
een drug eluting stent (DES). In deel 2 wordt de rol van ‘epigenetische epidemiologie’ 
besproken, een relatief nieuw onderzoeksgebied in atherosclerose en restenose.
Angiografische restenose wordt gedefinieerd als een 50% afname van de lumen diame-
ter, die geleidelijk optreedt in het eerste jaar na een PCI. Omdat niet al deze angiografische 
re-occlusies tot klachten leiden, wordt de klinische definitie van restenose, target vessel 
revascularization (TVR) op dit moment beschouwd als het meest waardevolle eindpunt. 
Sinds lange tijd is duidelijk dat het restenotische proces multifactorieel van aard is. Het 
begint als een normale wondhelingsreactie na interventie-geïnduceerde schade aan de 
vaatwand. Vorming van een trombus wordt gevolgd door een inflammatoire reactie 
en proliferatie/migratie van vasculaire gladde spiercellen (VSMC’s). Eerder onderzoek 
door Monraats et al. heeft aangetoond dat met name het immuunsysteem overactief is. 
Dit wordt nu beschouwd als de  drijvende kracht in de ontwikkeling van restenose. Het 
is ook bekend dat gladde spiercelproliferatie en matrixvorming een rol spelen bij het 
ontstaan van restenose, hoewel er nog steeds weinig bewijs is voor de invloed van geneti-
sche variatie in deze processen op neointima vorming. Vanuit dit oogpunt bekeken heeft 
het proces dus enige gelijkenis met het ontstaan van kanker, een proces wat ook voor een 
groot deel bestaat uit inflammatie, proliferatie en veranderingen in de matrix. Echter 
een belangrijke uitzondering in deze vergelijking is het zelf-begrenzende karakter van 
restenose: de celgroei zal niet doorgaan nadat een arterie volledig is afgesloten.
Omdat de bevindingen van Monraats et al. duidelijk hebben gemaakt dat inflamma-
toire genen een belangrijke rol spelen, is deel 1 van dit proefschrift vooral gericht op de 
andere processen die, zoals is gebleken uit histologisch en niet-genetisch onderzoek, re-
levant kunnen zijn in neointima vorming. Het gaat hier om hemostase, matrix vorming, 
VSMC proliferatie en endotheel functie. In hoofdstuk 3 en 4 worden nieuwe inzichten 
in de rol van hemostase in restenose besproken en wordt ook de invloed van bekende 
genetische varianten in stollingsfactoren op het risico op TVR beschreven. Het lijkt 
waarschijnlijk dat stolling een rol speelt in restenose omdat iedere vasculaire interventie 
leidt tot de vorming van een trombus. Echter, uit de vele genetische studies die op dit ge-
bied gedaan zijn, bleek dat slechts enkele stollingsvarianten associeerden met het risico 
op restenose na een PCI. Bovendien bleek dat een sterke (Factor V Leiden, hoofdstuk 
3) en ook een meer subtiele (Marburg 1, hoofdstuk 4) pro-trombotische risicofactor 
192
Samenvatting en slotopmerkingen
het risico op restenose zelfs reduceerde. Op basis hiervan lijkt de waarde van trom-
botische factoren in de ontwikkeling van restenose dus mee te vallen. In tegenstelling 
tot deze bevindingen, is gebleken dat de PAI-1 4G/5G variant, die geassocieerd is met 
hogere PAI-1 plasma niveaus, het risico op restenose wel verhoogt. De diversiteit van 
functies van PAI-1, dat ook inflammatoire effecten kan hebben, vormen een mogelijke 
verklaring hiervoor. De meeste bevindingen in hoofdstuk 3 en 4 suggereren dat stolling 
geen belangrijke determinant is van het lange termijn proces wat leidt tot restenose. 
Hoofdstuk 4 beschrijft ook de bevinding dat het Marburg 1 polymorfisme, wat leidt tot 
minder activiteit van FSAP, het risicio op een CVA en de totale mortaliteit verhoogt. 
De Marburg 1 geassocieerde toename van de mortaliteit bleek vooral het gevolg van 
een toename van fatale CVA’s. We vonden onverwacht een trend tot een lager risico 
op restenose in dragers van het Marburg 1 allel. Deze schijnbare tegenstelling zou het 
gevolg kunnen zijn van het diverse functionele profiel van FSAP, dat enerzijds zorgt voor 
een toename van de proliferatie van VSMC’s via het klieven van Platelet Derived Growth 
Factor (PDGF), en anderszijds matrix metalloproteinases (MMP’s) activeert en daarmee 
mogelijk de plaque-stabiliteit vermindert.
Door hun belangrijke rol in vasculaire remodeling wordt verwacht dat MMP’s een rol 
spelen bij restenose en andere aspecten van hart- en vaatziekten. Van bijna alle MMP’s 
is een verhoogde expressie gevonden in atherosclerotische plaques. Er werden reeds 
associaties gevonden tussen genetische varianten in MMP2 en MMP3, twee uitvoerig 
onderzochte MMP’s, en de incidentie van hartinfarcten. Het bekende 5A/6A MMP3 
promoter polymorfisme, waarvan we weten dat het 6A allel leidt tot minder MMP3, 
bleek geassocieerd met restenose na PCI in enkele, maar niet alle studies die dit onder-
zochten. In hoofdstuk 5 van dit proefschrift hebben we resultaten van de kandidaat gen 
benadering gecombineerd met een genome wide association scan (GWAS) om de invloed 
van variatie in de MMP2 en MMP3 genen op  restenose na een PCI te onderzoeken. We 
vonden echter geen significante associatie tussen de MMP2 en MMP3 polymorfismen 
en restenose. Sommige van deze polymorfismen, zoals het MMP3 5A/6A polymorfisme 
en de polymorfismen in de MMP2 promoter, zouden nog steeds functioneel kunnen 
zijn, zoals blijkt uit studies die hun rol in hartinfarcten onderzochten. Hun invloed 
op het risico op hartinfarcten is mogelijk een gevolg van de neiging van MMP’s om 
atherosclerotische plaques te destabilizeren. Bij restenose, waar plaquestabiliteit geen 
rol bij speelt, leiden subtiele effecten van MMP2 en MMP3 polymorfismen op MMP 
functie of expressie waarschijnlijk tot kleine veranderingen in neointima volume, die 
niet voldoende zijn om klinische restenose te veroorzaken.
Hoewel proliferatie van VSMC’s door velen wordt beschouwd als een van de drij-
vende krachten achter neointima vorming, is er weinig genetisch bewijs voor deze 
hypothese. Recente bevindingen door Van Tiel et al. hebben een associatie laten zien 
tussen het -838 G/A polymorfisme in de cyclin-dependent kinase inhibitor p27(kip), 
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een belangrijke regulator van gladde spiercel proliferatie, en in-stent restenose in twee 
verschillende studies. Bij 715 patiënten die coronaire angioplastiek met stent plaatsing 
ondergingen hadden patiënten met het p27(kip1) -838 AA genotype een lager risico op 
in-stent restenose (HR: 0.28; 95% CI: 0.10–0.77). Deze bevinding werd gerepliceerd in 
een andere cohort studie met 2309 patiënten (HR: 0.61; 95% CI: 0.40–0.93). Het -838A 
allel kwam overeen met een verhoogde promoter activiteit, wat een afname in gladde 
spiercel proliferatie zou kunnen verklaren. Hoofdstuk 6 van dit proefschrift vormt een 
belangrijke bijdrage aan dit vakgebied en beschrijft een aantal sterke associaties tussen 
polymorfismen in het Quaking gen en klinische restenose na PCI. Het Quaking eiwit, 
dat tot nu toe vooral bekend was om zijn rol in myelinisering, staat nu opnieuw in de be-
langstelling vanwege een mogelijke rol in hart- en vaatziekten. Recente bevindingen van 
Van der Veer en Kraaijeveld et al., die ook worden beschreven in hoofdstuk 6, tonen aan 
dat het eiwit een belangrijke rol speelt bij proliferatie en migratie van VSMC’s. Quaking 
viable (qkv) muizen, die het Quaking ewit zeer laag tot expressie brengen, lieten sterk 
gereduceerde neointima vorming zien in een muizenmodel voor restenose. Het effect 
van single nucleotide polymorphisms (SNP) in het gehele Quaking gen op restenose na 
PCI hebben we onderzocht in de GENDER-studie. In deze studie werden de sterkste 
associaties gevonden in de promoter regio (-2616 T/C: HR: 2.14, 95%CI: 1.24-3.68, 
P=0.006) en in intron 3 (57896 A/G: HR: 0.74, 95%CI: 0.6-0.92, P=0.005 and 65752 A/G: 
HR: 1.5, 95%CI: 1.14-1.98, P=0.003). Hoewel tot nu toe nog maar enkele proliferatieve 
genen werden onderzocht, benadrukt de kracht van de gevonden associaties het belang 
van proliferatieve genen in neointima vorming. Het gecombineerde effect van de 5752 
GG/GA genotypen en het 57896 AA genotype was zelfs groter (HR 1.77, 95% CI 1.29-
2.44; p<0.001). Deze genotype combinatie was aanwezig in 10% van de totale populatie.
Door zijn inhibitoire rol in VSMC proliferatie, adhesie van leukocyten aan de vaatwand 
en stolling, werd gesuggereerd dat nitric oxide (NO) zou beschermen tegen het ontstaan 
van restenose. De rol van NO in restenose werd verder ondersteund door de observatie 
dat L-arginine, de precursor van NO, neointima hyperplasie reduceert 6 maanden 
na stent plaatsing. Ondanks deze bevindingen hebben studies die de invloed van het 
Glu298Asp polymorfisme in het NOS3 gen op restenose onderzochten, tegenstrijdige 
resultaten geproduceerd. Vooral de grotere studies vonden geen significant effect van dit 
polymorfisme op TVR.
Na hun bevinding dat 298Asp homozygote patiënten met ischemisch hartlijden 
gevoeliger waren voor de vasoconstrictieve effecten van phenylephrine, suggereerde 
Sofowora et al. dat het belang van dit polymorfisme alleen duidelijk wordt onder 
condities van endotheeldysfunctie. In hoofdstuk 7 bevestigen we deze hypothese en 
geven we aan dat de hazard ratios mogelijk afhankelijk zijn van de aanwezigheid van het 
metabool syndroom, een syndroom dat gekenmerkt wordt door endotheeldysfunctie. 
We onderzochten de relatie tussen deze polymorfismen en het risico op restenose in 
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een subpopulatie van patiënten met het metabool syndroom die deelnamen aan een 
grote follow-up studie met achtereenvolgende patiënten die een PCI ondergingen, 
waarop geen selectie werd toegepast. We toonden aan dat de  -949G, -716T and 298Asp 
varianten in het NOS3 gen geassocieerd waren met een hoog risico op TVR in patiënten 
met het metabool syndroom, terwijl geen associatie gevonden werd in patiënten zonder 
het metabool syndroom. Onze hypothese is dat de metabole veranderingen in patiënten 
met het metabool syndroom het belang van deze polymorfismen beïnvloeden en de ont-
vankelijkheid van dragers van deze varianten in het NOS3 gen om na een PCI restenose 
te ontwikkelen.
Zoals geïntroduceerd werd in hoofdstuk 2 hebben DES de restenose-incidentie 
enorm teruggebracht. De ervaring van de laatste jaren toont echter een verhoogde kans 
op LASM en stent trombose bij gebruik van DES. LASM zou een gevolg kunnen zijn 
van positieve remodeling van de vaatwand of van een afname van het plaquevolume 
rondom de stent. De precieze mechanismen die tot LASM leiden zijn tot nu toe niet 
bekend. Hoewel een hypersentiviteitsreactie mogelijk een rol speelt, zou het ook een 
gevolg kunnen zijn van toegenomen apoptose of chronische ontsteking. In hoofdstuk 
8 vonden we ondersteuning voor de hypothese dat het proces veroorzaakt zou kunnen 
worden door ontsteking. We vonden een significant hoger risico op LASM in patiënten 
die het caspase 1 (CASP1) 5352 A allel dragen (RR: 2.32;95% CI: 1.22–4.42). Ook was 
de gemiddelde neointimagroei significant lager in dragers van dit allel (1.6 vs 4.1%; p = 
0.014). Het caspase 1 eiwit, ook wel bekend als IL-1β converting enzyme, zorgt voor een 
toename van ontsteking via activatie van IL-1 β and IL-18. Echter, omdat caspase 1 ook 
aptose kan induceren door het proteolytisch klieven van andere leden van de caspase 
groep, zou caspase 1 ook effecten kunnen hebben op celoverleving, afhankelijk van welk 
substraat bij voorkeur wordt gekliefd. Er bestaat dus een kleine mogelijkheid dat caspase 
1 een rol speelt bij LASM via invloed op apoptose. Vervolgonderzoek, bij voorkeur in 
grotere populaties, is nodig om te ontdekken welke van deze processen overheersend is 
bij het ontstaan van LASM.
Deel 2 van dit proefschrift introduceert een relatief nieuw onderzoeksgebied, de 
epigenetica, de studie naar omkeerbare erfelijke veranderingen in genfunctie die optre-
den zonder wijzigingen in de sequentie van het DNA. Hoofdstuk 9 geeft een overzicht 
van bevindingen die aantonen dat epigenetische mechanismen de expressie reguleren 
van proliferatieve en inflammatoire genen en daarmee een rol zouden kunnen spelen 
bij hart- en vaatziekten. Het feit dat epigenetische modificaties reversibel zijn maakt 
dit onderzoeksgebied zeer interessant. Nieuwe farmaca die ingrijpen in epigenetische 
processen zouden effectief kunnen zijn bij de behandeling van hart- en vaatziekten. 
Deel 2 heeft zich vooral gericht op  covalente post-translationele modificaties van his-
tonstaarten, een voorbeeld van een epigenetische verandering die leidt tot herschikking 
van nucleosomen. Van de verschillende typen chemische modificatie, wordt vooral 
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acetylatie van lysineresiduen in de histonstaarten beschouwd als een sleutelproces in 
genregulatie. Lysine acetyltransferases (KAT) acetyleren histonen door een acetyl-groep 
te plaatsen op het ε-gedeelte van lysine residuen, wat resulteert in het openen van de 
chromatinestructuur. Dit geeft transcriptiefactoren toegang tot het DNA, wat leidt tot 
gen activatie. Repressie van genen wordt gemedieerd door lysine deacetylases (KDAC’s), 
die een acetyl-groep verwijderen en daarmee de activiteit van HATs antagoneren, wat re-
sulteert in het sluiten van chromatine. Zoals eerder genoemd in de algemene introductie 
lag tot nu toe het accent vooral op onderzoek naar de invloed van omgevingsfactoren op 
epigenetische processen. Deel 2 van dit proefschrift introduceert het concept dat epige-
netische processen ook onder genetische controle staan. Variatie in genen die coderen 
voor KAT’s en KDAC’s kan ook een belangrijke determinant zijn van gevoeligheid voor 
het krijgen van complexe ziekten zoals hart- en vaatziekten.
In hoofdstuk 10 toonden we aan dat het -2481C allel in het PCAF gen geassocieerd is 
met een significant overlevingsvoordeel in de PROSPER en de WOSCOPS studies. PCAF 
is een KAT met een sleutelrol in de epigenetica, die histonen acetyleert op loci waar 
belangrijke inflammatoire genen zoals NFκB liggen. De bevinding dat het -2481C allel 
ook beschermt tegen restenose, een proces wat vooral wordt gedreven door ontsteking 
en proliferatie, ondersteunt de hypothese dat het PCAF gen effect heeft op de mortaliteit 
van coronaire hartziekten via zijn rol in inflammatoire en proliferatieve processen. De 
effecten van het
-2481C allel op de totale mortaliteit, op sterfte aan coronaire hartziekten en op 
klinische restenose, waren sterker in patiënten met een hogere leeftijd (>58 jaar). Dit 
leeftijdsafhankelijke effect suggereert dat het polymorfisme geassocieerd is met een 
veranderde neiging tot histon acetylatie, wat alleen tot uiting komt in oudere patiënten 
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Dit proefschrift is tot stand gekomen op de afdeling cardiologie van het LUMC. Graag 
wil ik iedereen die hieraan heeft bijgedragen bedanken. Heel in het bijzonder Wouter. 
Verder is dit proefschrift voortgekomen uit de goede samenwerking met een aantal 
andere afdelingen in het LUMC, de afdeling moleculaire epidemiologie, de afdeling 
nierziekten en het Einthoven laboratory for vascular research. Graag wil ik iedereen van 
deze afdelingen bedanken met wie ik in deze periode heb mogen samenwerken. Een 
aantal mensen wil ik met name noemen.
Dennis en Eka, heel veel dank voor jullie eindeloze geduld om mij de Sequenom tech-
nieken te leren. Het heeft veel voor me betekend om hier zelf mee aan de slag te kunnen. 
Dit heeft de basis gelegd voor een groot deel van mijn proefschrift.
Stella, hartelijk dank voor de prettige samenwerking aan de grote studies. De mogelijk-
heid om de genetische bevindingen te repliceren in de PROSPER-studie is belangrijk 
geweest in een aantal van onze artikelen.
Beste Sandrin, met jou heb ik altijd met plezier samengewerkt. Je bent in de loop der 
jaren een goede vriend van me geworden. In het lab ging het soms meer over NGC 
documentaires dan over diepgaande genetica... daar heb ik van genoten. Fijn dat je mijn 
paranimf wilt zijn.
Lieve papa, mama en Daniëlle, dank jullie wel voor de onvoorwaardelijke steun en het 
vetrouwen. Jullie hebben me alle kansen gegeven en nooit aan me getwijfeld. Ontzettend 
fijn dat jullie er altijd voor me zijn.
Lieve vrienden en vriendinnen, dank jullie wel voor de belangstelling en morele steun. 
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De auteur van dit proefschrift werd geboren 8 maart 1979 te Steenbergen. In 1997 
behaalde hij zijn eindexamen aan gymnasium Juvenaat ‘t Heilig Hart in Bergen op 
Zoom. Datzelfde jaar begon hij aan de studie biomedische wetenschappen in Leiden. 
Interesse voor ‘al het medische’ was op jonge leeftijd al aanwezig. Toch bestond er ook 
altijd aantrekkingskracht tot genetica en immunologie. Dit bewoog hem tot stages bij de 
afdeling medische farmacologie (Gorleus) en de afdeling longzieken (LUMC). Al snel 
werd hem duidelijk dat hij ook graag geneeskunde wilde gaan studeren. Na 4 maal loten 
kreeg hij deze kans en kon hij in 2001 eindelijk beginnen. Gedurende de wachttijd voor 
zijn co-schappen heeft hij een jaartje met plezier gewerkt bij zorgverzekeraar DSW. In 
december 2005 behaalde hij zijn artsexamen en begon hij aan een promotieonderzoek 
onder leiding van Prof. Dr. J.W. Jukema. Dit cardiologische onderzoek had een geneti-
sche inslag en sloot dus mooi aan bij de gecombineerde biomedische wetenschappen/
geneeskunde achtergrond. De resultaten hiervan staan beschreven in dit proefschrift. 
Naast het promotieonderzoek was hij  werkzaam bij de trombosedienst Leiden.
